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Summary  
The GABAB receptor has been postulated as a possible drug target in the treatment of 
anxiety disorders and cocaine addiction. Indeed, a wealth of preclinical data is emerging 
that has shown that mice lacking functional GABAB receptors display a highly anxious 
behaviour across a range of behavioural models of anxiety. Additionally, novel compounds 
that act by altering the allosteric conformation of the GABAB receptor to a more active 
state; the GABAB receptor positive modulators, have been repeatedly demonstrated to have 
anxiolytic effects in animals. In addition to being a putative anxiolytic drug target, the 
GABAB receptor has been identified as a novel target for anti-addictive therapies. Indeed 
GABAB receptor positive modulators have been demonstrated to have anti-addictive 
properties across a broad variety of behavioural paradigms. 
 
Despite these findings, several gaps in our knowledge of the role played by the GABAB 
receptor in both anxiety and drug abuse disorder exist. The aim of this thesis was to use 
preclinical animal models in an effort to further probe the role played by the GABAB 
receptor in anxiety and addiction.  
 
Our studies initially examined the role played by the GABAB receptor in the 
neurodevelopmental processes underpinning of anxiety. Our studies demonstrated that 
treating mouse pups in early life with the GABAB receptor agonist baclofen produced an 
anxious phenotype in adult life, whereas treatment with the GABAB receptor antagonist 
CGP52432 produced no effects on adult behaviour. Further to this, we examined whether 
the anxious behaviour induced by early life blockade of the serotonin reuptake transporter 
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was dependant on alterations in GABAB receptor function. Our studies however revealed 
no effect of early life selective serotonin reuptake inhibitor treatment on adult life baclofen 
sensitivity. 
 
The next issue addressed in this thesis is the characterization of the effects of a GABAB 
receptor positive modulator and a GABAB receptor antagonist in a behavioural model of 
conditioned fear behaviour. These novel classes of GABAB receptor ligands have been 
considerably less well characterized in this facet of preclinical anxiety behaviour than in 
terms of innate anxiety behaviour. Our study however revealed that the GABAB receptor 
positive modulator GS39783 and the GABAB receptor antagonist CGP52432 were without 
effect on the acquisition, expression or extinction of conditioned fear in our model. 
 
The next element of this thesis dealt with the characterization of a novel mouse model, the 
GABAB(2)-S892A  mouse. This mouse has been engineered to express a form of the 
GABAB(2) receptor subunit wherein the function determining serine phosphorylation site 
cannot be phosphorylated. We initially tested this mouse in terms of its GABAB receptor 
function in adult life, followed by testing it in a battery of tests of unconditioned and 
learned anxiety behaviour. We also examined the behavioural and molecular responses of 
the GABAB(2)-S892A mouse to cocaine. All of our studies appear to show that the 
GABAB(2)-GABAB2-S892A  mouse is indistinguishable from wildtype controls. 
 
The final aim of the thesis was to investigate the behavioural and molecular sensitivity of 
the GABAB(1) subunit isoform null mice, the GABAB(1a)
-/- 
and GABAB(1b)
-/-
 mice to cocaine. 
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Our studies revealed that these mice display differing behavioural responses to cocaine, 
with the GABAB(1a)
-/- 
mouse displaying a hypersensitivity to the acute locomotor effects of 
cocaine, while the GABAB(1b)
-/-
 displayed blunted locomotor sensitisation to cocaine. 
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Chapter 1  
Introduction 
  
 2 
1.1 The GABAB receptor 
-amino butyric acid (GABA) was established as the major inhibitory neurotransmitter in 
the brain in the 1950’s (Bowery, 2010). However, our understanding of the pharmacology 
of GABA was, until the 1980’s, limited to its activity at the ionotropic GABAA receptor 
(Curtis, 1978). This consensus was challenged in the early 1980’s by the work of Norman 
Bowery and colleagues with the discovery of a receptor that displayed pharmacological 
properties markedly distinct from the GABA receptor as understood at the time. This novel 
receptor was initially characterised as being insensitive to the GABAA receptor agonist 
bicuculline (Bowery et al., 1981), and further characterised using radioligand binding 
experiments which demonstrated that these bicuculline insensitive receptors were bound 
by both 3H-baclofen and 3H-GABA (Hill & Bowery, 1981). The new receptor was coined 
the GABAB receptor in contrast to the classical bicuculline sensitive GABAA receptor 
(Bowery et al., 1981).  
 
The GABAB receptor was then cloned in 1997 (Kaupmann et al., 1997), and it was 
subsequently discovered that the physiologically functional GABAB receptor is a 
heterodimer of two heptameric membrane spanning receptor subunits, the GABAB(1) and 
GABAB(2)  subunits, which interact at their c-terminus and membrane spanning, and 
extracellular regions (Jones et al., 1998; White et al., 1998). The GABAB receptor is a G-
protein coupled receptor and exerts its post-synaptic effects via inducing activity of the G-
protein coupled inwardly rectifying potassium channel, or GIRK, which mediates the late 
phase of the inhibitory post-synaptic current (ISPC) via efflux of K
+
 ions. Presynaptically 
the GABAB receptor is positively coupled to Ca
2+
 receptors which cause an influx of Ca
2+
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ions which inhibit the synaptic release of GABA or glutamate in the case of auto- and 
hetero- receptors respectively. Despite the existence of several splice variants, only two 
native functional isoforms of the GABAB receptor have been identified, comprising the 
GABAB(2) subunit in a heterodimeric assembly with one of two GABAB(1) subunit variants, 
the GABAB(1a) and the GABAB(1b) isoforms. These isoforms differ by the presence of two 
“sushi” domains at the N-terminal of the GABAB(1)a isoform and the absence thereof in the 
GABAB(1)b subunit (Couve et al., 2000) (Fig 1). 
 
Although the GABAB agonist baclofen was synthesized 50 years ago and indeed played a 
crucial role in the initial discovery of the GABAB receptor (Froestl, 2010; Bowery, 2010), 
a parallel development to the genetic elucidation of the GABAB receptor has been the 
development of novel pharmacological agents that act at the GABAB receptor. One such 
class of compounds are the positive allosteric modulators of the GABAB receptor. 
Allosteric positive modulators are drugs that act on G-protein receptors at sites distinct 
from the orthosteric binding region where classical agonists and antagonists bind (Keov et 
al., 2011). In binding at this site positive allosteric modulators alter the pharmacological 
properties of the receptor making receptor activation by agonists more likely (Jensen & 
Spalding, 2004; Urwyler, 2011). 
Positive allosteric modulators of the GABAB receptor act by enhancing the potency and 
maximal efficacy of GABA and other agonists at the GABAB receptor and their effects can 
be blocked by GABAB receptor antagonists  (Urwyler et al., 2001a, 2003). They are 
devoid of effect in the absence of GABA (Urwyler et al., 2001a, 2003), although GS39783 
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can function as an allosteric agonist at desensitized GABAB receptors (Gjoni & Urwyler, 
2009). Characterisation of these compounds in vivo has demonstrated that positive 
allosteric modulation of the GABAB receptor does not generate the same physiological 
effects as the GABAB receptor agonist baclofen. Indeed GS39783 is completely devoid of 
the ataxic, sedative and profound hypothermic effects of baclofen, suggesting these 
medicines may be of greater therapeutic utility than full agonists (Cryan et al., 2004).  
An equally important development in GABAB receptor pharmacology has been the 
development of highly selective and potent GABAB receptor antagonists. The evolution of 
these compounds can be traced from the first generation GABAB receptor antagonists 
phaclofen  and 2-hydroxy-saclofen,  as well as the blood brain barrier penetrating 
compounds CGP35348 , CGP36742, CGP46381, CGP51176, all with potencies in the 
millimolar range (Froestl, 2010). Second generation of GABAB receptor antagonists 
display binding affinities in the nanomolar (nM) range and includes compounds such as 
CGP52432, CGP54626A, CGP55845A, CGP56433A, CGP56999A, CGP61334 (, 
CGP62349 and CGP63360A (Froestl, 2010). The most recent development in the 
chemistry of GABAB receptor antagonists has been the development of 
125
I labelled high 
affinity antagonists of particular use in the crystallographic characterisation of the GABAB 
receptor (Froestl, 2010). 
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Figure 1. Diagram of the GABAB receptor and its anatomical location in vivo. (a) The GABAB 
receptor is an obligate heterodimer of the GABAB(1) and the GABAB(2) subunits. The GABAB(1) 
subunit exists as two isoforms distinguished by the presence (GABAB(1a)) and the absence 
(GABAB(1b)) of two sushi domains at the n-terminus. The GABAB(1) subunit acts as a ligand binding 
domain whereas the GABAB(2) subunit acts as an effector domain. (b) In vivo GABAB receptors are 
located both post-synaptically triggering K+ ion efflux in response to GABA release from the 
synaptic terminal as well as presynaptically, where they trigger Ca2+ influx in response to 
activation by GABA spillover from nearby synapse. The GABAB receptor acts postsynaptically as 
both an autoreceptor on GABAergic terminals and as an autoreceptor on glutamatergic terminals 
(From Cryan and Kaupmann, 2005). 
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Functionally, the GABAB(1a) isoform appears to predominantly act as a heteroreceptor 
modulating glutamate release in response to spill over of GABAB from GABAergic 
synapses, whereas the GABAB(1b) isoform appears to mediate the post-synaptic inhibitory 
effects of GABA. Both isoforms act as autoreceptors inhibiting GABA release (Vigot et 
al., 2006; Waldmeier et al., 2008). Recent evidence suggests that the sushi domain of the 
GABAB(1a) isoform may act as an axonal targeting signal (Biermann et al., 2010). The role 
the GABAB receptor plays in mediating the effects of GABA in the brain has only recently 
begun to be elucidated thanks to a novel, and ever-expanding array of genetic (transgenic 
and knockout mice) and pharmacological tools (selective and potent GABAB receptor 
antagonists and positive allosteric modulators) (Cryan & Kaupmann, 2005). Evidence 
suggests that the GABAB receptor may play an important role in regulating disease 
processes in a number of serious illnesses, including psychiatric disorders, and may indeed 
prove a valuable target for future drug development (Bowery, 2010). 
 
1.1.1 Functional heterogeneity of GABAB receptors 
GABAB receptors display a large degree of heterogeneity in vivo in terms of agonist 
affinity; however, this functional heterogeneity is not determined by receptor subtype but 
by post translational modification of the receptor and protein-protein interactions resulting 
in the formation of complex multimeric structures (Pinard et al., 2010). Development of 
the isoform specific GABAB(1a) and GABAB(1b) knockout mouse has revealed a very 
limited impact on innate anxiety behaviour with effects mainly on cognitive and taste 
aversion paradigms (Jacobson et al., 2006b, 2007a, 2007b). One such mechanism of 
function and activity modulation is the association of the GABAB receptor, at the carboxyl 
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terminal of the GABAB(2) subunit with tetrameric KCTD (potassium channel 
tetramerization domain-containing) protein complexes, which increases agonist potency, 
accelerating G-protein signalling onset and promoting receptor desensitization in KCTD 
isoform specific manners (Schwenk et al., 2010).  
 
Another important factor in regulating the activity of the GABAB receptor in vivo is that of 
receptor phosphorylation. N-methyl d-aspartate (NMDA) receptor-dependant 
phosphorylation of the GABAB receptor at various regulatory sites has recently been 
shown to markedly alter the function and desensitisation properties of the GABAB receptor 
(Guetg et al., 2010; Terunuma et al., 2010b). One such regulatory site on the GABAB 
receptor is the serine 892 residue of the GABAB(2) subunit. Cyclic AMP (cAMP) 
dependant phosphorylation of this residue can drastically modify the ligand potency, 
effector coupling and desensitisation behaviour of the GABAB receptor (Couve et al., 
2002; Fairfax et al., 2004). To investigate the GABAB receptor phosphorylation on 
behaviour, a transgenic mouse has been developed with a serine to alanine mutation at the 
892 position of the GABAB(2) subunit, rendering the protein impossible to phosphorylate at 
this site (Bettler et al. unpublished). Behavioural characterisation of this mouse will 
provide an important insight into the role this mode of GABAB receptor regulation plays in 
the processes underlying the pathophysiology of neuropsychiatric disorders. Furthermore, 
because positive modulators of the GABAB receptor potentially act in vivo by interfering 
with GABAB phosphorylation (Urwyler et al., 2001a), characterisation of the GABAB(2)-
S892A mouse may provide an insight into pharmacological effects of these drugs, both 
chronically and acutely. 
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1.2 Anxiety Disorders 
The anxiety response is an important mechanism by which we adapt and respond to real 
and perceived threats to homeostasis. Dysregulation of this healthy response leading to 
‘marked, persistent, and excessive or unreasonable fear’ (American Psychiatric 
Association, 2000) and culminating in a significant interference in normal life can be 
described as an anxiety disorder. From a clinical perspective, anxiety disorders are 
described by DSM-IV in terms of subtypes distinguished by the nature of the anxiety 
provoking stimulus. Most common among these anxiety disorder subtypes are generalized 
anxiety disorder, panic disorder (diagnosed with or without agoraphobia), specific phobia, 
social phobia, obsessive-compulsive disorder, and posttraumatic stress disorder (see Table 
1). It should be noted that DSM-V, published in May 2013 expands and modifies 
classification of the anxiety disorders and reclassifies obsessive compulsive disorder in a 
different diagnostic category (Holden, 2010; Miller & Holden, 2010).
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Table 1 – Anxiety disorders as described by DSM IV 
Disorder Trigger factors Main Symptoms/ Characteristics Treatment 
Generalized 
Anxiety 
Disorder (GAD) 
Anxiety in GAD is generalised to the point of 
becoming associated with life in general. 
Symptoms are typically gradual in onset. 
General feelings of anxiety, heart palpitations, dizziness, and excessive 
worry. GAD is distinguished from PTSD by the lack of a specific 
triggering factor and from panic disorder by a lower level of symptom 
severity. 
Behavioural and 
psychological 
therapies e.g. CBT, 
SSRIs , 
benzodiazepines 
(short term only) 
Panic Disorder 
(diagnosed with 
or without 
agoraphobia) 
Triggers for panic disorder tend to be subtle in 
nature. Patients tend to have a history of 
elevated anxiety. 
Abrupt bouts of intense fear or anxiety, normally presenting with 
physical symptoms such as heart palpitations, rapid breathing, shortness 
of breath, blurred vision, dizziness, and racing thoughts. 
Behavioural and 
psychological 
therapies e.g. CBT, 
SSRIs, TCAs 
Social/Specific 
phobia 
Anxiety is associated with specific stimuli or 
situation. 
Anxiety and fear associated with the specific stimuli or situation or 
deliberate avoidance.  
Behavioural and 
psychological 
therapies 
Post traumatic 
stress disorder 
(PTSD) 
PTSD exclusively occurs in the aftermath of a 
traumatic and fearful experience.  Symptoms 
may develop between months and years of the 
triggering incident and are persistent in nature. 
Re-experiencing the traumatic experience in the form of nightmares, 
flashbacks and obsessive thoughts. Patients may attempt to avoid stimuli 
associated with the traumatic event and may display generally elevated 
levels of anxiety. 
Trauma focused 
psychological 
therapy, SSRIs, 
mirtazapine 
Obsessive 
compulsive 
disorder (OCD) 
 OCD is characterised by obsessions (persistent, often irrational, and 
seemingly uncontrollable thoughts) and compulsions (actions which are 
used to neutralize the obsessions).  Symptoms must result in significant 
impairment in daily life. 
Behavioural and 
psychological 
therapies, SSRIs, 
TCAs 
*CBT: Cognitive Behavioural Therapy, SSRI: Selective Serotonin Reuptake inhibitor, TCA: Tricyclic Antidepressant 
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Although these sub-disorders are to a degree epidemiologically comorbid they display 
differential responsiveness to the spectrum of anxiolytic drugs currently in clinical use. 
This suggests that divergent etiological factors may underlie the different disorders. Rating 
scales such as the Hamilton Rating Scale for Anxiety and the Clinical Global Impression 
Scale are used by clinicians both as tools to quantify symptom severity and as measures of 
treatment efficacy (Hoge et al., 2012). These disorders furthermore display distinct 
neurobiological and neuroendocrine characteristics, indicative of differing underlying 
pathology (Sramek et al., 2002). 
 
Anxiety disorders are currently the most prevalent psychiatric diseases in Europe and the 
USA and as such represent, a grave and ever increasing strain on healthcare resources 
(Kessler, 2007; Nutt et al., 2007b; Kessler et al., 2005b; Alonso & Lépine, 2007) . 
Separate large scale epidemiological studies in both Europe (ESEMeD) (Alonso et al., 
2004) and the USA (NCS-R) (Kessler & Merikangas, 2004)  have demonstrated that 
anxiety disorders have the highest lifetime prevalence estimates (13.6 - 28.8%) and the 
earliest age of onset (11 years) among psychiatric disorders (Kessler et al., 2005a, 2005b; 
Kessler, 2007). Patients suffering from anxiety disorders also frequently present with other 
comorbid diseases including not only psychiatric disorders such as depression 
(Merikangas, 2003; Kessler et al., 2005b), but also medical conditions including functional 
gastrointestinal disease, asthma, cardiovascular disease, cancer and chronic pain, 
hypertension and migraine (Roy-Byrne et al., 2008; Härter et al., 2003). As such, anxiety 
disorders represent a huge burden in terms of both their social impact and their economic 
cost (Kessler, 2007; Nutt et al., 2007b) .  
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1.2.1 Current drug treatment of anxiety 
For millennia humans have sought out chemical agents to modify the effects of stress and 
feelings of discomfort, tension, anxiety, and dysphoria; the oldest of these being ethanol. 
In the 19th century, alkaloids, bromide salts and choral hydrate were used for their 
sedative hypnotic effects. A major breakthrough came with the introduction of barbiturates 
into the clinical practice in the early part of the 20
th
 century (López-Muñoz et al., 2005). 
They induce their effects by facilitating the Cl
-
 channel of the GABAA receptor to open, 
even in the absence of GABA tone. Animal models, especially canine-based paradigms, 
were particularly useful in identifying the sedative and anticonvulsant properties of such 
drugs although self-testing was also very popular in the early days of modern 
psychopharmacology.  Although barbiturates were popular as major tranquillizers, their 
side effects, including sedation and behavioural changes, tolerance and dependence issues 
coupled with the fact that their therapeutic dose limit is dangerously close to its toxic level 
led the pharmaceutical industry to seek out safer alternatives (López-Muñoz et al., 2005).  
 
It was in this context that the development of the benzodiazepines emerged and 
revolutionised the treatment of anxiety disorders. The first clinically available 
benzodiazepine was chlordiazepoxide, which was synthesised by Sternbach in the 1950s at 
the Hoffman La Roche Pharmaceutical Company (Sternbach, 1979).  At a molecular level, 
benzodiazepines elicit their effects by allosterically activating the GABAA receptor 
channel at a site distinct from GABA itself and thus only induce effects in synapses where 
GABA is present.  Key behavioural studies by Randall and colleagues (Hanson, 2005) 
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indicated that chlordiazepoxide might have a distinct pharmacological profile compared 
with that of barbiturates and other psychoactive drugs such as the antipsychotic 
chlorpromazine and anti-hypertensive reserpine.  These initial tests were carried out in 
mice and cats and included the mouse inclined screen test indicative of muscle relaxation 
and sedation, a foot shock test showing “taming effects”, the anaesthetized cat model of 
muscle relaxation, seizure-based pentylenetetrazole and electroshock tests (Randall, 1960).  
Later more sophisticated tests included Skinner-box based Sidman avoidance task 
(Sidman, 1953; Boren et al., 1959) in rats and monkeys which provided a sensitive and 
reliable, measure of depressant action on behaviour.  
 
The clinical realisation that anxiety and depression are comorbid has led to the clinical 
observation that selective serotonin reuptake inhibitors (SSRIs) are effective in treating 
anxiety disorders following on from observations regarding the efficacy of tricyclic 
antidepressants in anxiety (Rickels et al., 1974, 1993). Indeed, today SSRIs are first-line 
therapy for many anxiety disorders (Hoffman & Mathew, 2008). The development of 
SSRIs for depression and subsequently anxiety was firmly driven by mechanistic studies 
focusing on modulation of monoamine neurotransmission in vitro and in vivo with little 
input of behavioural models initially (Wong et al., 2005). Indeed, the reliance on 
traditional animal models of anxiety shows little positive effects of SSRIs and indeed 
anxiogenic effects are often observed (Borsini et al., 2002; Sánchez & Meier, 1997). It 
should however, be borne in mind that a transient period of increased anxiety is often 
reported in patients initiated onto SSRI therapy (Vaswani et al., 2003; Baldwin et al., 
2010).  This has led to much criticism of the models used.  Likewise, there has been a 
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growing discussion focused on whether anxiety and depression should be isolated from a 
drug development perspective (Shorter & Tyrer, 2003). Moreover, given the relative 
success of SSRIs it is becoming clear that many pharmaceutical companies are compelled 
to develop a “one pill fits all” approach to anxiety and mood disorders. This propelled 
research in the area of neuropeptides, such as CRF receptor antagonists, NK1 receptor 
antagonists and melanocortin antagonists which to date have yet to fulfil its initial promise 
(Takahashi, 2001; Ebner et al., 2009; Shimazaki et al., 2006). Recent drug discovery 
efforts have additionally focused on ligands acting at G-protein coupled receptors for the 
non-monoaminergic neurotransmitters GABA and glutamate (Chojnacka-Wójcik et al., 
2001; Cryan & Kaupmann, 2005). The current status of several promising putative drug 
classes for Anxiety Disorders is given in Table 2. 
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Table 2 - Novel anxiolytic targets 
Brain Target Drug Action Sample Compound References 
GABA    
GABAA Receptors α2 subunit specific agonists MRK-409 (Atack et al., 2011)  
GABAB Receptors Positive Allosteric Modulators GS39783, CGP7930, BHF177, rac-BHFF (Cryan et al., 2004; Cryan & Kaupmann, 
2005) 
Glutamate    
NMDA receptor Partial agonists d-cycloserine (Amaral & Roesler, 2008; Ressler et al., 
2004) 
mGluR2/3 Agonists LY354740, LY314582, APDC (Monn et al., 1997; Helton et al., 1998; 
Kłodzińska et al., 1999; Benvenga et al., 
1999; Spooren et al., 2002; Dunayevich et 
al., 2008)  
mGluR2 Positive Allosteric Modulators 4-MPTTS, CBiPES, ADX71149 (Johnson et al., 2005) Addex company 
website) 
mGluR4 Agonists LSP1-2111 (Wierońska et al., 2010) 
mGluR5 Antagonists MPEP, MTEP (Kuhn et al., 2002; Spooren & Gasparini, 
2004; Ballard et al., 2005; Varty et al., 2005) 
mGluR7 Agonists AMN082 (Fendt et al., 2008; Stachowicz et al., 2008) 
mGluR8 Agonist 
positive allosteric modulator 
DCPG  
AZ12216052  
(Duvoisin et al., 2010) 
Serotonin    
5-HT7 receptor Antagonist SB269970 (Wesolowska et al., 2006) 
5-HT1A receptor Antagonists WAY100635, p-MPP, ISL88.0338 (Griebel et al., 1999) 
5-HT2C receptor Antagonists S32006 (Dekeyne et al., 2008; Wacker & Miller, 
2008)  
Neuropeptide Systems    
CRH1 receptor Antagonists Antalarmin, Pexacerfont, GSK561679, 
CP154-526 
(Kehne & De Lombaert, 2002; Takahashi, 
2001; Coric et al., 2010) 
CRH2 receptor Antagonists Anti-savagine-30 (Takahashi, 2001) 
NK1 receptor Antagonists Vestipitant (Ebner & Singewald, 2006; Brocco et al., 
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2008; Ebner et al., 2009) 
(www.clinicaltrials,gov) 
Translocator protein 
(18kD) 
Neurosteroid production enhancement XBD173 (Rupprecht et al., 2009, 2010) 
MCH1 Antagonists SNAP -7941, TPI 1361-17 (Doggrell, 2003; Shimazaki et al., 2006; Lee 
et al., 2010) 
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1.3 Measuring Anxiety-related Behaviour in Rodents 
Many of the symptoms of anxiety disorders are dependent on the processing of complex 
psychological and cognitive concepts that clearly cannot be measured in animals such as 
“fear of losing control or going crazy” or a “sense of a foreshortened future”. It is thus clear 
from the clinical presentation of anxiety disorders that they can never be fully emulated as a 
syndrome in animals (Arguello & Gogos, 2006; Cryan & Holmes, 2005; Crawley, 2007). If 
however, we consider the substantial conservation of genetic, neurochemical and 
neuroanatomical features seen across mammals (Jones, 2002; Tecott, 2003; Arguello & 
Gogos, 2006) as well as Darwin’s observations regarding the conservation of many 
fundamental behavioural and pharmacological responses between species (Darwin, 1871, 
1872), theoretically, by studying the neural and genetic determinants of animal behavioural 
response we can, by inference, develop our understanding of the neural and genetic basis of 
human behaviour under both normal and pathological states (Geyer & Markou, 2002; 
Cryan & Holmes, 2005; Crawley, 2007). A necessary extension of this theory is that the 
validity of any animal model of psychiatric disease is determined by the robustness of the 
diagnostic techniques used to describe the disease state in the clinic. Translational 
interspecies comparisons are dependent on combined advances in the fields of both human 
diagnostics and animal modelling as well as developments in our understanding of 
behavioural, genetic and neurobiological function in healthy humans and animals (Geyer & 
Markou, 2002; Markou et al., 2009). Likewise novel reverse translational approaches such 
as measuring human exploratory behaviour (Perry et al., 2009) may provide novel ways to 
model anxiety disorder endophenotypes in animals. 
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To determine the validity of an experimental model of a neuropsychiatric endophenotype, 
standardised criteria such as those proposed by McKinney and Bunney (1969) for 
depression, and which are equally applicable to anxiety disorders, can be used. These 
authors suggest that animal models should bear a reasonable analogy to the human disorder 
in either manifestation or symptoms, induce a behavioural change that can be objectively 
monitored, display sensitivity to effective clinical treatments and display inter-researcher 
reproducibility in order to be considered valid (McKinney & Bunney, 1969). Current 
thinking on the validity of animal models acknowledges the existence of several types of 
validity including face validity (similar symptom manifestation to the clinical condition); 
construct validity (similar underlying biology); predictive validity (responsiveness to 
clinically effective therapeutic agents); etiological validity (induced by similar stimuli as 
the clinical condition); convergent validity  (convergent measures with other construct 
based models) and divergent validity (divergent measures from other construct based 
models)  while maintaining that the reliability and predictive validity are the most 
important criteria in determining the overall validity of the system (Geyer & Markou, 
2002). 
 
In the context of anxiety it has been argued by Treit (2010) that the validity of behavioural 
tests of anxiety should be based on three principles arising from the evolutionarily 
conserved roles the fear response plays in normal survival behaviour. Firstly, a 
correspondence between the behavioural fear expressions in the animal model biochemical 
or physiological correlates of these behaviours, and the expression of isomorphic 
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behavioural responses in humans; Secondly, if no isomorphism is present, biological 
function should be conserved between the anxiety-like behaviour in the animal model and 
the human fear response; and thirdly, conservation of the neural mechanisms, engaged 
during the fear response, that underlie anxiety-related behaviour in both animals and 
humans (Treit et al., 2010). 
 
In preclinical psychiatry research there remains some confusion on the distinction between 
an animal model versus a test (see Cryan & Slattery 2007).  When describing preclinical 
anxiety research, it is important to try and draw a distinction between animal models of 
anxiety and experimental tests of anxiety (Rodgers 2010). In general, when the term 
“animal model of anxiety” is used it refers to an animal that exhibits a phenotype 
behaviourally relevant to clinical anxiety disorders. When we use the term “test of anxiety” 
we refer to a behavioural paradigm that induces a quantifiable fear related behaviour related 
to the normal adaptive fear response (Young & Liberzon, 2002; Rodgers, 2010). We can 
thus say that a model comprises both an independent variable i.e. the inducing 
manipulation; and a dependent variable; i.e. the behavioural/neurochemical readout (Geyer 
& Markou, 2000), whereas a test simply comprises a dependent variable. Thorough clinical 
understanding of the underlying pathophysiology of anxiety disorders is vital to 
determining appropriate independent variables in preclinical research. Identification of 
appropriate anxiety endophenotypes has been useful in this regard (Cryan & Slattery, 
2007). Tests of anxiety are often described as “models of anxiety” based on the 
translationally questionable premise that anxiety disorders represent an exaggerated 
activation of the normal fear response, when in fact they more accurately represent models 
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of particular behavioural endophenotypes present in anxiety disorders and indeed models of 
anxiolytic drug activity (Young & Liberzon, 2002; Cryan & Holmes, 2005; Holmes & 
Cryan, 2006). Rodgers (2010) points to the fact that the distinction between animal test and 
animal model in anxiety research highlights the crucial difference in the knowledge we can 
garner from their use in understanding the neural circuitry of anxiety. Studying the 
induction of fear in an animal test in a normal animal can provide insight into the 
neurobiology of the adaptive fear response but may not necessarily be appropriate for 
investigating the dysregulated fear responses observed in anxiety disorder patients 
(Rodgers, 2010). It is thus important to remember that symptoms could conceivably arise 
from pathological processes upstream of the fear response and not from an abnormal fear 
response per se.  Knowledge of the dysregulated anxiety response in humans is thus best 
derived from animals with a translationally relevant dysregulation of their anxiety response, 
evidenced by greater levels of anxiety in etiologically valid behavioural tests. This may 
explain why, although our knowledge of the basic fear response has significantly advanced 
over the past number of decades, the pathophysiology of anxiety disorders remains to be 
fully undestood (Rodgers, 2010). 
 
By far the most commonly used species in preclinical anxiety research are the mouse (Mus 
musculus) and the rat (Rattus norvegicus) although as noted early studies in dogs and 
pigeons have played an important role in anxiety research historically. Traditionally rats 
have been the species of choice for behavioural pharmacology due to the practical 
considerations of their size and amenity to surgical intervention as well as superior 
cognitive ability and superior performance in operant and cognitive tasks. Many commonly 
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used behavioural paradigms were initially developed and validated as screens of anxiolytic 
activity in the rat before adaptation to use with other species (Cryan & Holmes, 2005). The 
development of novel genetic modification techniques, developed most extensively in the 
murine models has led to a surge in the popularity of the mouse in neuropsychiatric 
research. The mouse additionally has the advantages as regards ease of breeding, low cost, 
short generation turnover and smaller size from a drug dosing perspective (Joyner & 
Sedivy, 2000; Tarantino & Bucan, 2000; Phillips et al., 2007; Tecott, 2003; Cryan & 
Holmes, 2005; Jacobson & Cryan, 2007; Crawley, 2007).  However, this has brought with 
it its own logistical problems in terms of difficulty in combining blood collection for 
pharmacokinetic – pharmacodynamic studies or biomarker analysis.  Moreover, the 
enormous inter-strain difference in mouse behaviour across many anxiety tests both under 
baseline conditions and in response to pharmacological manipulation (Jacobson & Cryan, 
2010) can make the interpretation of data difficult. The question which invariably arises as 
to which mouse strain is most like human is not an easy question to try and answer. Thus, it 
is becoming clear that testing of putative anxiolytic drugs requires testing across multiple 
strains (and species if possible) to ensure the risk of a false negative is minimised.  It 
should be also noted that the manner in which a rodent responds to an anxiety-provoking 
situation may be qualitatively different to that of humans but it is becoming clear that many 
of the same neuronal circuits are recruited (Singewald, 2007). Often efforts at developing 
translational models of anxiety are interpreted as forming completely homologous models 
in both humans and rodents, although this may be possible in certain domains (e.g. startle 
response, stress-induced hyperthermia), it also may be a very narrow approach and 
disregards the ethological and species-specific aspects of mouse behaviour (Rodgers et al., 
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1997). The most commonly used experimental paradigms used in the assessment of anxiety 
behaviour in mice are outline in Table 2 and several common tests are depicted in Figure 2.
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Table 2 – Commonly used animal models of anxiety     
Test Brief Description Principles Animals References 
Ethological Tests      
Elevated-plus Maze  Animals are placed on an elevated, plus shaped 
maze consisting of two open arms and two enclosed 
arms connected by a central connecting square 
The open arms of the maze are 
considered to be more aversive than the 
closed arms. Anxiolytic drug treatment 
results increased entries to and time 
spent in the open arms 
Mice, Rats, 
Gerbils 
 (Handley & Mithani, 
1984; Lister, 1987; Wilks 
& File, 1988; Moser et 
al., 1990; Filip et al., 
1992; Hogg, 1996; Braun 
et al., 2011)  
Elevated Zero Maze  Animals are placed on an elevated circular maze 
consisting of four segments; two exposed segments 
and two walled segments of equal length 
 The open segments of the maze are 
considered to be more aversive than the 
closed segments. Anxiolytic drug 
treatment results increased entries to 
and time spent in the open segments 
 Mice  (Shepherd et al., 1994; 
Mombereau et al., 2007; 
Braun et al., 2011) 
Light-dark Box  Mice are placed in an apparatus consisting of two 
compartments; an illuminated “light” compartment 
and a dark compartment. The compartments are 
connected by a small opening at floor level. 
Animals are allowed to freely explore the apparatus 
 The light compartment is believed to be 
more aversive to the mouse than the 
dark compartment. Anxiolytic drug 
administration increases the number of 
entries to the light compartment; time 
spent in the light compartment and 
reduces freezing behaviour. 
 Mice  (Crawley & Goodwin, 
1980; Jones et al., 1988; 
Onaivi & Martin, 1989; 
Bourin et al., 1996; 
Hascoët et al., 2000b; De 
Angelis & Furlan, 2000; 
Bourin & Hascoët, 2003)  
Open Field  Mice are placed in a brightly lit arena and allowed 
to freely explore 
 The brightly lit exposed arena is a 
highly anxiogenic environment. 
Anxiety levels are assessed by a variety 
of ethological parameters as well as by 
the amount of time the animal spends in 
the more anxiety provoking central 
compartment 
 Mice, Rats (Crawley, 1981; Lucki et 
al., 1989; Stefański et al., 
1992; Sherif & Oreland, 
1995; de Angelis, 1996; 
Schmitt & Hiemke, 1998; 
Prut & Belzung, 2003)  
Defensive Marble 
Burying/ Shock Probe 
 Animals are placed in a novel cage containing 
bedding and a number of novel marbles or an 
 Burying of the marbles is interpreted as 
anxiety-like behaviour. Anxiolytic drug 
 Mice, Rats (Treit et al., 1981; Craft 
et al., 1988; Njung’e & 
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burying Test electrical shock probe. treatment reduces the number of 
marbles buried 
Handley, 1991; Czech & 
Quock, 1993; Picazo & 
Fernández-Guasti, 1995; 
De Boer & Koolhaas, 
2003; Joel, 2006)  
Ultrasonic Vocalisations  Mouse pups are separated from their mothers and 
the frequency of ultrasonic distress calls is recorded 
 A reduction in the number of USVs 
emitted from separated pups is regarded 
as an anxiolytic effect 
Mice, Rats,  
Guinea Pigs  
 (Nastiti et al., 1991b, 
1991a; Groenink et al., 
2008; Scattoni et al., 
2009)  
Staircase test  Animals are placed in an enclosed staircase, with 
the number of steps climbed and the number of 
rearing behaviours measured. 
 The climbing of steps in this test is 
regarded as a measure of exploratory 
behaviour, with the number of rearing 
behaviours being regarded as an 
anxiety-like behaviour 
 Mice, Rats  (Molinengo & Ricci-
Gamalero, 1970; Hughes, 
1972; Cunha & Masur, 
1978; Simiand et al., 
1984),  
Social Interaction Test Animals are introduced to a novel animal of the 
same species and social behaviour is monitored 
Anxiolytic drugs increase levels of 
social interaction with the novel mouse 
Mice (File, 1980) 
Suok Ropewalking/ 
Elevated alley test 
Animals are placed in the centre of an elevated 
beam or alley and allowed to freely explore the 
apparatus. Can be modified to the light-dark Suok 
test by illuminating one half of the beam and 
leaving the other half in darkness  
The elevated beam induces anxiety by 
virtue of its novelty and elevation. 
Increased horizontal exploration in this 
test is regarded as a decrease in anxious 
behaviour. In the light-dark test 
increased time spent in the illuminated 
area is regarded as a decrease in 
anxiety. The Suok test is also able to 
detect non-specific drug effects e.g. 
ataxia and is of specific use in 
examining anxiety-vestibular system 
interactions. 
Mice, Rats (Kalueff & Tuohimaa, 
2005; Kalueff et al., 
2007, 2008),  
T-Maze The elevated T-maze consists of an elevated 
platform consisting of two opposing exposed arms 
and one enclosed arm perpendicular to the open 
arms. Animals are placed at the distal end of the 
enclosed arm and are allowed to explore the 
Learned fear (inhibitory avoidance) can 
be assessed by measuring the time taken 
for the animal to leave the enclosed arm 
subsequent to initial exposure. 
Anxiolytic agents decrease the amount 
Mice, Rats (Graeff et al., 1998; 
Carvalho-Netto, 2004)  
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apparatus. After several trials, the animal is placed 
on the distal end of an open arm and allowed to 
explore the apparatus 
of time taken by the animal to leave the 
open arm. Unconditioned fear is 
measured using the latency of the 
animal to escape into the closed arm 
from the open arm 
Seed-finding test Hamsters are fasted overnight and are then removed 
from their home cages to a novel environment. 
Sunflower seeds are then placed under the bedding 
of the home cage 
Latency to find the seed when returned 
to the cage is taken as a marker of 
anxious behaviour 
Hamster (King et al., 2002) 
Anxiety/Defence Test 
Battery, Mouse Test 
Defence Battery (MTDB) 
Rats or mice are confronted with a dead or heavily 
anaesthetised predator (rat) and the defensive 
behaviour exhibited by the mouse is measured 
Risk assessment, flight responses and 
defensive attack behaviours are 
measured as well as the development of 
context dependant defensive behaviours 
i.e. in the absence of threat are 
ethologically examined   
Mice, Rats,  
Non-Human 
Primates 
(Griebel et al., 1995a, 
1995b, 1999; Barros et 
al., 2008)  
(Modified) Hole Board 
test 
Rats or mice are placed in an open field containing 
an opaque holed board. The board contains several 
holes with removable plastic covers 
The number of entries onto the board 
and duration spent on the board are 
measures of anxiolyitc activity. 
Exploratory behaviours (no. of holes 
visited) and locomotor activity as well 
as a number of ethological parameters 
can be measured 
Mice, Rats (Ohl et al., 2001b, 2001a; 
Sillaber et al., 2008; 
Thoeringer et al., 2010)  
Conflict Tests      
Geller–Seifter task  Food deprived animals are trained to activate a 
lever to receive food (unpunished period). Once 
trained the delivery of the food reward coincides 
with an electrical shock (punished period) 
 The paradigm generates a conflict 
between hunger stimulated approach 
behaviour and fear of the shock. 
Anxiolytic drugs increase approach 
behaviour during the punished period 
 Rats (Geller & Seifter, 1960, 
1962; Geller et al., 1962; 
Wiley et al., 1993; Millan 
& Brocco, 2003; Paterson 
& Hanania, 2010),  
Vogel punished Drinking  Water deprived rats are given access to water. 
Drinking behaviour is “punished” with electrical 
shocks 
 The paradigm generates a conflict 
between thirst stimulated approach 
behaviour and fear of the 
shock. Increases in “punished” water 
consumption is viewed as an anxiolytic 
 Rats  (Vogel et al., 1971; 
Depoortere et al., 1986; 
Shibata et al., 1989; Filip 
et al., 1992; Matsuo et al., 
1997; Dekeyne et al., 
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effect 2000; Millan & Brocco, 
2003) 
Four-plate test Apparatus consists of a cage with a floor comprised 
of four metal plates. The animal is allowed to freely 
explore the novel apparatus but crossing between 
floor plates results in a mild electrical shock 
In the four plate test, the aversive shock 
can only be avoided by immobility. The 
number of crossings between quadrants 
in this paradigm is inversely related to 
the levels of passive avoidance 
behaviour. 
 Mice (Aron et al., 1971; 
Hascoët et al., 2000a)  
Hyponeophagia Tests     
Novelty Suppressed 
Feeding 
 Food deprived animals are introduced to a novel 
anxiogenic environment where food is presented. 
 Thus paradigm generated a conflict 
between the anxiogenic stimulus and 
hunger induced approach behaviour. 
Anxiolytic drugs reduce the latency of 
the animal to approach the food 
 Mice, Rats (Bodnoff et al., 1988, 
1989)  
Novelty Induced 
Hypophagia 
 Animals are trained to consume a desirable food, 
e.g. sweetened milk before being presented with the 
milk in a novel environment 
 Hesitation on the part of the animal to 
consume the highly palatable food in 
the novel environment is regarded as a 
measure of both anxiety and of 
anhedonia 
 Mice, Rats (Rex et al., 1998; Merali 
et al., 2003; Santarelli et 
al., 2003; Dulawa & Hen, 
2005) 
Cognitive-Based Tests         
Pavlovian fear 
conditioning 
 Animals are trained to associate a particular 
contextual or cue related stimulus (CS) with an 
unpleasant stimuli such as an electric foot shock, 
acoustic stimulus or an aversive odour (US).  The 
animal then learns to display an observable startle or 
freezing response to the CS independent of the 
presence of the US 
Increased levels of freezing behaviour 
and enhanced startle responses when the 
CS is presented in the absence of the 
US are used as measures of fearful 
behaviour 
 Mice, Rats (Davis, 1990; Fendt & 
Fanselow, 1999; Borsini 
et al., 2002)  
Conditioned emotional 
response 
 Animals are trained to associate a specific operant, 
feeding or drinking behaviour (CS) with unpleasant 
stimuli (US).  
 Association of the US behaviour results 
with the CS results in a decrease in the 
US behaviour. Anxiolytic drugs reduce 
this effect. 
 Mice, Rats (Davis, 1990; Goddyn et 
al., 2008) 
Conditioned taste 
aversion 
Consumption of sweetened milk is paired with the 
injection of the malaise inducing compound Lithium 
Association of the sweetened milk with 
the LiCl induced malaise results in a 
Rats (Ervin & Cooper, 1988; 
Yasoshima & Yamamoto, 
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Chloride (LiCl). Animals are then offered a free 
choice between consumption of water and the same 
sweetened milk 
decrease in consumption of the 
sweetened milk. Anxiolytic drugs 
reduce this effect 
2005)  
Physiological tests         
Stress-Induced 
Hyperthermia 
 Mice are singly housed over night prior to rectal 
temperature measurement. Temperature is measured 
twice at an interval of 10-15 minutes.  
Rectal temperature measurement is used 
as a stressor in this procedure. The 
increase in temperature seen between 
the first and second measurements is 
taken regarded as a physiological 
anxiety response. Drugs regarded as 
having an anxiolytic effect in this test 
reduce the magnitude of this 
temperature increase. 
 Mice, Rats. (Bouwknecht et al., 2007; 
Van Bogaert et al., 2006; 
Conley & Hutson, 2007; 
Vinkers et al., 2008)  
Autonomic Telemetry Electrocardiogram transmitters are surgically 
attached to the mouse allowing remote monitoring 
of heart rate, body temperature and locomotor 
activity 
The autonomic response to stressful 
stimuli, such as heart rate, blood 
pressure, body temperature and 
locomotor activity can be measured and 
recorded in freely behaving animals 
Mice, Rats (van Bogaert et al., 2006) 
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A) B)
C) D)
 
 
Figure 2 – Diagrams of commonly used tests of anxiety-like behaviour as well as an image 
of the forced swim test; a commonly used screen for antidepressant activity. A) The 
elevated plus maze, B) the light dark box, C) the apparatus for defensive marble burying 
and D) the forced swim test. Adapted from Cryan and Holmes, 2005.
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Many tests have an ethological foundation based on the conflict that exists in small rodents 
such as rats and mice between the natural exploratory drive in these animals and aversion 
to exposed brightly lit environments (Rodgers, 1997). These models emerged over the past 
40 years or so and relied on an ethological approach to understanding anxiety as opposed to 
the pharmacological approaches used in the development of drugs such as the 
benzodiazepines (see above). Behavioural paradigms based on approach-avoidance conflict 
include the elevated plus maze (Handley & Mithani, 1984; Pellow et al., 1985; Lister, 
1987; Rodgers, 1997; Holmes, 2001; Crawley, 2007), elevated zero maze (Lee & Rodgers, 
1990; Shepherd et al., 1994)  the open field test , the light-dark box test (Crawley, 2007),  
the staircase test (Simiand et al., 1984), and the mirrored arena (Rodgers, 1997; Rodgers et 
al., 1997; Belzung & Griebel, 2001; Crawley, 2007) where avoidance of exposed, brightly 
lit or elevated areas is measured. The modified hole-board test combines the approach-
avoidance aspects of the open field with the addition of board containing several holes 
which allows for the direct measurement of exploratory behaviour (Ohl et al., 2001a, 
2001b). Within these approach avoidance procedures, several species-specific behaviours 
and postures are quantified and used as behavioural readouts. Reductions in these 
“ethological parameters” such as head dipping over the edges of elevated apparatuses, 
rearing and stretch-attend postures regarded as a manifestation of increased anxiety 
(Shepherd et al., 1994; Rodgers, 1997; Rodgers et al., 1997; Belzung & Griebel, 2001). 
Ethological analysis is taken to its extreme in the measurement of mouse risk-assessment, 
flight and defensive attack behaviour following threat cue exposure in the Mouse Defence 
Test Battery (MDTB) (Blanchard, 2003). Apprehension and heightened levels of vigilance 
are frequently a component of anxiety disorders and measurement of risk assessment 
behaviour, indexed by relevant ethological parameters, are regarded as a model of this 
endophenotype (Rodgers, 1997; Blanchard, 2003; Cryan & Holmes, 2005). 
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Although the constructs underlying each of these approach avoidance tests is similar, it is 
important to emphasise that the pharmacology and underlying neurobiology is not 
necessarily identical. To add to the complexity large species and strain differences occur.  
Thus it is very difficult to define which test is the best to model human anxiety responses. 
This necessitates the use of a battery style approach for assessing novel pharmacological 
agents.  However, questions always emerge on whether a compound that is showing an 
anxiolytic effect in more tests is it going to be more effective in the clinic? The reciprocal 
experiences of researchers with SSRIs [very little activity, (Borsini et al., 2002)] and NK1 
receptor antagonists [activity in a number of tests (Heldt et al., 2009; Varty et al., 2002; 
Vendruscolo et al., 2003)] would suggest not. 
1.3.1 Conflict-based anxiety tests in laboratory animals  
Conflict situations, in which a subject experiences two opposing impulses, are a common 
and clinically relevant feature of anxiety and therefore employed in many models 
employed for the detection of anxiolytic agents in rodents. Conflict-based models have 
been among the most sensitive to GABAergic manipulation and have play an important 
role in assessing anxiolytic potential. In conflict-based tests of anxiety in laboratory 
animals, subjects receive a punishment (mild electric shock) leading to suppression of a 
conditioned (learned) response for reinforcement (food or water) (Rodgers, 1997). 
Punishment-based conflict procedures have been employed for over 50 years in the 
identification and characterisation of anxiolytic agents (Geller & Seifter, 1960). Studies 
demonstrated that when rats are trained to lever press for a food reward, during the 
"conflict" component, responses are inhibited by concomitant, mild electric shocks. This 
paradigm is known as the Geller-Seifter test. Anxiolytic properties are deduced for drugs 
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which selectively enhance punished responses in the presence of shock as compared to 
unpunished responses emitted in its absence. Benzodiazepines and barbiturates were 
initially demonstrated to exert specific anxiolytic properties active in the Geller–Seifter test 
and, subsequently, many classes of potential anxiolytic agents have been characterized 
employing this procedure. However, major disadvantages remain: (1) the necessity for 
long-term (months) and daily training of subjects and (2) their repeated utilization. That is, 
exposure to drugs may modify the actions of those subsequently evaluated. 
 
In an effort to overcome these problems Vogel and colleagues (Vogel et al., 1971) 
developed a novel conflict procedure in which male rats were water-deprived for 48h and, 
during a test session of 3 min, drinking was punished by a mild, but aversive, shock 
delivered via the spout of the bottle every 20 licks. Accordingly, a specific, drug-induced 
increase in the number of shocks taken was considered to reflect anxiolytic properties. 
Today Vogel’s test is one of the most widely used tests for assessing anxiolytic activity in 
rodents (Millan & Brocco, 2003).  
 
A similar conflict procedure is the four-plate test, where the drive to explore a novel 
environment is conflicted with the drive to avoid floor-delivered foot shocks (Ripoll et al., 
2006). Defensive marble and shock-probe burying tests, where animals bury novel or 
aversive items, differ from other tests of anxious behaviour in that an active behaviour i.e. 
burying is used as an index of anxiety as opposed to other tests relying on passive 
avoidance behaviour. It should however be noted that controversy exists as to the precise 
nature of the behaviour elicited in the defensive marble burying assay in mice. It has been 
argued that this assay may be more ethologically relevant to obsessive compulsive disorder 
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than to the rest of the anxiety disorders (Witkin, 2008) or may represent a species specific 
repetitive and perseverative behaviour with little correlation to levels of anxiety-like 
behaviour (Thomas et al., 2009). As such they make valuable additions to anxiety test 
batteries (Broekkamp et al., 1986; Sluyter et al., 1996, 1999; Spooren et al., 2000; Jacobson 
et al., 2007a).  
 
1.3.2 Other unconditioned anxiety tests in laboratory animals 
Anxiolytic activity in many of the abovementioned tests can be confounded by aspects of 
altered locomotor activity induced by genetic or pharmacological manipulations (Cryan & 
Holmes, 2005; Holmes & Cryan, 2006; Jacobson & Cryan, 2010). Thus, it is important to 
consider other tests in battery style approaches that are less dependent on motor outputs. 
The following are some of the more widely used:  
 
Hyponeophagia 
Hyponeophagia, the suppression of eating due to anxiety-related states caused by novelty, 
can be assessed by measuring the latency to begin eating in a variety of potentially 
anxiogenic situations. Once again, it is a conflict-based model which has a long history in 
the assessment of emotionality and anxiety with Hall (Hall, 1934) observing an inverse 
relationship between feeding and defecation in animals exposed to a novel environment. In 
hyponeophagia tests the level of anxiety-related stimuli is manipulated by using novel food 
and by conducting the experiment in novel, potentially anxiogenic environments 
(Bannerman et al., 2002, 2003; Dulawa & Hen, 2005; Deacon & Rawlins, 2005; Finger et 
al., 2010). These paradigms are ethologically relevant and therefore do not require complex 
training procedures, are not confounded by painful stimuli, are simple to conduct, and are 
relatively cost-effective. Hyponeophagia-based models are conducted either by presenting 
  
 32 
chow to food-deprived animals, or by presenting a highly palatable and familiar food to 
satiated animals, and measuring the latency to feed and/or the amount eaten in a novel 
environment. The same dependent measures should also be assessed in the home 
environment to control for effects of the independent variable on appetite. As in all anxiety 
assays inbred mouse strains show baseline differences in levels of hyponeophagia (Trullas 
& Skolnick, 1993). A number of genetic manipulations resulting in anxious phenotypes 
including leptin-deficient mice (Finger et al., 2010); 5-HT1A receptor (Gross et al., 2000) 
and the NK1 receptor (Santarelli et al., 2002) have also increases in hyponeophagia.  
 
Several variations of hyponeophagia-based behavioural paradigms exist. These include the 
novelty suppressed feeding paradigm where animals are presented with normal food in a 
novel anxiogenic environment and the latency to begin eating is taken as an index of the 
anxiety state of the animal (Bodnoff et al., 1988, 1989; Gross et al., 2002). Repeated 
exposures to hyponeophagia paradigms in different environments and to different food 
stuffs can be used to modulate the levels of anxiety generated in these paradigms in order 
to optimise the sensitivity of the behavioural output in this test (Deacon & Rawlins, 2005; 
Finger et al., 2010). Another variant is the novelty-induced-hypophagia model in which 
animals are trained to consume a highly palatable food such as sweetened milk and then 
later presented this food in a novel aversive environment (Soubríe et al., 1975; Santarelli et 
al., 2003; Gross et al., 2002).  
 
Separation-induced ultrasonic vocalisations (USVs) 
Rodent pups produce vocalisations in the ultrasonic range when separated from their 
mother and littermates. This distress behaviour is intended to elicit maternal attention and 
retrieval as well as to modulate maternal care behaviour by stimulating prolactin 
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production (Noirot, 1972; Farrell & Alberts, 2002; Hashimoto et al., 2001). These distress 
behaviours can be recorded and analysed both quantitatively and qualitatively in order to 
measure levels of distress like behaviour in both infant mice and rats (Scattoni et al., 2009; 
Groenink et al., 2008). Suppression of ultrasonic vocalisation emission is an ethologically 
valid marker of anxiolytic drug efficacy (Groenink et al., 2008). Anxiolytic effects in this 
test can be elicited with administration of benzodiazepines, 5-HT1A receptor agonists and 
SSRIs. Agents acting on the noradrenergic system such as tricyclic antidepressants, are 
however, less consistent in their anxiolytic effects (Borsini et al., 2002). USV reduction is 
also seen with administration of a range of putative anxiolytic agents including NK1 
receptor antagonists (Groenink et al., 2008). 
 
Measurement of USV production in response to painful or stressful stimuli has also been 
proposed as a potential measure of anxiety behaviour in adult rodents. 5-HT1A receptor 
antagonists and SSRI antidepressants are effective at suppressing USV emission in this 
model although benzodiazepines have limited effects (Sánchez, 2003). 
 
Stress-Induced Hyperthermia (SIH) 
A key element of the adaptive anxiety response is activation of the autonomic nervous 
system and subsequent physiological responses including an increase in body temperature. 
This process is conserved across mammalian species including rodents and humans. 
Measurement of the hypothermic response generated subsequent to stressful stimuli 
represents a translationally valid and useful approach to modelling anxiety disorders 
(Bouwknecht et al., 2007; Vinkers et al., 2008). The hyperthermic response to stress can be 
attenuated using benzodiazepines as well as buspirone and ethanol (Spooren et al., 2002) 
and chronic but not acute SSRI treatment (Conley & Hutson, 2007). The SIH paradigm is 
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additionally sensitive to the effects of numerous putative anxiolytic agents (Spooren et al., 
2002) as well providing a useful technique for exploring the role of individual 
neurotransmitter systems in the anxiety response (Vinkers et al., 2010). 
 
1.3.3 Fear conditioning-based models of anxiety  
Alterations in conditioned fear-learning and cognitive defects form an important facet of 
the clinical manifestation of anxiety disorders (American Psychiatric Association, 2000; 
Lang et al., 2000). These include inappropriate processing of potentially threatening stimuli 
in GAD, panic disorder and phobias as well as the long-term salience of traumatic 
memories seen in PTSD. In order to model these aspects of anxiety disorders several 
conditioned tests of anxiety such as Pavlovian fear conditioning have been developed and 
validated (Cryan & Holmes, 2005; Ledgerwood et al., 2005; Delgado et al., 2006; 
O’Connor et al., 2010). More recently the discovery that insular cortex dysfunction may 
play a role in anxiety disorders (Paulus & Stein, 2006) has led to the insular-cortex 
dependent, conditioned taste aversion paradigm becoming more widely used (Bermúdez-
Rattoni et al., 2004; Guitton & Dudai, 2004; Mickley et al., 2004; Yasoshima & 
Yamamoto, 2005; Jacobson et al., 2006b; Hefner et al., 2008) .  
 
Conditioned fear paradigms revolve around the association of innocuous stimuli such as a 
tone or palatable taste (conditioned stimulus) with a painful or stressful stimulus such as a 
foot-shock or chemically induced malaise (unconditioned stimulus).  Levels of conditioned 
fear generated in these paradigms are indexed by a number of behavioural outputs 
including conditioned freezing, fear potentiated startle, active defensive behaviours, 
vocalisations, physiological responses as well as alterations in sucrose preference in the 
conditioned taste aversion paradigm (Fendt & Fanselow, 1999; Cryan & Holmes, 2005). 
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Sleep disturbances form part of the diagnostic criteria for several forms of anxiety disorder 
(Prut & Belzung, 2003; American Psychiatric Association, 2000) and also represent a 
sensitive output in select fear conditioning paradigms (Sanford et al., 2003b, 2003a). 
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Figure 2 - Diagram of a model of learned fear behaviour in rodents. Using a classical 
Pavlovian model of fear conditioning, rodents are trained to associate an innocuous 
conditioned stimuli (CS), with a painful unconditioned stimuli (US). Animals will display a 
fear response e.g. freezing in response to both the context of the conditioning and to the 
CS. With repeated exposure to the CS in the absence of the US, animals will gradually 
extinguish the conditioned fear. In this example the three stages of fear conditioning are 
shown. In session one, the acquisition session animals are presented with a painful US 
(auditiory tone and light) presented in combination with the innocuous CS (footshocks). In 
the second session animals display fear behaviour in response to the previously innocuous 
stimuli. Extinction is a process that occurs after several presentations of the CS in the 
absence of US whereby the CS-induced fear behaviour is no longer expressed. 
 
 
The brain circuitry that underpins Pavlovian fear conditioning essentially revolves around 
the convergence of auditory (CS) and nociceptive (US) sensory pathways from thalamic 
and cortical regions in the lateral amydala (LA). The LA both directly and indirectly 
innervates the central nucleus of the amygdala; a key region in activating the behavioural, 
autonomic and endocrine stress responses (Phelps & LeDoux, 2005). Molecular plasticity 
in the LA results in increased neuronal activation in response to the CS and thus increased 
central nucleus mediated responses (Johansen et al., 2011). Emerging data suggests that 
another key component of the brain’s fear conditioning circuitry, particularly in the 
extinction of conditioned fear, is the prefrontal cortex which likely mediates its effects via 
  
 37 
indirect input to the central nucleus of the amygdala or by direct input to the LA (Sotres-
Bayon et al., 2006). The hippocampus is another important region the neurocircuitry of fear 
conditioning, with its function appearing to be related to the acquisition and consolidation 
of contextual stimuli related to the US  (Sanders et al., 2003). The neuronal pathways that 
underlie auditory fear conditioning and extinction are outlined in Figure 3. 
 
 
 
Figure 3 –a) The neuronal pathways that underlie the acquisition and expression of 
auditory fear conditioning. Inputs related to CS and US converge in the lateral amygdala. 
Neuronal plasticity in the lateral amydala (LA) resuling in re-exposure to the conditioned 
stimuli (CS) activating the LA. The LA activates the central nucleus of the amydala directly 
and also through the intercalated cell masses (ICM) and the basal nucleus of the amydala. 
The basal nucleus is processes information related to spacial context from the 
hippocampus. The central nucleus controls the expression of fear behaviours such as 
freezing b) The neuronal pathways that underlie auditory fear extinction. Initial 
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presentations of CS in the absence of US result in decreased firing rates in some inhibitory 
amygdala neurons. Later,  input from the ventromedial prefrontal cortex to LA and ICM, as 
well as hippocampal input to the LA directly suppress amugdala activity in response to 
both CS and contextual cues. Adapted from Sotres-Bayon et al., 2006. 
 
The behavioural process demonstrated in the Pavlovian conditioning model can be broken 
down into three distinct phases; acquisition, consolidation and retrieval.  A consensus is 
growing to the effect that synaptic plasticity in the basolateral amygdala is a central 
molecular mechanism across all three of these processes (Fanselow & LeDoux, 1999). A 
central finding regarding the molecular mechanisms of fear conditioning, was the discovery 
that the acquisition of conditioned fear memory could be inhibited by intra-amygdala 
administration of NMDA receptor antagonists (Miserendino et al., 1990). Another crucial 
discovery were the in vivo findings that changes in neural activity in the lateral amygdala 
are very similar to those observed in LTP and that these changes indeed parallel the 
emergence of conditioned fear responses (Rogan et al., 1997). Activation of NMDA 
receptors and in cases of more robust neuronal activation voltage gated Ca2+ channels 
results in an increase in levels of intracellular calcium and a corresponding increase in 
activity of the protein kinase CaMKII. The isoform αCaMKII is specifically implicated in 
the development of synaptic plasticity (Wayman et al., 2008). Activation of protein kinase 
pathways via NMDA receptor activation marks the beginning of a molecular cascade of 
alterations in intracellular protein trafficking, as well as transcriptional, post-transcriptional 
and translation control of protein expression, culminating in the development of structural 
plasticity (Pape & Pare, 2010). 
 
Extinction of the fear response generated in fear conditioning and conditioned taste 
aversion paradigms is of particular use in modelling the persistence of traumatic memories 
associated with PTSD and panic disorder (Ressler et al., 2004; Barad, 2005; Cryan & 
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Holmes, 2005; Ledgerwood et al., 2005; Delgado et al., 2006; Jacobson et al., 2006b). The 
efficacy of the NMDA receptor antagonist D-cycloserine in facilitating fear extinction in 
both the rat fear-potentiated startle paradigm and in human acrophobic patients indicate a 
predictive validity for this approach (Ressler et al., 2004; Davis et al., 2006; Ledgerwood et 
al., 2005). Other drugs that have been shown to alter fear conditioning processes in animals 
and are currently proposed as adjunctive therapeutic agents are propanolol, 
benzodiazepines, SSRIs, yohimbine and glucocorticoids (Graham et al., 2010). In addition 
several novel classes of drug have been put forward as putative anxiolytic strategies 
including fibroblast growth factor 2, brain derived neurotrophic factor (BDNF), histone 
deacetylase inhibitors, oestrogen, the metabolic enhancer methylene blue as well as drugs 
affecting the endocannibinoid (eCB) system such as CB1 agonists and eCB uptake 
inhibitors (Graham et al., 2010). 
 
In order to discuss the extinction of conditioned fear it is imperative to define the qualities 
that define extinction as a behavioural process as opposed to “forgetting”. It is the loss of a 
conditioned behaviour response that is produced through a specific training paradigm that 
is robust and cue specific although not permanent i.e. the extinguished behaviour can 
become re-established by presentation of the US or CS context with spontaneous recovery 
also being observed in some studies (Myers & Davis, 2007). Much like the learning of 
conditioned fear behaviour, the extinction of these behaviours can be broken down into the 
three phases of acquisition, consolidation and retrieval (Quirk & Mueller, 2008). The 
neural processes underpinning fear extinction have a distinct neuroanatomical basis, based 
upon inhibitory input from the ventromedial prefrontal cortex (vmPFC) and the 
hippocampus to the lateral amygdala. Extinction formation is underpinned by NMDA 
receptor dependant cellular cascades that result in the development of synaptic plasticity 
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(Orsini & Maren, 2012). Interestingly, evidence also suggests a crucial role for synaptic 
plasticity in the GABAergic interneurons of the amygdala in the extinction of conditioned 
fear (Pape & Pare, 2010). 
 
1.4 The GABAB Receptor in Anxiety 
Behavioural experiments using GABAB receptor subunit-deficient mice and 
pharmacological manipulation of the GABAB receptor have shown that the GABAB 
receptor clearly plays a vital role in the control of anxiety behaviour (Cryan & Kaupmann, 
2005; Gassmann & Bettler, 2012). The GABAB(1) knockout mouse has a phenotype 
characterized by  hyperalgesia, impaired memory and a susceptibility to epileptiform 
seizures in adult life (Schuler et al., 2001) and behaviourally, displays an increased level of 
anxious behaviour in the light dark box, staircase test and displays a panic type response to 
the elevated-zero maze (Mombereau et al., 2004a), additionally the GABAB(2) knockout 
mouse displays increased anxiety in the light dark box (Mombereau et al., 2005). 
 
Analysing the effects of pharmacological manipulation of the GABAB receptor on anxiety 
behaviour in rodents produces a complex picture. In later life the GABAB receptor 
antagonist CGP36742 has an anxiolytic effect in rats in both the elevated plus maze and 
conflict drinking paradigm and in mice in the four-plate test (Partyka et al., 2007). 
Furthermore in the elevated plus maze in the rat, the GABAB receptor antagonist 
SCH50911 (CGP35024) has shown an anxiolytic effect (Frankowska et al., 2007). It must 
however be said that the GABAB receptor antagonist CGP51176 has no effect in the mouse 
four-plate test (Partyka et al., 2007), chronic treatment with the GABAB receptor antagonist 
CGP56433A has no effect on behaviour in the light dark box paradigm (Mombereau et al., 
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2004a)
 
and that the GABAB receptor antagonist CGP35348 has no effect on anxiety 
behaviour in the elevated-plus maze (Dalvi & Rodgers, 1996). 
 
On the clinical side, the potent selective GABAB agonist baclofen has been shown to be 
effective in treating anxiety symptoms associated with alcohol withdrawal (Addolorato et 
al., 2006) and post traumatic stress disorder (Drake et al., 2003), a more complex picture 
has been observed in rodent models. Baclofen has previously been shown to reduce 
ultrasonic separation vocalisations in mouse pups (Nastiti et al., 1991a), and display 
anxiolytic effects in both the Vogel conflict test and in animal models of drug-withdrawal 
induced anxiety (Cryan & Kaupmann, 2005). More recent evidence suggests that direct 
pharmacological activation of the GABAB receptor by agonists has a limited anxiolytic 
effect in behavioural tests of innate anxiety. Acute treatment with the GABAB receptor 
agonists baclofen and SKF 97541 (CGP 35024) produces no effect on anxiety behaviour in 
the elevated-zero maze in rats (Frankowska et al., 2007) and the agonist CGP 44532 even 
has an anxiogenic effect in the mouse four-plate test (Partyka et al., 2007). 
 
The newly developed GABAB receptor allosteric positive modulators however, are not 
confounded by many of the behavioural side-effects of baclofen and have shown an 
anxiolytic profile in rodents. These compounds act at the GABAB(2) subunit of the GABAB 
receptor causing a conformational change in the receptor increasing the potency and 
affinity of GABA for the receptor (Cryan & Kaupmann, 2005). The positive allosteric 
modulator of the GABAB receptor GS39783 has anxiolytic effects in the in passive 
avoidance test, elevated zero maze and SIH paradigm in mice and in the passive avoidance 
test, elevated-plus maze and elevated-zero maze in rats with no effects on locomotion, 
memory, temperature or cognition. Other positive modulators have shown anxiolytic 
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activity in a host of rodent tests of anxiety behaviour such as GS7930 in the SIH paradigm 
and staircase test in mice as well as the elevated plus maze and elevated zero maze in both 
rats and mice (Partyka et al., 2007; Jacobson & Cryan, 2008)
,
 and the positive modulator 
rac-BHFF in the SIH paradigm (Malherbe et al., 2008). 
 
GABA is well-characterised as playing a crucial role in modulating the acquisition and 
extinction of conditioned fear. GABAergic interneurons within the amygdala have been 
shown to regulate neuronal activity and the induction of LTP, while GAD65 levels are 
notably reduced subsequent to fear conditioning (Johansen et al., 2011). Indeed, 
pharmacological studies have shown that intra-LA infusions of the GABAA  agonist 
muscimol can inhibit the acquisition of conditioned fear (Muller et al., 1997; Wilensky et 
al., 1999). More recent studies however have pointed to a role for the GABAB receptor in 
this process. Studies using GABAB(1a) subunit isoform knockout mice have revealed that 
the receptor functions as a brake on the development of synaptic plasticity at presynaptic 
sites on cortico-amygdala afferents. Indeed genetic ablation of the GABAB(1a) receptor 
isoform results in generalisation of LTP in the amygdala, with animals generalising 
conditioned fear in behavioural assays (Shaban et al., 2006). It has furthermore been shown 
that GABAB receptors specifically inhibit glutamatergic input to primary neurons of the 
amygdala and not to the GABAergic interneurons thus playing a crucial role in the 
maintenance of normal fear-learning behaviour (Pan et al., 2009; Bolshakov, 2009). 
 
The varying nature of these findings points to a complex pharmacological profile for the 
GABAB receptor as a modulator of anxiety behaviour. Different GABAB receptor agonists 
either lack effect, or produce either anxiogenic or anxiolytic effects in different behavioural 
paradigms. GABAB antagonism produces some degree of anxiolytic activity in some 
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behavioural tests. Only positive allosteric modulation of the receptor appears to produce a 
robust anxiolytic effect. The diverse effects elicited by ligands of varying potency may 
suggest that several populations of GABAB receptors with varying pharmacological 
properties are involved in the control of different aspects of anxiety behaviour. The current 
body of evidence surrounding the role of the GABAB receptor in the modulation of anxiety 
states in animal models is summarised in Table 5. 
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Table 5 - The GABAB receptor in anxiety – behavioural evidence.    
Compound Behavioural Test(s) Effect Reference 
Agonists    
Baclofen Separations induced 
vocalisations 
Anxiolytic effect (Nastiti et al., 1991a) 
 Social interaction test 
following social defeat 
0.5, 1 mg/kg anxiolytic. 2mg/kg confounding sedative effects (File et al., 1991) 
 EPM No behavioural effect. 3.0 mg/kg caused non specific behavioural 
disruption 
(Dalvi & Rodgers, 1996) 
 EZM No behavioural effect (Frankowska et al., 2007) 
SKF 97541 EZM No behavioural effect (Frankowska et al., 2007) 
CGP 4453 Four plate test 0.125 mg/kg has anxiogenic effects (Partyka et al., 2007) 
Positive Allosteric 
Modulators 
   
GS39783 EPM  (rats only), EZM (mice 
and rats), SIH (mice only) 
Anxiolytic effects in all tests at all doses (Cryan et al., 2004) 
 LD box (acute + chronic), 
EZM 
Anxiolytic activity in all tests at all doses (Mombereau et al., 
2004a) 
 Geller Seifter test No behavioural effect (Paterson & Hanania, 
2010) 
CGP 7930 EZM Anxiolytic effect at 1mg/kg (Frankowska et al., 2007) 
 SIH, staircase test (mouse), 
EZM, EPM (rat) 
Anxiolytic in mouse SIH (100 mg/kg), staircase (100 and 300 
mg/kg) and EZM (3–100 mg/kg). No anxiolytic effects in the rat 
EPM 
(Jacobson & Cryan, 
2008) 
rac-BHFF SIH Anxiolytic effects at 100mg/kg (Malherbe et al., 2008) 
Antagonists    
CGP 35348 EPM No effect (Dalvi & Rodgers, 1996) 
CGP 56433A EPM No effect (Mombereau et al., 
2004a) 
CGP 35024 (SCH50911) EZM Anxiolytic effects at 1-3 mg/kg (Frankowska et al., 2007) 
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CGP 36742 EPM, conflict drinking test 
and four-plate test 
Anxiolytic effects at 30 mg/kg in all tests  (Partyka et al., 2007) 
CGP 51176 Four plate test No behavioural effect (Partyka et al., 2007) 
CGP 46381 Geller Seifter test No behavioural effect Paterson & Hanania, 
2010) 
Knockout mice    
GABAB(1) KO LD box, staircase test, EZM Enhanced anxiety in LD box, staircase test. Panic response to 
EZM. Reduced benzodiazepine response in LD box 
(Mombereau et al., 
2004a, 2004b) 
GABAB(2) KO LD box Enhanced anxiety (Mombereau et al., 2005) 
GABAB(1a) null LD box, DMB, EPM, EZM. 
Conditioned taste aversion, 
Pavlovian fear conditioning 
No behavioural phenotype in tests of innate anxiety. Fail to acquire 
CTA. Generalise conditioned fear 
(Jacobson et al., 2006b, 
2007b; Shaban et al., 
2006) 
GABAB(1b) null LD box, DMB, EPM, EZM. 
Conditioned taste aversion 
No behavioural phenotype in tests of innate anxiety. Fail to 
extinguish CTA. Normal sensitivity to early life stress in terms of 
visceral hypersensitivity. 
(Jacobson et al., 2006b, 
2007a; Moloney et al., 
2012) 
 
*EPM: Elevated Plus Maze, EZM: Elevated Zero Maze, SIH: Stress-Induced Hyperthermia paradigm, LD box: Light/Dark box 
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1.4.1 Anxiety as a developmental disorder: Role of serotonin 
Evidence is accumulating that an individual’s risk for developing neuropsychiatric 
disorders are strongly determined by early life developmental problems. Central to the 
emergence of this theory are two landmark studies by Avshalom Caspi and colleagues 
demonstrating an interaction between early life stress and a polymorphism of the 5-HTT 
gene, which predisposed to both aggressive behaviour and depression (Caspi et al., 2002, 
2003). Further studies have confirmed and developed upon these studies (for review see 
(Nugent et al., 2011). Recent developmental studies in rodents, using both genetic and 
pharmacological techniques have further elucidated the vital role played by the 
serotonergic system in the development of normal anxiety-related behaviour, particularly 
with regard to the serotonin reuptake transporter and the 5-HT1A receptor (Leonardo & 
Hen, 2008).  
 
Pharmacological studies have indicated that blockade of the serotonin reuptake transporter 
using the SSRI antidepressant fluoxetine during a postnatal days P4-21 results in an anxiety 
phenotype in later life (Ansorge et al., 2004). This effect appears to be mediated solely by 
serotonergic agents and not by noradrenergic acting antidepressants and furthermore 
appears to be dependant on the pharmacokinetic profile of the SSRI used with citalopram 
having a less pronounced effect on anxiety behaviour in adult life than fluoxetine due to its 
shorter elimination half life (Ansorge et al., 2008). Fluoxetine treatment at later periods in 
adolescence, in either the C57BL/6J or BALB/cJ mice, has little effect on conditioned or 
innate anxiety in later life (Norcross et al., 2008).  
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5-HT1A receptor knockout mice display increased anxiety behaviour in models of both 
conditioned and innate anxiety (Gross et al., 2000). Use of a conditional 5-HT1A receptor 
knockout mouse, where 5-HT1A receptor expression can be modulated in a temporal and 
region specific manner has shown that receptor expression rescue, restricted to the post-
synaptic receptors in the forebrain in early postnatal life (prior to P21), is sufficient to 
reverse this behavioural phenotype (Gross et al., 2002). Treatment with a 5-HT1A receptor 
antagonist from P13-34 also produces an increase in anxiety-related behaviour in adult life 
(Lo Iacono & Gross, 2008). Similar treatment with the 5-HT1A receptor antagonist WAY 
100,635 from P0-21 also increases levels of anxiety-like behaviour in both the adolescent 
mouse in the EPM test and in adult mice in the open-field test (Vinkers et al., 2009). 
Transient 5-HT1A receptor antagonist treatment in the third and fourth postnatal week is 
sufficient to induce aberrant conditioned fear responses in the mouse akin to that of a 
knockout phenotype, which can be reversed by the in vivo silencing of the hippocampal 
dentate gyrus cells (Tsetsenis et al., 2007)
 
These findings, taken together, have led to the 
postulation of a period in early adolescent life in the rodent, from P15 to P21, during which 
5-HT1A receptor-mediated signalling and the activity of the serotonin reuptake transporter 
play a vital role in determining levels of anxious behaviour in adult life (Leonardo & Hen, 
2008) (Fig 4). 
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5-HTT suppression P4-21 (Ansorge et al. 2004)
5-HTT suppression P21-49 (Norcross et al. 2008)
P15 P21
5-HT1A expression rescue from P21 (Gross et al 2002)
5-HT1A expression rescue from P15 (Gross et al 2002)
5-HT1A blockade P0-21 (Vinkers et al. 2009)
5-HT1A blockade P13-34 (Lo Iacono and Gross 2008)
 
Figure 4 - The effects of serotoninergic modulation on the early life programming of 
anxiety behaviour. Interventions that result in enhanced anxiety in adult life are depicted in 
pink; those that do not affect anxiety behaviour are shown in green. The literature clearly 
suggests a period of critical period from P15-21 where serotonergic function determines 
adult life anxiety behaviour (Modified from Leonardo and Hen, 2008).  
 
1.4.2 The GABAB receptor – serotonin interaction 
Evidence is growing to suggest a strong reciprocal relationship between the GABAB 
receptor and the serotonergic system at both a behavioural and molecular level. The 
behavioural effects of positive allosteric modulators of  the GABAB receptor are dependant 
on serotonergic activity, being abolished where serotonin is depleted in the mouse brain 
(Slattery et al., 2005a). Further evidence for this interaction has been demonstrated with in 
vitro studies showing that application of GABA or the clinically used GABAB receptor 
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agonist baclofen to the neurons from the dorsal raphe nucleus (DRN), the main location of 
serotonergic cell bodies in the brain, strongly implicated in the behavioural regulation, 
results in an inhibition of serotonin release. These results are suggestive two distinct 
receptor GABAB receptor subgroups in the DRN at both serotonergic neurons and 
GABAergic interneurons (Abellán et al., 2000). This is supported by immunostaining co-
localisation studies which identified GABAB receptors in both serotonergic and 
GABAergic cells of the DRN (Serrats et al., 2003). Interestingly, recent findings have 
shown that GABAB receptor activation, but not blockade in the DRN can increase levels of 
aggressive behaviour. Crucially this increase in aggression can be blunted by activation of 
5-HT1A receptors on serotonergic neurons in this brain region (Takahashi et al., 2010). 
These results both point to a complex mechanism by which the GABAB receptor is 
involved in the regulation of the function of the serotonergic system.  
 
Current evidence suggests that the GABAB receptor and the 5-HT1A receptor share a 
common transduction pathway utilizing G-protein coupled inwardly rectifying potassium 
channels (GIRKs). The capacity of both the 5-HT1A and GABAB receptors to inhibit 
neuronal firing in both the dorsal raphe nucleus and hippocampus are both reduced in the 5-
HTT knockout mouse (Mannoury la Cour et al., 2004).  This is further supported and 
indeed illuminated by pharmacological studies where chronic treatment with the serotonin 
transporter inhibitor, fluoxetine decreases the capacity of both these receptors to recruit 
GIRK channels (Cornelisse et al., 2007). The hypothermic response to both the 5-HT1A 
receptor agonist 8-OH-DPAT and the GABAB agonist baclofen is markedly reduced in the 
GIRK2 subunit null mouse, indicating the GIRK as a key mediator of the anxiety 
modulating effects of drugs which alter the function of these receptors (Costa et al., 2005). 
This suggests a shared transduction pathway for the two receptors, converging on a 
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downstream target, the activity of which can be modulated by fluoxetine. The GABAB 
receptor thus interacts on a molecular level with pharmacological targets heavily implicated 
in the development of the anxiety circuits of the brain. Although the implications of this 
interaction are yet to be elucidated, it seems possible that the GABAB receptor plays a 
functional role in the development of the anxiety circuits by a shared mechanism to 5-HT1A 
receptors. This possible mechanistic convergence in the development of anxiety disorders 
is further supported when we consider that GABAB and 5-HT1A receptor knockout mice 
share not only a behavioural phenotype, but both appear to have lowered levels of forebrain 
benzodiazepine sensitivity. The GABAB receptor knockout mouse appears to exhibit 
resistance to the behavioural effects of benzodiazepines, while the 5-HT1A receptor 
knockout mouse appears to have a reduction in GABAA receptor expression and 
benzodiazepine binding when generated on certain background strains (Sibille et al., 2000).  
 
1.5 Cocaine Addiction 
From a clinical perspective, substance use disorders are described by the diagnostic terms 
“substance abuse” and “substance dependence”. Substance abuse refers to a pattern of 
substance consumption leading to impairment or distress associated with specific social, 
legal and interpersonal problems. Substance dependence differs slightly in that it specifies 
tolerance i.e. (increased doses of drug are required to achieve a rewarding response) and 
presence of withdrawal syndrome in the absence of the substance, a lack of control over 
intake levels to the cost of other activities as well as persistent substance use despite 
obvious deleterious effects on the patients health (American Psychiatric Association, 
2000). In the literature, the more commonly used term “drug addiction” is synonymous 
with the DSM-IV classification “drug dependence” (Koob & Volkow, 2010). It should 
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however be noted that with the publication of DSM-V the diagnostic classification of 
substance use related disorders is likely to be altered to a classification system based on the 
individual drugs being abused by the patient. Additionally the drug abuse/dependence 
dichotomy as described in DSM-IV will likely be removed, with major additions being the 
description of drug craving as a symptom of drug dependence (O’Brien, 2011). 
 
Cocaine is a highly addictive drug and is strongly associated with physical harm, i.e. 
serious cardiovascular disorders, psychiatric illness and increased risk of violence and 
accidents as well as other health risks; with both chronic and acute use (Nutt et al., 2007a; 
EMCDDA, 2010). The last decade has seen a trend for an increase in levels of cocaine 
abuse in Europe, which represents a major emerging public health issue (EMCDDA, 2010). 
There is a growing recognition that medical interventions are crucial in the recovery of 
patients from addiction (Volkow et al., 2011). However, initiation and maintenance of 
treatment for problem cocaine users is intrinsically challenging for clinicians due to social 
and lifestyle factors surrounding cocaine abuse (Penberthy et al., 2010). These issues are 
exacerbated in a context where effective pharmacotherapy for reducing use and 
maintaining abstinence is unavailable (Penberthy et al., 2010).  
 
An alkaloid, derived from the coca plant, cocaine has long been recognised as having 
sympathomimetic effects and acting as a catecholamine reuptake inhibitor. Although, data 
from knockout mice have been controversial (Rocha et al., 1998; Caine et al., 2012) the 
primary pharmacological action, and indeed the mechanism underlying the addictive 
effects of cocaine, is thought to be the blockade of the dopamine transporter. The 
consequence of this is enhancement of both tonic and phasic dopaminergic 
neurotransmission, effectively blurring the distinction between the two (Sulzer, 2011). 
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The behavioural effects of all drugs of abuse can be parsed into three phases; the acute 
binge / intoxication phase, the preoccupation / anticipation phase  and the the withdrawal / 
craving phase with each stage being mediated by different brain circuits and structures 
(Koob & Volkow, 2010).  The primary rewarding effects of cocaine are primarily mediated 
by the mesolimbic dopaminergic system. This system comprises the dopaminergic neurons 
emanating from the ventral tegemental area (VTA) and innervating basal forebrain 
structures such as the nucleus accumbens and dorsal striatum. The acute rewarding effects 
of cocaine are due to the strength of this dopaminergic signal being enhanced at the nucleus 
accumbens (Koob & Volkow, 2010). Several molecular targets have been identified as 
mediating the structural and transcriptional changes that underlie the development of drug 
addiction. These include elements of the cAMP/Creb signalling pathway (Chao & Nestler, 
2004), ΔFosB, a transcription factor whose expression is markedly increased in the reward-
related structures of the brain in response to exposure to almost all drugs of abuse (Nestler, 
2008) as well as molecules related to these pathways such as DARPP-32 (Goodman, 2008). 
ΔFosB is of particular interest as a mediator of the effects of long term exposure to drugs of 
abuse. It is a splice variant of the FosB, a key element of the AP-1 transcription factor, and 
has a particularly long half-life in the brain, persisting for several weeks after drug 
administration has ceased (Nestler, 2008). ΔFosB then mediates addictive behaviours via 
alterations the expression of genes such as dynorphina and mGluR2 reward-related brain 
regions such as the nucleus accumbens (Nestler, 2008). The molecular changes induced by 
chronic cocaine exposure are outlined in Figure 5. 
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Figure 5 – Simplified diagram of a proposed neurobiology of drug addiction. Drugs of 
abuse such as cocaine exert their behavioural effects via enhancement of dopaminergic 
neurotransmission from the VTA to forebrain structures such as the frontal cortex, dorsal 
striatum, nucleus accumbens and the amygdala. The transition from habitual drug use to 
addiction may be based on the induction of transcription factors, in particular ΔFosB, a 
stable truncated splice variant of FosB, in these reward-related brain areas. This induces 
long lasting transcriptional changes that result in alterations to neuronal function and 
ultimately to behaviour. VTA: Ventral tegemental area, Amyg.: Amygdala, N.Acc: Nucleus 
accumbens, D.Stri: Dorsal Striatum, FC: Frontal cortex, DA: Dopamine, DR: Dopamine 
receptor. Adapted from Koob and Volkow, 2010; Nestler, 2008. 
 
 
Current medical interventions for addiction consist of both behavioural and 
pharmacological techniques. Generally speaking, current behavioural techniques are most 
effective at altering the pre-frontal cortex mediated cognitive elements of addiction 
whereas pharmacological treatments tend to target subcortical reward- and mood-regulating 
pathways (Potenza et al., 2011). Pharmacological strategies currently licensed for use in the 
clinic are methadone (μ opioid receptor agonist), buprenorphine (μ opioid receptor partial 
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agonist, κ opioid receptor antagonist) and naltrexone (opioid receptor agonist, also used 
clinically in alcohol addiction) for treatment of opioid addiction; disulfiram (aldehyde 
dehydrogenase inhibitor) and acamprosate (NMDA receptor modulator) for alcohol 
addiction; as well as nicotine replacement therapy, buproprion (dopamine and 
noradrenaline reuptake inhibitor, nAch receptor agonist) and varenicline (α4β2 nAch 
receptor partial agonist and α7 nAch receptor agonist) for nicotine addiction (Potenza et al., 
2011). Currently licensed treatments for drug addiction are listed in Table 6
 Table 6 – Currently licensed drugs for the treatment of addiction  
Drug Clinical Use Drug Class Mechanism of Action References 
Methadone 
 
Treatment of 
opioid 
addiction 
μ opioid receptor agonist, NMDA 
antagonist. 
μ opioid receptor activation results in relief of craving 
and withdrawal symptoms. Blocks the euphoric and 
sedating effects of opiates at steady state 
(Bart, 2012) 
Buprenorphine Treatment of 
opioid 
addiction 
μ opioid receptor partial agonist, 
κ opioid receptor antagonist 
Not fully understood. Buprenorphine acts as an 
antagonist at the μ opioid receptor in the presence of 
full agonists (addictive opioids), but has a low 
dependency liability. 
(Lutfy & Cowan, 2004) 
Naltrexone  Treatment of 
opioid 
addiction, 
alchoholism 
Opioid receptor antagonist Antagonises the behavioural effects of opioid 
administration. Naltrexone reduces the urge to drink, 
antagonises the rewarding effects of alcohol intake and 
causes adverse effects in combination with alcohol 
(Gonzalez & Brogden, 
1988; Hillemacher et al., 
2011) 
Disulfiram  Alcoholism Aldehyde dehydrogenase 
inhibitor 
Produces unpleasant physical effects in the presence of 
alcohol due to acetaldehyde accumulation. 
(Barth & Malcolm, 2010) 
Acamprosate Alcoholism NMDA receptor modulator Thought to prevent development of a hyper-
glutamatergic state subsequent to alcohol withdrawal, 
reducing craving and preventing relapse 
(Mann et al., 2008) 
Nicotine 
Replacement 
Therapy 
Tobacco 
dependence 
 Nicotine from tobacco is replaced with other forms of 
nicotine, (dermal, sublingual administration) easing the 
transition to abstinence. 
(Stead et al., 2012) 
Buproprion Tobacco 
dependence 
Dopamine/noradrenaline reuptake 
inhibitor 
Reduces symptoms of acute nicotine withdrawal, 
inhibits nicotine reward, may decrease cue-induced 
nicotine craving 
(Paterson, 2009) 
Varenicline Tobacco 
dependence 
α4β2 nAch receptor partial 
agonist ( also α7 nAch receptor 
agonist) 
Binds to the α4β2 nAch receptor with a greater affinity 
than nicotine but produces a lesser receptor response, 
thus acting as an agonist when alone (alleviating 
withdrawal and symptom craving levels) while acting 
as an antagonist in the presence of nicotine (blocking 
(Foulds, 2006) 
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the rewarding effects of the drug.) 
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1.6 Animal Models of Drug Abuse 
Like anxiety disorders, in order to explore the pathogenesis of drug addiction and to assess 
novel therapeutic modalities, animal models and tests have been developed. These animal 
models are all based on the clinical features of addicted patients and relate to the three 
proposed stages of the addiction cycle with different models relating to different facets of 
the clinical disorder (Koob, 1995). When modelling drug addiction, as with all psychiatric 
disorders, assessment of the validity of a particular model is based on multiple factors 
described by Geyer and Markou (Geyer & Markou, 2000). Transgenic mice have played a 
crucial role in this process (Sora et al., 2010). The various behavioural paradigms used to 
model drug addiction in rodents are outlined in table 7. 
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Table 7 – Commonly used behavioural models of addiction. Adapted from Koob and Volkow, 2010. 
 
   
 Element(s) of Addiction 
Modelled 
Test Description Reference 
Drug self-adminstration Acute Binge/ Intoxication Animals are trained to self administer drugs of abuse via an 
operant task 
(Koob, 1995) 
Conditioned Place Preference 
(CPP) 
Acute Binge/ Intoxication Animals are trained to associate the rewarding effects of a drug 
of abuse with a previously neutral administration context. 
Preference of the drug associated context is regarded as a 
measure of drug reward sensitivity 
(Tzschentke, 
1998, 2007) 
ICSS reward threshold Acute Binge/ Intoxication, 
Drug Withdrawal 
Animals are trained to deliver rewarding electrical stimuli to the 
brain associated with an operant task. Administration of drugs 
of abuse results in increased thresholds for brain stimulation, 
drug withdrawal results in a decrease. 
(Koob & 
Volkow, 
2010) 
Hyperlocomotor response Acute Binge/ Intoxication Administration of psychostimulant drugs of abuse results in 
increased levels of locomotor activity 
(Morgan et 
al., 2012) 
Drug withdrawal induced 
anxiety 
Withdrawal associated 
negative affect 
Drug withdrawal results in an anxiety-like state measurable 
using common animal models of anxiety-like behaviour 
 
Conditioned Place Aversion 
(CPA) 
Withdrawal associated 
negative affect 
Animals are trained to associate the aversive experience of drug 
withdrawal with a previously neutral context. Animals will 
avoid this context in a free choice situation.  
(Tzschentke, 
1998, 2007) 
Reinstatement of Drug self-
adminstration 
Drug preoccupation and 
anticipation 
Animals previously trained to self administer a drug of abuse 
extinguish the behaviour in the absence of drug. Drug 
administration can be reinstated by exposure to the drug, 
exposure to stress or re-exposure to a drug associated cue. 
(Koob, 1995) 
Locomotor sensitisation Incentive sensitisation Repeated administration of psychostimulant drugs of abuse 
results in progressively enhanced levels of locomotor response. 
Regarded as analogous to the human phenomenon of incentive 
sensitisation. 
(Robinson & 
Berridge, 
2008) 
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16.1.1 Self-adminstration studies 
Beginning with the experiments of James Weeks, who demonstrated that morphine could 
act as a positive reinforcer in rats in an operant task (Weeks, 1962), self-administration 
studies, both in primates and rats, have formed a cornerstone of the preclinical study of 
addiction. It is now known that animals will readily self-administer drugs of abuse to the 
extent of animal self-administration being regarded as a screen for abuse potential of novel 
compounds in man (Koob, 1995). Drug self-adminstration studies take the form of operant 
tasks, whereby animals in particular rats are shown expected to perform set tasks e.g. lever 
presses which are associated with intravenous drug administration. Several variations of 
drug self-adminstration paradigms exist which vary in terms of the pattern of responding 
necessary to achieve the reward. Such response patterns are based on a fixed-ratio 
schedule i.e. drug reward after a fixed number of lever presses; second order schedules, 
multiple order schedules and progressive-ratio schedules where the number of responses 
required to receive the drug reward progressively increases to the point where the animal 
will no longer continue to respond, a so-called breakpoint (Koob, 1995). 
 
Self-administration paradigms primarily model the acute binge intoxication stage of drug 
addiction and are a measure of the acute rewarding potential of the drug; however they can 
also be used to model other aspects of addiction. When performed in drug dependant 
animals, self-adminstration studies can also be used to explore the negative reinforcing 
effects of drug withdrawal (Koob, 1995) or the chronic abuse potential of drugs/conditions 
humans.  
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A major effect of almost all drugs of abuse is the lowering of the brain reward threshold 
(Koob & Volkow, 2010). In animals this effect can be modelled using intracranial self 
stimulation (ICSS) paradigms, where reward associated brain regions are directly activated 
by electrical stimulation in response to an operant response from an animal. These 
responses required to receive electrical brain stimulation are, like in drug self-
administration responses, organised along several different operant response schedules.  
Just as drug administration decreases ICSS thresholds, drug withdrawal can indeed 
increase ICSS thresholds. As such ICSS paradigms can be used to model drug withdrawal 
states. 
 
1.6.2 Conditioned place preference  
Conditioned place preference (CPP) is a Pavlovian training procedure where animals are 
trained to associate different physical environments with the presence or absence of drug 
reward. Then, in a free choice situation, the animal will display a preference for the drug 
associated context, presumably due to association with the positive reinforcing effects of 
the drug. Similarly, animals trained to associate the negative reinforcing effects of drug 
withdrawal with a particular place will develop place aversion. Thus, CPP and conditioned 
place aversion (CPA) can be used to model both the acute rewarding and the negative 
withdrawal effects of drugs of abuse (Koob, 1995; Shippenberg & Koob, 2002, 
Tzschentke, 1998, 2007 ). A typical CPP apparatus is depicted in Fig 5. 
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Figure 5 – 3-compartment CPP apparatus consisting of two choice compartments with a 
central connecting compartment. The choice compartments are distinguished from both a 
visual (Black vs white) and a tactile (Barred floor vs grid floor) perspective with the 
potential for the addition of differential olfactory stimuli. Doors connecting the chambers 
can be closed for conditioning and left open for preference testing. This model 
additionally features a beam-break system for the tracking the movement and location of 
mice. 
 
CPP paradigms present a wide variety of advantages to researchers such as their sensitivity 
to a broad array of drugs of abuse, their capacity for adaptations allowing the study of 
preference reinstatement and drug tolerance as well as their utility in assessing alterations 
in the reward circuitry of transgenic mice (Tzschentke, 2007). The pharmacology of CPP 
has been comprehensively reviewed by Thomas Tzchentke in both 1998 (Tzschentke, 
1998) and 2007 (Tzschentke, 2007).  Conditioned place preference can be generated by 
drugs from across the range of  those commonly abused including amphetamines, cocaine, 
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nicotine, caffeine, opiates, ethanol and benzodiazepines (Tzschentke, 1998, 2007; Bardo & 
Bevins, 2000). 
 
Several methodological issues surround CPP. The most obvious choice is that of whether 
to use a two-chamber or three-chamber apparatus design. Another crucial methodological 
decision is that of biased vs. non-biased study and apparatus design, that is the design of a 
protocol wherein non drug-treated animals display either a clear preference towards one 
chamber (biased design) or spend as much time in all chambers as one would predict via 
probability, i.e. 50%, of total time in each chamber for a two-choice apparatus (unbiased) 
(Cunningham et al., 2006). Other equally important parameters are the time between drug 
exposure and context exposure, the time for which an animal is exposed to the apparatus 
and the duration of time between conditioning sessions (Cunningham et al., 2006). When 
using inbred mice in a CPP experiment, mouse strain also becomes a crucial factor in 
study design, particularly given the manner in which temporal aspects of the experimental 
procedure can alter behaviour in a strain dependent manner (Cunningham et al., 1999). 
 
Bardo and Bevin (2000) succinctly outline the main advantages and disadvantages of CPP 
as a method for studying the pharmacology of drug reward. In addition to the ease of 
conduct and relatively high throughput of CPP, the fact that animals are tested in a drug-
free state, its capacity to detect both reward and aversion, that most protocols also yield 
data on the locomotor responses to drugs, its utility across a broad species range, the 
monophasic dose-response curves typically generated as well as its use in studying the 
neuronal basis of drug reward are particular advantages of the CPP procedure (Bardo & 
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Bevins, 2000; Cunningham et al., 2006). Conditioned place preference testing does, 
however, carry the downsides of difficulty in assessing data where animals display a 
baseline preference, limitations in its utility for generating graded dose-response curves, a 
potential for novelty-seeking behaviour to influence results (particularly where drug 
treatment interferes with context familiarisation), as well as an inherent lack of face 
validity (Bardo & Bevins, 2000). 
 
1.6.3 Locomotor activity  
One of the most commonly used behavioural techniques used in assessing the behavioural 
effects of stimulant drugs of abuse, such as cocaine, is measurement of the 
hyperlocomotor effects of the drug. The popularity of this approach is due to a relative 
ease of measurement and rapidity of output (Morgan et al., 2012). Furthermore, lesion 
studies have demonstrated that the hyperlocomotor effects of both d-amphetamine and 
cocaine are blunted when the mesolimbic dopaminergic system is ablated suggesting that 
hyperlocomotor behaviour may represent a measurable index of dopaminergic activity 
(Kelly & Iversen, 1976). Based on this finding, many studies couple examination of 
locomotor activity with examination of neuronal activation in frontal regions innervated 
by mesolimbic dopaminergic neurons (Lhuillier et al., 2007). 
 
A distinctive feature of the hyperlocomotor effect of cocaine administration is how the 
effect is modulated with repeated dosing, and indeed how the regimen of administration 
and cocaine dose can influence this. As an example of this, when animals are dosed with 
cocaine (40 mg/kg), a tolerance to the locomotor effects is observed, whereas with lower 
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doses a sensitisation effect is seen (Reith, 1986). The context of drug administration also 
appears to be important with animals developing sensitisation to cocaine only when 
delivered in a novel environment (Badiani et al., 1995).   
 
Psychomotor senstisation, the process where psychostimulant drugs generate an enhanced 
locomotor response with repeated administration, is regarded as being a particularly useful 
for modelling the clinical phenomenon of incentive sensitisation (Robinson & Berridge, 
2008). Incentive sensitisation is a proposed theory of drug addiction whereby initially 
neutral stimuli are attributed with increasing levels of incentive salience in response to 
repeated drug administration. This is suggested as a possible mechanism by which drug 
abuse can develop into a drug addiction (Robinson & Berridge, 2008). Although  the 
construct validity of these models is in question due to the lack of free choice in the 
administration paradigm, locomotor sensitisation and tolerance are still useful indices of 
the molecular changes that occur in the brain in response to chronic exposure to drugs of 
abuse (Nestler & Aghajanian, 1997). 
 
1.7 The GABAB Receptor and Addiction  
The GABAB receptor exerts a strong influence in vivo on the reward circuitry of the brain 
and has been suggested as a potentially valuable drug target in the clinical treatment of 
drug addiction (Tyacke et al., 2010; Vlachou & Markou, 2010). Indeed, the prototypical 
GABAB receptor agonist baclofen has been well-characterised as a potentially useful drug 
in the management of cocaine abuse across a wide range of behavioural paradigms in 
animals. In particular the effects of baclofen on cocaine self-adminstration are well-
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characterised. Baclofen dose dependently attenuates cocaine self-adminstration delivered 
in both progressive-ratio (Roberts et al., 1996; Brebner et al., 2000a) and fixed-ratio 
schedules (Shoaib et al., 1998; Brebner et al., 2000a),  in addition to attenuating self-
adminstration in discreet trials based on a predictable circadian pattern of cocaine 
consumption (Roberts & Andrews, 1997). Baclofen furthermore can prevent the 
reinstatement of self-adminstration behaviour (Campbell et al., 1999) and reduce 
responding to drug associated cues in a second-order schedule based paradigm (Di Ciano 
& Everitt, 2003). An attenuation of reinstatement of cocaine self-administration in 
response to baclofen has also been reported in primates (Weerts et al., 2007). Recent 
evidence from a novel animal model of drug self-adminstration, where a fixed response 
results in a decreasing amount of drug, suggests that baclofen selectively decreases the 
amount of effort the animal is prepared to exert for cocaine reward (Oleson et al., 2011). 
The effects of baclofen in progressive-ratio based and discreet-trial paradigms are also 
generated by administration of the GABAB agonist CGP 44532 (Brebner et al., 1999) and 
the effects of baclofen on cocaine, but not heroin, self-adminstration can be blocked by 
concurrent administration of a GABAB receptor antagonist (Brebner et al., 2002) 
confirming that GABAB receptor activation underlies these effects.  
 
GABAB receptor agonist administration can also antagonise several other behavioural 
effects of cocaine in addition to self-adminstration. Baclofen reduces the locomotor 
response of mice to drug-associated cues (Hotsenpiller & Wolf, 2003). Baclofen is also 
effective in preventing the onset of cocaine induced seizures (Gasior et al., 2004).  
GABAB receptor agonism additionally attenuates locomotor sensitisation following 
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chronic cocaine administration (Frankowska et al., 2009). In addition, both blockade and 
stimulation of GABAB receptors can attenuate increases in depression-like behaviour in 
rats following discontinuation of cocaine (Frankowska et al., 2010).  Baclofen, and indeed 
other GABAB receptor-active compounds including antagonists and positive modulators 
have however been demonstrated to have little effect on drug discrimination paradigms 
(Munzar et al., 2000; Filip et al., 2007a). 
 
Several trials have attempted to assess whether baclofen administration is an effective 
intervention in the clinic. Despite the fact that baclofen, at clinically relevant doses, does 
not inhibit the subjective or physiological effects of acute intranasal cocaine consumption 
(Lile et al., 2004), in a pilot randomised placebo controlled trial, cocaine-dependent 
patients maintained on  (-)baclofen, combined with cognitive behavioural therapy (CBT) 
used less cocaine than placebo-treated patients (Shoptaw et al., 2003).  Subsequent studies 
have shown that baclofen can reduce cocaine self-adminstration in the absense of co-
morbid opioid dependancy (Haney et al., 2006) and that baclofen in combination with 
amantadine can indeed reduce self-reported cocaine craving (Rotheram-Fuller et al., 
2007). However, when tested in a multi-centre double-blind clinical trial, baclofen proved 
ineffective in reducing cocaine consumption among heavily dependent users (Kahn et al., 
2009). 
 
The development of potent selective GABAB receptor antagonists and positive allosteric 
modulators has further elucidated the role the GABAB receptor plays in mediating the 
behavioural effects of cocaine. The positive modulators CGP7930 and GS39783 have been 
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demonstrated to reduce cocaine responding on both fixed and progressive-ratio schedules 
of reinforcement (Smith et al., 2004). In addition, the GABAB receptor positive modulator 
CGP 7930 prevents the reinstatement of cocaine seeking behaviour in response to both 
cocaine- and cue-priming without affecting food-seeking behaviour (Filip & Frankowska, 
2007). GS39783 also reduces the acute hyperlocomotor responses generated by cocaine 
administration and cocaine induced biochemical changes in key reward structures in the 
brain such as the nucleus accumbens and the dorsal striatum (Lhuillier et al., 2007). 
GS39783 also inhibits cocaine induced reductions of intracranial self-stimulation 
threshold, a measure of the rewarding effect of drugs of abuse, in rats (Slattery et al., 
2005b).  
 
Chronic administration of GABAB receptor positive modulators reduces nicotine self-
adminstration, but not food-seeking behaviour in rats and can inhibit reinstatement of 
extinguished nicotine-seeking behaviour (Paterson et al., 2008; Vlachou et al., 2011a). 
Furthermore, treatment with GS39783 in a CPP paradigm can reduce the rewarding effects 
of nicotine as well as inhibit ΔFosB accumulation in the nucleus accumbens of nicotine-
treated rats (Mombereau et al., 2007).  Preliminary evidence thus suggests a potential role 
for GABAB positive allosteric modulators in the treatment of cocaine abuse and other drug 
addictions.  
 
The GABAB receptor antagonist SCH 50911 has also been shown to selectively prevent 
(compared to food) the reinstatement of cocaine seeking behaviour in rats (Filip & 
Frankowska, 2007), however other studies have found GABAB receptor antagonism to be 
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ineffective in altering cocaine self-adminstration on a fixed-ratio schedule (Filip et al., 
2007a), suggesting that tonic GABAB receptor signalling may play a role in the 
reinstatement but not the maintenance of cocaine self-adminstration.  
 
It must however be borne in mind that GABAB receptor positive modulators, as well as 
agonists and antagonists have been shown to further increase elevated ICSS thresholds 
during nicotine withdrawal, suggesting an increase in anhedonic behaviour (Vlachou et al., 
2011b) and, consistently with the above study, that both GABAB receptor agonists and 
antagonists have been shown to lower ICSS reward in the absence of a drug of abuse 
(Macey et al., 2001). Controversy also exists as to the selectivity of GABAB receptor 
agonism for cocaine self-adminstration as opposed to general reward circuitry disruption. 
Both baclofen and SKF 97541 prevent the reinstatement of both cocaine- and importantly 
food-seeking behaviour in rats (Filip & Frankowska, 2007). Similarly in primates, GABAB 
receptor agonist administration generates lower rates of drug self-adminstration coupled 
with lower rates of food-dependant task-responding (Weerts et al., 2005).  
 
GABAB receptors are expressed both pre- and postsynaptically in the VTA (Calver et al., 
2002).  The demonstration that GABAB receptors can modulate the activity of mesolimbic 
dopaminergic afferents (Kalivas et al., 1990; Westerink et al., 1996, 1998) strongly 
suggests that the anti-addictive effects of GABAB receptor activation are mediated by this 
pathway. Microinjection of baclofen of directly into the VTA, but not to the striatum and 
nucleus accumbens produces a specific reduction in cocaine administration on a 
progressive-ratio response (Brebner et al., 2000b; Backes & Hemby, 2008). The 
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demonstration that baclofen dose dependently reduces cocaine (as well as other drugs of 
abuse) induced dopamine release in the nucleus accumbens (Fadda et al., 2003) further 
suggested that baclofen exerts its anti-addictive effects by exerting an inhibitory influence 
on the mesolimbic dopamine neurons.  
 
The role of the GABAB receptor in the VTA is complicated when we consider that the low 
potency GABAB agonist γ-hydroxybutyric acid (GHB) is actually an addictive drug of 
abuse (Nicholson & Balster, 2001). The reason for this may lie in the fact that GABAB 
receptors expressed in dopaminergic neurons of the VTA couple to effector molecules 
with a much lower affinity than those expressed in GABAergic neurons. This finding 
suggests that low affinity agonists such as GHB would primarily activate GABAB 
receptors on GABAergic neurons, resulting in disinhibition of the dopaminergic neurons 
in the VTA, whereas baclofen, a high affinity agonist, acts preferentially at GABAB 
receptors on dopaminergic neurons (Cruz et al., 2004). GABAB receptors in the VTA are 
expressed both presynaptically on GABAergic interneurons and postsynaptically on 
dopaminergic neurons projecting to reward structures in the forebrain. The two 
populations of GABAB receptors are pharmacologically distinct, with the GABAB 
receptors located on dopaminergic neurons having a lower EC50 than those located 
presynaptically on GABAergic interneurons (Bettler et al., unpublished observations). The 
manner in which GABAB receptors can thus bidirectionally modulate the reward circuitry 
of the brain in the VTA is depicted in Figure 6. 
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Figure 6 - The dual effects of the GABAB receptor in the VTA. GABAB receptors in the 
ventral tegemental area (VTA) appear to act in two opposing manners. One population of 
GABAB receptors act as post-synaptic receptors, responding to GABAergic input to VTA 
and inhibiting activation of dopaminergic neuronal pathways leading to reward-related 
brain centres such as the nucleus accumbens, dorsal striatum, amygdala and frontal 
cortex. Another population of GABAB receptors act as auto-receptors on GABAergic 
interneurons within the VTA. Activation of these receptors inhibits GABA release from 
these interneurons exerting a net excitatory effect on the forebrain projecting 
dopaminergic neurons. (N. Ac = Nucleus accumbens, D. Striatum = Dorsal Striatum, 
Amyg = Amygdala, FC = Frontal cortex) 
 
It must also be noted that just as GABAB receptors can modulate the behavioural and 
pharmacological effects of cocaine, administration of cocaine can influence the 
functionality of GABAB receptors in vivo. Chronic cocaine treatment in rats can reduce the 
functionality of presynaptic GABAB receptors in several brain regions, including the VTA 
(Shoji et al., 1997; Kushner & Unterwald, 2001; Jayaram & Steketee, 2004); this is 
associated with alteration in Ser –phosphorylation of the GABAB(2) receptor subunit (Xi et 
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al., 2003). The behavioural consequence of this is that the locomotor effects of cocaine 
cannot be attenuated by baclofen in cocaine-sensitised animals (Steketee & Beyer, 2005). 
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1.8 Thesis Goals 
Both anxiety disorders and cocaine abuse both represent emerging crises in health care for 
which current pharmacological care interventions are inadequate. As previously said a 
prerequisite to the development of novel care interventions is dependant on a deeper 
understanding of the processes in the brain underlying the pathophysiology of these 
conditions. The GABAB receptor has been shown to be a key player in modulating both 
the anxiety circuits and the reward pathways that dictate the behavioural response to drugs 
of abuse as being a promising drug target (Cryan & Kaupmann, 2005; Vlachou & Markou, 
2010). However, the mechanisms underlying this remain unclear. The overall aim of this 
thesis is therefore to elaborate on the role of GABAB receptors in both anxiety behaviour 
and brain reward/addiction behaviour using both novel and established pharmacological 
and genetic methods. 
 
Aim 1 -To determine the role played by the GABAB receptor on the development of 
anxiety-related behaviour.  
Given the established role for the serotonergic system in developmentally priming adult 
anxiety behaviour, and the well-established interactions observed between the serotonergic 
system and the GABAB receptor, the question arises as to the role the GABAB receptor 
plays in the early life programming of adult anxiety behaviour and the role of GABAB-
serotonin interactions in this process. This will be examined by administering both 
GABAB receptor agonists and antagonists to mouse pups and assessing their effect on 
anxiety-like behaviour in adult life. In addition, the effects of early life blockade of the 
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serotonin transporter, using SSRIs, on GABAB receptor function in adult life will be 
examined. 
 
Aim 2 – To determine the role of the GABAB receptor in modulating the effects of 
conditioned fear 
Although the effects of GABAB receptor ligands have been well-characterised in animal 
models of unconditioned fear, the effects of these ligands in conditioned fear are less well 
established. Using Pavlovian fear conditioning techniques, the effects of positive 
modulators of the GABAB receptor and GABAB receptor antagonists on both hippocampus 
and amygdala dependant conditioned fear behaviour will be assessed.  
 
Aim 3 -To characterise the anxiety phenotype of the novel GABAB(2)-S892A transgenic 
mouse. 
We have developed a novel transgenic mouse where the serine 892 residue of the 
GABAB(2) subunit has been changed to an alanine residue, markedly altering the 
pharmacological properties of the receptor. This mouse will be characterised in terms of its 
behaviour across a battery of tests for anxiety-related behaviour as well as in terms of its 
GABAB receptor agonist sensitivity. 
 
Aim 4 – To characterise the sensitivity of models of altered GABAB receptor function to 
the behavioural and molecular effects of both acute and chronic cocaine administration. 
As we have seen, an accumulating body of evidence suggests an influential role for the 
GABAB receptor in regulating the behavioural and molecular effects of drugs of abuse. In 
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order to expand on the literature in this field the GABAB(2)-S892A mouse, as well as the 
GABAB(1a) and GABAB(1b) receptor subunit knockout mice will be assessed for alterations 
in sensitivity to the acute rewarding and locomotor effects of cocaine. This will involve 
use of a conditioned place preference paradigm and locomotor activity paradigms in 
addition to biochemical assessment of striatal and accumbens activation in response to 
acute and repeated cocaine administration. We will specifically quantify cFos levels 
subsequent to acute cocaine treatment as a marker of neuronal activation and examine 
FosB levels subsequent to repeated cocaine administration. 
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Activation but not Blockade of GABAB Receptors During 
Early–life Alters Anxiety in Adulthood in BALB/c mice 
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 Abstract  
Although the underlying pathophysiology of anxiety disorders is unknown, it is clear that a 
combination of genetic and environmental factors in early life predispose to disease risk. 
Preclinical research increasingly suggests an important role for the GABAB receptor in 
modulating anxiety behaviour, with GABAB receptor-deficient mice having increased 
anxiety behaviour. Previous studies have highlighted critical windows during development 
where adult anxiety behaviour is primed. However, little is known regarding the role played 
by the GABAB receptors in the developmental processes that underlie adult anxiety 
behaviour.  To this end, we treated male BALB/c mouse pups with the either the selective 
GABAB receptor agonist, R-baclofen (2 mg/kg, s.c), the GABAB receptor antagonist CGP 
52432 (10 mg/kg and 30 mg/kg) or vehicle from postnatal days (PND) 14 to 28. The anxiety 
behaviour of these mice was then assessed in adulthood (PND 62 onwards) in a battery of 
behavioural tests comprising; the Stress-Induced Hyperthermia (SIH) test, the defensive 
marble burying test (DMB), the elevated-plus maze test (EPM) and the forced swim test 
(FST). Postnatal R-baclofen treatment resulted increased anxiety-like behaviour in the EPM 
as shown by approach-avoidance and ethological measures. Other behavioural measures 
were not significantly altered. Interestingl,y blockade of GABAB receptors with the GABAB 
receptor antagonist CGP52432 in early life caused no alterations in emotional behaviour. 
These data suggest that during early life GABAB receptor signalling can play a functional 
role in programming anxiety behaviour in adulthood. The underlying neurodevelopmental 
processes underlying these effects remain to be discovered. 
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2.1. Introduction 
Emerging evidence suggests that anxiety disorders in the adult may be heavily influenced by 
stress during early life as well as various genetic risk factors (Gross & Hen, 2004). 
Longitudinal studies in humans have presented a clear link between polymorphisms in 
genes governing serotonergic function, adverse experiences in childhood and behavioural 
disturbances in adult life (Caspi et al., 2002, 2003).  Moreover, chronic treatment with drugs 
that increase synaptic concentrations of serotonin (selective serotonin reuptake inhibitors) 
are frequently used in the treatment of some anxiety disorders (Hoffman & Mathew, 2008). 
A role for the serotonergic system in developmentally priming anxiety circuits has been 
further bolstered by the demonstration that pharmacological inhibition of either the 
serotonin transporter (Ansorge et al., 2004) or blockade of the 5-HT1A receptor (Vinkers et 
al., 2009) from PND15-21  results in increased anxiety in adulthood in mice (Leonardo & 
Hen, 2008). Moreover, it has been demonstrated that a transient genetic inactivation of 5-
HT1A receptors specifically in the forebrain during early-life (until PND 21) is sufficient to 
increase anxiety levels in adulthood (Gross et al., 2002).  
 
One of the most effective strategies for the acute treatment of anxiety is the positive 
modulation of the GABAA receptor by benzodiazepines such as diazepam (Hoffman & 
Mathew, 2008; Cryan & Sweeney, 2011).  However, it has been demonstrated that transient 
pharmacological positive modulation of the GABAA receptor in mice during early-life from 
both P14-28 and P10-16 results in an anxious phenotype in adulthood (Depino et al., 2008; 
Shen et al., 2012). It has also been shown that partial genetic inactivation of the γ2 GABAA 
receptor subunit on P13-14 also results in enhanced anxiety behaviour in adult life (Shen et 
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al., 2012). Together with the findings from the serotonergic studies, these data suggest that 
there is a period of vulnerability during early life in mice, ranging from P15-21, during 
which alterations in serotonergic and GABAergic neurotransmission can significantly alter 
anxiety behaviour in adulthood (Leonardo & Hen, 2008; Depino et al., 2008; Shen et al., 
2012).  
 
Despite being well-established therapies for the treatment of anxiety disorders, 
benzodiazepines are limited clinically in terms of tolerability (Hoffman & Mathew, 2008). 
This has led to an increasing focus on the GABAB receptor as a drug target in anxiety 
(Cryan & Kaupmann, 2005). The GABAB receptor acts via G-protein coupling to induce 
slow postsynaptic K
+
 mediated neuronal hyperpolarisation and inhibiting Ca2+ channels 
presynaptically, thus inhibiting neurotransmitter release. The recent synthesis of novel 
GABAB receptor-active ligands coupled with the advent of GABAB subunit KO mice has 
revealed a key role for the GABAB receptor in the regulation of anxiety in adult life (Cryan 
& Kaupmann, 2005). Specifically, genetic ablation of either of the GABAB receptor 
subunits throughout life results in an increased anxiety-like behaviour in adulthood 
(Mombereau et al., 2004b, 2005). Interestingly, pharmacological blockade of the GABAB 
receptor in adulthood failed to recapitulate these findings from knockout mice suggesting a 
developmental genesis for the elevated levels of anxiety behaviour seen (Mombereau et al., 
2004a).  However, there is a paucity of evidence regarding the role the GABAB receptor 
plays, if any, in the developmental programming of anxiety behaviour. 
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Thus, we hypothesised that pharmacological modulation of GABAB receptor function 
during adolescence using the GABAB receptor antagonist (CGP52432) or agonist (baclofen) 
may result in alterations in anxiety-related behaviour in adulthood.  
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2.2 Methods 
2.2.1 Animals 
BALB/cOlaHsd mice were used for all studies (Harlan, UK). This strain was chosen as 
GABAB receptor knockout mice that have been tested previously in our laboratory come 
from a BALB/c background.  
 
Mice, aged 6-8 weeks were mated after 1 week acclimatisation to the laboratory. Fathers 
were removed before parturition after which mothers were singly housed with their pups. 
Male pups were weaned at P23 and were housed in groups of 2-5 per cage. Drug 
treatments were distributed randomly between littermates. Mice were maintained on a 12h 
light/dark cycle with lights on at 7.00am.  All experiments were conducted in accordance 
with the European Directive 86/609/EEC, the Recommendation 2007/526/65/EC and 
approved by the Animal Experimentation Ethics Committee of University College Cork. 
All efforts were made to minimize animal suffering and to reduce the number of animals 
used. 
2.2.2 Drug treatment 
Two separate cohorts of male pups were used for the study. One cohort was treated with 
either R(+)baclofen  HCl (2 mg/kg; Sigma; n=10) or with vehicle (phosphate buffered 
saline, PBS; n=13). The second cohort was treated with the GABAB receptor antagonist 
CGP52432 (Tocris; 10, 30 mg/kg; n=10) or vehicle (PBS; n=10). Drugs were freshly 
prepared for injection each day, by dissolution in PBS with vortexing and brief sonication 
at room temperature. Doses of R(+)baclofen and CGP52432 were chosen based on those 
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previously shown to be well tolerated in adult mice (Colombo et al., 2001; Voigt et al., 
2011). All drug treatments were given via subcutaneous injection, once daily from 
PND14-28 in a volume of 0.05ml. This treatment regime was chosen as PND14-28 has 
been demonstrated to be a period of vulnerability to the developmental effects of drugs 
acting on the GABAergic system (Depino et al., 2008). 
2.2.3 Behavioural testing 
Subsequent to drug treatment, animals were allowed to mature to adulthood, prior to being 
tested in a battery of behavioural tests, consisting of SIH (PND62), DMB (PND64), 
EPM(P76) and FST (PND83). Elevated plus maze and forced swim test experiments were 
recorded and subsequently scored by a trained observer who was blind to the treatment 
group. 
2.2.4 Stress-induced hyperthermia 
The Stress-Induced Hyperthermia paradigm is a well validated technique used to measure 
the physiological response to an acute stressor in mice as well as a valid measure of levels 
of innate anxiety (Vinkers et al., 2008) and is particularly useful for determining the 
effects of modulating the GABAergic system on anxiety behaviour (Vinkers et al., 2010). 
Testing was conducted in a similar manner to that previously described (Jacobson & 
Cryan, 2008). Briefly, mice were singly housed 24 hours prior to testing. The rectal 
temperatures were then taken using a thermistor probe ca. 2mm (Model DM852, Ellab, 
Denmark) in diameter inserted 20mm into the mice rectum (T1) for 15 seconds. The 
temperature was measured again 15 minutes later (T2). The increase in temperature due to 
the stress of the initial temperature measurement (T2 value minus T1 value) was taken as a 
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measure of the physiological response to an acute stressor. Mice were returned to their 
home cage immediately after testing. 
 
2.2.5 Defensive marble burying 
The defensive marble burying paradigm provides a measure of active anxiety behaviour 
following an acute stressful challenge. The test was adapted from a protocol previously 
described (Jacobson et al., 2007a). Briefly, mice were placed in the centre of a cage 
(38x25x18cm) containing 4cm of bedding with 20 blue glass marbles (1.5cm diameter) on 
top, arranged in 4 rows of 5 marbles (2cm apart). The lid of the cage was used to prevent 
mice from escaping the test chamber. Mice were allowed to explore the chamber for 30 
minutes and then returned to their home cage.  Following removal of the mouse, the 
number of marbles that were covered in bedding by at least two thirds were counted. 
 
2.2.6 Elevated plus maze 
The elevated plus maze was conducted as previously described (Savignac et al., 2011). 
The apparatus consists of a plus-shaped maze that is elevated by 91cm from the ground.  It 
consists of two enclosed arms and two arms exposed, joined by an intersecting square area. 
This test is a behavioural assay designed to test levels of passive anxiety-like behaviour, 
based on the conflict between the exploratory instinct of the mouse and its aversion to the 
exposed open arms of the maze. Mice were introduced to the centre of the maze facing into 
the open arm and were allowed to explore the maze for a period of 6 minutes. The 
experiment was performed under dim light (circa 30 lux) Parameters measured were time 
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in the open arms, time in the closed arms, entries to the open arms and time in the open 
arms. An animal was judged to have entered an arm of the maze only when all four paws 
were inside the arm in question. In addition to these measures the behaviour of animals in 
the elevated plus maze was assessed in terms of ethological parameters. The behaviours 
analysed were open and protected stretch-attend postures, head-dips and grooming 
behaviours. These were scored based on criteria previously described in the literature 
(Rodgers et al., 2002). 
 
2.2.7 Forced swim test 
The forced swim test is a behavioural test commonly used to assess levels of 
antidepressant-like behavioural activity in mice (Cryan & Mombereau, 2004). Mice are 
placed in glass cylindrical tank containing 17cm of water at 23-25°C for 6 minutes and 
their behaviour is recorded. The length of time the mouse spends immobile, i.e. not 
actively swimming, during the last 4 minutes of the test is scored manually by a trained 
observer blinded to the treatment group.  
2.2.8 Statistical analyses 
Data from the R(+)baclofen and CGP52432 experiments were analysed separately. 
Behavioural parameters in the R(+)baclofen experiment were analysed by Student’s t-test. 
Behavioural analysis in the CGP52432 experiment were analysed via one-way ANOVA 
followed by Bonferonni post-hoc tests where appropriate. Statistical analyses were carried 
out using the Statistical Package for Social Sciences (SPSS) 20.0. P values of less than 
0.05 were considered significant. 
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2.3. Results 
2.3.1 Elevated plus maze 
The effects of early-life treatment with R(+)baclofen or CGP52432 on behaviour on the 
elevated-plus maze are shown in Figure 1. Although the behaviour of control animals 
indicates an inherent innate anxiety this is in line with previous data from our lab and others 
using the BALB/c mouse (Browne et al., 2012). Mice treated with the GABAB receptor 
agonist R(+)baclofen spent significantly less time in the open arm of the elevated plus maze 
(P<0.05; Panel A) and spent significantly more time in the closed arms (p<0.05; Panel B). 
When the ratio of open arm entries to total entries, a measure of anxiety behaviour 
independent of locomotor activity, was calculated, mice treated postnatally with 
R(+)baclofen trended towards a decreased ratio of open arm entries to closed arm entries 
(p=0.07; Panel C). The total number of arm entries was not affected by drug treatment (p= 
0.66; Panel D). Treatment with CGP52432 had no effect on time spent in the open arm 
(F2,23=0.3101, p=0.74; Panel E), time spent in the closed arm (F2,23=0.5160, p=0.60; Panel 
F) or on the ratio of open arm entries to closed arm entries (F2,23=0.6413, p=0.54; Panel G). 
Total arm entries were not affected by drug treatment (F2,23=0.3391, p=0.72; Panel H). 
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Figure 1 - (A)Time in open arm, (B) time in closed arm and (C) ratio of open arm/ total entries in the elevated plus maze by mice treated with 
baclofen and (D) time in open arm, (E) time in closed arm and (F) ratio of open arm/ total entries in the elevated plus maze by mice treated  
CGP52432 early during postnatal development Data are expressed as mean±SEM. Statistical significance of p<0.05 in students t-test versus 
relevant vehicle treated control represented as *.
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Ethological analysis of the behaviour exhibited by baclofen and CGP52432-treated mice is 
exhibited in Figure 2. Mice treated with baclofen in early life displayed a significantly 
decreased total number of head dips (Panel A, p<0.05), and an increased percentage of 
stretch-attend postures (SAPs) in these animals was performed in a protected space (Panel 
D). The percentage of protected head dips showed a trend towards being decreased but did 
not reach significance (p=0.05); Panel B). Total SAPs (p=0.61;Panel C), and grooming 
behaviours were unchanged (p=0.82, ;Panels E) . Early life treatment with CGP52432 had 
no effect on total head dips (F2,23=0.41, p=0.67), percentage of protected head dips 
(F2,23=0.36, p=0.70) total SAPs (F2,23=0.41, p=0.67), percentage of protected SAPs 
(F2,23=1.24, p=0.31) or grooming behaviours (F2,23=0.07, p=0.93) (Panels F-J). 
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Figure 2 - (A) total head dips, (B) percentage of protected head dips, (C) total stretch attend postures SAPs, (D) percentage of 
protected SAPs and (E) grooming behaviours in the elevated plus maze by mice treated with baclofen in early life as well as (F) total 
head dips, (G) percentage of protected head dips, (H) total SAPs, (I) percentage of protected SAPs and (J) grooming behaviours in the 
elevated plus maze by mice treated with CGP52432 in early life. Data are expressed as mean±SEM. Statistical significance of p<0.05 
in students t-test versus relevant vehicle treated control represented as *. 
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2.3.2 Stress-induced hyperthermia 
The effects of early-life treatment with R(+)baclofen or CGP52432 in the stress-induced 
hyperthermia paradigm are shown in Figure 3.  Neither postnatal treatment with 
R(+)baclofen (P=0.263; Panel A) nor CGP52432 (F2,27= 2.197, P = 0.131; Panel C) 
resulted in changes in baseline body temperature (T1) in adult life. However, early life 
treatment with R(+)baclofen tended to increase the hyperthermic response to acute stress 
but this effect  did reach not statistical significance (P=0.07; Panel B). In contrast, 
CGP52432 did not affect the SIH response (F2,27=0.006, P=0.99; Panel D) 
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Figure 3 - (A) Baseline temperatures and (B)stress induced increases in temperature in 
mice treated during early life with baclofen and (C) baseline temperatures and (D) stress-
induced increases in temperature in mice treated during early life with CGP52432. Data 
are expressed as mean±SEM. Significance is expressed as p value from Student’s T-test vs 
vehicle treated control. 
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2.3.3 Defensive marble burying 
The effects of early-life treatment with R(+)baclofen or CGP52432 on behaviour in the 
defensive marble burying paradigm are shown in Figure 4. Neither R(+)baclofen (P=0.75; 
Panel A) nor CGP52432 (F2,26=0.5153, P=0.60; Panel B) had no effect on the number of 
marbles buried by mice in the defensive marble burying paradigm. 
 
Baclofen
0 mg/kg 2 mg/kg
0
2
4
6
8
10
12
14
16
18
20
M
a
rb
le
s
 B
u
ri
e
d
CGP52432
0 mg/kg 10 mg/kg 30 mg/kg
0
2
4
6
8
10
12
14
16
18
20
M
a
rb
le
s
 B
u
ri
e
d
A B
M
a
rb
le
s
 B
u
ri
e
d
M
a
rb
le
s
 B
u
ri
e
d
 
Figure 4 - (A)Number of marbles buried in the defensive marble burying paradigm by 
mice treated in early life with baclofen and (B) number of marbles buried in the defensive 
marble burying paradigm by mice treated in early life with CGP52432. Data are 
expressed as mean±SEM. 
 
2.3.4 Forced swim test 
The effects of early-life treatment with R(+)baclofen or CGP52432 on behaviour in the 
forced swim test are shown in Figure 5.  Postnatal treatment with either R(+)Baclofen 
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(P=0.95; Panel A) or CGP52432 (F2,23=1.208,P=0.31; Panel B) had no effect on the levels 
of immobility seen in the forced swim test. 
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Figure 5 - (A)Time spent immobile during  the forced swim test by mice treated in early 
life with baclofen and (B) time spent immobile during the forced swim test by mice treated 
in early life with CGP52432. Data are expressed as mean±SEM. 
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2.4 Discussion 
The aim of the present study was to investigate the role played by the GABAB receptor in 
the early life processes that govern adult anxiety behaviour.  The main finding of the 
present study is that GABAB receptor plays an important role in programming anxiety 
levels in adulthood. Transient treatment with R(+)baclofen from postnatal days 14-28 
resulted in an increase in anxiety behaviour in the elevated plus maze paradigm in adult 
life with a trend towards increased anxiety behaviour in the stress-induced hyperthermia 
paradigm. Interestingly, an anxiogenic effect was not detected in the defensive marble 
burying test. In further contrast, treatment with the GABAB receptor antagonist CGP52432 
during this period did not produce any distinct anxiety phenotype. Neither treatment with 
the agonist nor the antagonist altered levels of immobility in the forced swim test, an index 
of antidepressant-like drug activity.  
Clinically, there have been some reports of the selective GABAB receptor agonist baclofen 
being effective in treating anxiety symptoms in adults during alcohol withdrawal 
(Addolorato et al., 2006) and post traumatic stress disorder (Drake et al., 2003), a more 
complex picture has been observed in rodent models. Although baclofen has previously 
been shown to reduce ultrasonic separation vocalisations in mouse pups (Nastiti et al., 
1991a), and display anxiolytic effects in both the Vogel conflict test (Ketelaars et al., 
1988) and animal models of drug-withdrawal induced anxiety (File et al., 1992), more 
recent studies have shown that acute treatment with the GABAB receptor agonists baclofen 
or SKF 97541 (CGP 35024) produces no effect on anxiety behaviour in the elevated-zero 
maze in rats (Frankowska et al., 2007) and the GABAB receptor agonist CGP 44532 even 
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has an anxiogenic effect in the mouse four-plate test (Partyka et al., 2007). Most recent 
pharmacological efforts have been directed towards developing positive allosteric 
modulators of the receptor which have a more robust anxiolytic profile in animal while not 
generating the undesirable side-effects of either benzodiazepines or baclofen (Urwyler et 
al., 2001a; Cryan et al., 2004; Cryan & Kaupmann, 2005; Urwyler et al., 2005; 
Frankowska et al., 2007; Partyka et al., 2007; Malherbe et al., 2008) The generally 
anxiolytic effects of GABAB receptor activation in adult life contrast sharply with the 
anxiolytic effects of early life GABAB receptor agonist treatment. 
 
Early-life GABAB receptor blockade did not generate behavioural effects in the current 
study. Similarly, chronic treatment with the GABAB receptor antagonist CGP56433A has 
been shown to have no effect on behaviour in the light dark box paradigm (Mombereau et 
al., 2004a)
 
and that the GABAB receptor antagonist CGP 35348 has no effect on anxiety 
behaviour in the elevated-plus maze (Dalvi & Rodgers, 1996). However, more recently the 
GABAB receptor antagonist CGP36742 has been shown to have an anxiolytic effect in rats 
in both the elevated plus maze and conflict drinking paradigm and, in mice, in the four-
plate test (Partyka et al., 2007). Likewise, the GABAB receptor antagonist SCH 50911 
(CGP35024) has shown an anxiolytic effect in the rat elevated plus maze (Frankowska et 
al., 2007). Furthermore, when GABAB receptor function is genetically ablated the resulting 
phenotype is characterised by heightened anxiety behaviour as well as by antidepressant-
like behaviour (Mombereau et al., 2004b, 2005). While the bidirectional behavioural 
effects generated by adult pharmacological blockade of the GABAB receptor and lifelong 
loss of GABAB receptor function suggest a developmental basis for the phenotype of the 
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GABAB subunit knockout mouse, the current data suggests that impaired GABAB receptor 
function in early life is not sufficient to generate an anxiogenic phenotype in adulthood.  
Recent data has suggested that anxiety and depression like behaviours in rodents are 
critically controlled by GABAergic neurotransmission at discreet neurodevelopmental 
periods. Partial genetic inactivation of the γ2 subunit of the GABAA receptor has been 
shown to induce deficits in anxiety behaviour in adult life when induced from PND13-14, 
and deficits in antidepressant like behaviour when induced from PND27-28 (Shen et al., 
2012). Likewise, GABAA receptor potentiation with benzodiazepines appears to generate 
enhanced anxiety behaviour in adult life when administered from P10-16 and pro-
depressant behaviour when administered from PND29-32 (Shen et al., 2012).  The 
treatment period used in our experiment appears thus to extend into a critical 
neurodevelopmental period that governs forced swim test behaviour (PND27-P32), 
however neither baclofen nor CGP52432 altered adult life behaviour in the forced swim 
test. This suggests that this critical period is influenced by GABAA mediated 
neurotransmission, but not by GABAB receptor function. 
 
To our knowledge, only one study has previously looked at the effects of GABAB receptor 
antagonism early during postnatal development on behaviour in adulthood. This study 
examined the short and long term effects of a seizure generating dose of the GABAB 
receptor antagonist CGP56999A to rat pups at P15. The seizures generated were primarily 
hippocampal in nature. These rats furthermore exhibited long term reductions in 
hippocampal GABAB receptor activity coupled with an increased susceptibility to seizures 
induced by hippocampal kindling (Tsai et al., 2008). This may suggest that treatment with 
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GABAB receptor antagonists in early life may alter hippocampal dependant fear 
behaviours, such as context specific conditioned anxiety, in contrast to the unconditioned 
anxiety testing in the current study. 
 
The neurobiological circuits, pathways and substrates that are altered by early-life 
treatment with GABAB receptor agonists and thereby generating an anxious phenotype in 
adulthood remain to be elucidated.  However, given the role of the developing serotonergic 
system in programming anxiety in adulthood (Leonardo & Hen, 2008), it is possible that 
alterations in serotonergic neurotransmission may underlie some of the behavioural 
changes observed in the present study. Indeed, activation of GABAB receptors generated 
by systemic administration of baclofen can exert bi-directional effects on serotonin release 
from DRN serotonergic neurons (Abellán et al., 2000). Based on these findings it is 
plausible to suggest that baclofen may be acting preferentially on the presynaptic GABAB 
autoreceptors, resulting in a decrease in GABAergic inhibition of the serotonergic neurons 
of the DRN and a resultant increase in serotonin release during this sensitive period in the 
development of the anxiety circuits. This is supported by recent work demonstrating that 
direct application of baclofen, but not GABAB receptor antagonists to the DRN can 
increase aggression in mice, which can be blunted by 5-HT1A receptor-mediated inhibition 
of serotonergic neurons in the DRN (Takahashi et al., 2010). Furthermore, the failure of 
GABAB antagonists to alter serotonergic tone and modify aggressive behaviour in this 
study may explain the lack of effect of early-life exposure to CGP52432 on adult anxiety 
behaviour, even at doses which have been shown previously to produce a behavioural 
response in mice (Colombo et al., 2001). 
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Another mechanism underlying the developmental effects of baclofen treatment seen in the 
current study may be interactions between the GABAB receptor and glutamatergic 
neurotransmission. Glutamate receptors play a crucial role in regulating anxiety behaviour 
(O’Connor et al., 2010) and the GABAB receptor has been demonstrated to be a regulator 
of glutamatergic neurotransmission via its function as both an autoreceptor and post-
synapitc receptor on glutamatergic neurons (Waldmeier et al., 2008). It is thus conceivable 
that alterations in glutamatergic neurotransmission in early life may have long-lasting 
effects on anxiety behaviour. Similarly robust interactions have been demonstrated 
between the GABAB receptor and the dopaminergic system (Cruz et al., 2004; Vlachou & 
Markou, 2010). These interactions may also influence the neurodevelopmental processes 
that underlie adult anxiety behaviour. 
 
In vitro studies on cultured hippocampal neurons have revealed that baclofen can alter 
expression of mRNA transcripts for a variety of genes which play a key role in neural 
migration, proliferation, survival and synaptogenesis such as BDNF, butylcholinesterase 
and Rho-GTPase activating protein 4 (Ghorbel et al., 2005) and that protein and mRNA 
levels of the neurotrophins brain-derived neurotrophic factor (BDNF) and nerve growth 
factor (NGF) in the spinal cord are elevated by GABAB receptor antagonists (Heese et al., 
2000). Alteration of these important factors in determining neural growth and proliferation 
may represent a pathway by which the GABAB receptor mediates its early life effects.   
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An important caveat in the current study is the use of the inbred BALB/cJ mouse strain. 
Mouse strain plays an important role in determining the sensitivity of mice to the acute 
effects of treatment with baclofen (Jacobson & Cryan, 2005)  suggesting the possibility 
that the effects of early life baclofen may not be identical in different strains. Furthermore, 
BALB/cJ mice, despite being resistant to the lethal effects of GABAB receptor subunit 
knock-out (Schuler et al., 2001) are also associated with increased levels of anxious 
behaviour in tests of anxiety relative to other mice strains (Jacobson & Cryan, 2007). This 
may result in a “ceiling” effect where potentially anxiogenic interventions may induce 
little effect on due to already maximal levels of anxiety. 
 
The treatment period used in this study, P14-28 is equivalent to the perinatal and early 
childhood period in humans (Khazipov & Luhmann, 2006). The study thus raises a 
concern that clinical use of baclofen during pregnancy and in paediatric patients may carry 
a risk of long term vulnerability to emotional disorders. Although baclofen use in 
pregnancy is reported in the literature, administered both intrathecally and orally (Moran et 
al., 2004; Morton et al., 2009) as well as in paediatric patients (Borowski et al., 2010), 
little is known about the long term effects on emotional behaviour of early life baclofen 
treatment in humans. However, alterations in GABAB receptor activity may also be 
involved in the pathogenesis of foetal alcohol syndrome (Lee et al., 2008), a syndrome 
associated with maternal alcohol consumption during pregnancy which is, in part, 
characterised by neuropsychiatric disorders including an increased incidence of emotional 
disorders (O’Connor & Paley, 2009). The treatment period used in the current study also 
extends into periadolescence, a period hypothesised to be associated with increased 
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vulnerability to stress induced behavioural disorders (Sturman & Moghaddam, 2011; 
Buwalda et al., 2011). The current data raise the possibility that the GABAB receptor may 
be an important substrate in modulating the impact of environmental and social stress in 
this period.  
 
 The present study provides further evidence for the involvement of altered GABAB 
receptor function in the development of neuropsychiatric illness, however, it must be 
remembered that the neurodevelopmental processes that determine adult levels of anxiety 
behaviour are dependant on a number of different neurotransmitter systems and the precise 
manner in which these systems interact is unclear. Likewise the manner in which 
environmental and genetic factors influence these processes remain to be elucidated.  A 
deeper understanding of these processes and their neurochemical underpinning may allow 
for a more clear insight into the pathophysiology of anxiety disorders and indeed allow for 
more effective clinical interventions. 
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Abstract 
A significant body of data from both population based studies and from behavioural 
studies in animals has demonstrated that early life serotonergic function is a crucial 
determining factor in adult anxiety behaviour. In particular it has been demonstrated that 
perturbation of serotonergic neuorotransmission in early life via treatment with selective 
serotonin reuptake inhibitors (SSRI) antidepressants or transient genetic inactivation of 
serotonergic receptors, results in marked increases in adult anxiety behaviour in mice. In 
parallel with these findings has been the realisation that the GABAB receptor has a major 
role in regulating anxiety behaviour, with GABAB receptor knockout mice displaying 
pronounced increases in anxiety-like behaviour. Furthermore, the GABAB receptor has 
been shown to closely interact with the serotonergic system. Indeed, the antidepressant-
like effects of GABAB receptor antagonists seen in animal models are ablated when 
animals are depleted of serotonin. We therefore sought to examine if the anxiolytic effects 
of early life SSRI treatment were associated with alterations in GABAB receptor function. 
 
To investigate this we first treated C57/BL6 mice pups from PND 14-28 with the SSRI 
antidepressant fluoxetine (0, 5, 10 mg/kg via s.c. injection). Once these animals reached 
adulthood we examined the anxiety behaviour of these mice in the light-dark box and 
novelty-suppressed feeding paradigms. We also examined GABAB receptor function by 
measuring the hypothermic and ataxic effects of baclofen as well as the hypothermic 
effects of the 5-HT1A agonist 8-OH-DPAT in these mice. The mice displayed a mildly 
anxious phenotype in the light-dark paradigm, but displayed no alterations in baclofen 
sensitivity. The mice did, however, display enhanced sensitivity to the hypothermic effects 
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of 8-OH-DPAT. Overall, our data suggest that early life fluoxetine treatment does not alter 
GABAB receptor function in adult life. 
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3.1 Introduction 
Interactions between stress and genes governing serotonergic function in early life appear 
to be predisposing factors for psychiatric disease in adulthood (Caspi et al., 2002, 2003). 
This finding has been expanded upon by animal models which have demonstrated clearly a 
pivotal early life period in mice (P15-21), where serotonergic tone exerts a strong 
influence on adult anxiety behaviour (Leonardo & Hen, 2008). In mice, transient genetic 
inactivation or pharmacological blockade of the 5HT1A receptor during this period results 
in increased anxiety in adulthood in a variety of behavioural tests (Gross et al., 2002; 
Vinkers et al., 2009). Treatment of mice in early life with the SSRI antidepressant 
fluoxetine from P4-21 has been shown to robustly enhance anxiety-like behavioural 
responses in a host of behavioural tests (Ansorge et al., 2004; Karpova et al., 2009). 
However, although some studies have shown enhancements in brain derived neurotrophic 
factor (BDNF) mRNA expression in adult life subsequent to early life fluoxetine treatment 
(Karpova et al., 2009), the mechanisms that underlie the changes in behaviour resulting 
from early life alterations in serotonergic signalling and the molecular sequelae of early 
life SSRI treatment remain to be fully elucidated. 
 
The GABAB receptor has recently been identified as a key substrate in regulating anxiety-
like behaviour in animals and as a potential target for novel anxiolytic drugs (Cryan & 
Kaupmann, 2005). Molecules that act to enhance the activity of GABAB receptor activity, 
positive allosteric modulators have been characterised as having a broadly anxiolytic effect 
in animal models of anxiety (Cryan et al., 2004; Mombereau et al., 2004a; Frankowska et 
al., 2007; Jacobson & Cryan, 2008; Malherbe et al., 2008), whereas genetic models wherein 
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either GABAB receptor subunit is knocked out, display enhanced levels of anxiety 
(Mombereau et al., 2004a, 2005). 
 
Behavioural data suggests that the behavioural effects of the GABAB receptor antagonists 
are mediated to some degree via interactions with the serotonergic system with the anti-
depressant like effects of GABAB receptor antagonist being abolished when serotonin is 
depleted in the brain (Slattery et al., 2005a). Furthermore, it has been shown that the 
increase in aggressive behaviour in mice induced by GABAB receptor agonists can be 
reduced by 5-HT1A receptor blockade in the dorsal raphe nucleus (Takahashi et al., 2010). 
GABAB receptor mRNA is indeed expressed in both serotonergic neurons and GABAergic 
interneurons in the DRN (Serrats et al., 2003), and activation of these receptors in vitro can 
influence serotonin release (Abellán et al., 2000). 
 
Of particular interest in the GABAB-serotonin interaction is the relationship between the 
GABAB receptor, the 5-HT1A receptor and the serotonin transporter (5-HTT). Both the 
GABAB receptor and the 5-HT1A receptor act via recruitment of G-protein coupled 
inwardly rectifying potassium channels (GIRKs). Indeed the GIRK knockout mouse 
displays a reduced sensitivity to the hypothermic effects of both GABAB and 5-HT1A 
receptor agonists (Costa et al., 2005). More interestingly, genetic knockout of 5-HTT 
results in a reduced function for both of these receptors (Mannoury la Cour et al., 2004) 
and chronic pharmacological inhibition of 5-HTT function with fluoxetine results in both 
receptors displaying a reduced capacity to recruit GIRKs (Cornelisse et al., 2007). Both the 
GABAB receptor and the 5-HT1A receptor thus appear to share a transduction pathway, the 
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activity of which can be modulated by chronic fluoxetine treatment. However the effect of 
early life fluoxetine treatment on the functional properties of these two recep,tors in adult 
life is not currently known.  
 
Given that GABAB receptor subunit expression has been shown to be altered in a mouse 
model of altered anxiety behaviour (Bravo et al., 2011) and that the serotonergic system 
and the GABAB receptor display these strong reciprocal interactions, it is possible that 
GABAB receptor function may be altered in adult life subsequent to early life SSRI 
treatment. We intend, using the pronounced hypothermic and ataxic effects of the GABAB 
receptor agonist baclofen (Jacobson and Cryan, 2005) and the 5-HT1A receptor agonist 8-
OH-DPAT (Vinkers et al., 2008), as outputs of receptor function in adulthood, to examine 
whether the anxiogenic effects of early life SSRI treatment are coupled with alterations in 
GABAB and 5-HT1A receptor function. 
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3.2 Methods 
3.2.1 Animals 
Male and female C57/BL6 aged 6-8 weeks were acquired from Harlan laboratories, UK. 
After 1 week acclimatisation to the laboratory mice were mated. Fathers were removed 
before parturition after which mothers were singly housed with their pups. Male pups were 
weaned at P23 and were housed in groups of 2-5 per cage. Drug treatments were 
distributed randomly between littermates. Mice were maintained on a 12h light/dark cycle 
with lights on at 7.00am.  All experiments were conducted in accordance with the 
European Directive 86/609/EEC, the Recommendation 2007/526/65/EC and approved by 
the Animal Experimentation Ethics Committee of University College Cork. All efforts 
were made to minimize animal suffering and to reduce the number of animals used. 
 
 
3.2.2 Drug treatment 
Male pups were treated with fluoxetine (5,10 mg/kg; Sigma; n=10/11) or with vehicle (0.9% 
saline; n=11). Drugs were freshly prepared for injection each day, by dissolution in saline 
with vortexing. Fluoxetine or vehicle was given via subcutaneous injection, once daily from 
PND14-28 in a volume of 0.05ml. The treatment regime was chosen to include the period 
from PND15-21, that appears to be the critical period in which serotonergic perturbations 
result in altered adult anxiety behaviour (Leonardo & Hen, 2008).  
 
 
  
 106 
3.2.3 Behavioural testing schedule 
Subsequent to drug treatment, animals were allowed to mature to adulthood before being 
tested, beginning from ages of 9-10 weeks, in a battery of assays consisting of a light-dark 
box, rotarod performance and temperature sensitivity to baclofen and then 8-OH-DPAT 
followed by a novelty suppressed feeding assay. Animals were given at least 4 days between 
each test to recover and allow for wash out of drugs. 
 
3.2.4 Light dark box 
The light dark box is a behavioural test used to assess levels of unconditioned anxiety in 
rodents based on levels of passive avoidance behaviour. The apparatus consisted of a 
Plexiglas enclosure (44 × 21 × 21 cm) comprised of two adjoining compartments (one light 
and one dark). The light compartment had transparent Plexiglas walls and had an open top. 
Bright lighting (approximately 1,000 lx) was used to generate aversive conditions in this 
compartment. The dark compartment (14 cm width) consisted of a black Plexiglas wall and 
roof. The compartments were connected by a small opening (12  × 5 cm) at floor level. 
Animals were placed in the light compartment facing away from the dark compartment and 
were allowed to freely explore the apparatus for 10 minutes. During this period the 
behaviour of the animals was recorded. The latency of the animal to enter the dark 
compartment of the apparatus, the number of transitions between the two compartments and 
the total time spent in the light compartment were measured. An animal was adjudged to 
have entered a compartment when all four paws had crossed the threshold. The number of 
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faecal pellets produced by each animal during the test period was also recorded as a measure 
of the physiological response to a stressful stimulus. 
 
3.2.5 8-OH-DPAT and baclofen sensitivity measurements 
Mice were singly housed over night prior and acclimatised to the testing room for at least 
one hour prior to testing. Temperature was measured using a thermistor probe of 2mm in 
diameter (Ellab, Denmark – Model DM852). The thermistor probe was lubricated with 
petroleum jelly and inserted roughly 20mm into the rectum until a stable temperature was 
achieved (10-15s).  Measurement of the ataxic effects of baclofen was assessed via rotarod 
endurance. The rotarod (Ugo Basile, Italy - Model 47600) was set at 12RPM and each trial 
lasted for a maximum of 300 seconds. Endurance was determined by the time taken before 
mice fell off the rotarod. Mice clinging to the rotarod for more than 80% of the 300 
seconds test time were given a score of zero. Mice clinging to the rotarod for less than 
80% of the 300 seconds only had their time spent actively walking on the rotarod 
measured. 
3.2.6 Novelty suppressed feeding test 
The novelty suppressed feeding test is a measure of anxiety-like behaviour wherein 
animals that have been food deprived are presented with a novel food in the context of a 
novel environment. A conflict thus between the anxiogenic stimulus and hunger-induced 
approach behaviour. Clinically used anxiolytics reduce the latency of the animal to 
approach the food (Bodnoff et al., 1988, 1989). Animals were singly housed and food 
deprived overnight before being transported to the testing room for at least one hour of 
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acclimatisation. The apparatus consisted of a plexiglas cylinder (diameter - 24 × 21 cm) 
placed on white paper with a small well (1.2cm diameter x 0.9cm height) secured in the 
middle. The novel food used for the experiment was sweetened condensed milk mixed 
with equal amounts of water. Light levels were maintained at 100 lux. Animals were 
placed in the apparatus facing away from the well. Latency until the mice had commenced 
drinking for at least two seconds was measured. A cut off of 120 seconds was observed for 
each individual test session. 
3.2.6 Statistical analyses 
Behavioural results from the light dark box and novelty suppressed feeding test were 
analysed via one-way ANOVA followed by Bonferonni post-hoc tests where appropriate. 
The locomotor and hypothermic responses of mice to OH-DPAT and baclofen were 
analyses by repeated measures two-way ANOVA, followed by Bonferonni post-hoc tests 
where appropriate. Statistical analyses were carried out using the Statistical Package for 
Social Sciences (SPSS) 20.0. P values of less than 0.05 were considered significant. 
 
3.3 Results 
3.3.1 Light dark box 
The effects of early-life treatment with fluoxetine on behaviour in the light-dark box are 
shown in Figure 1. Mice treated with fluoxetine produced significantly greater numbers of 
faecal pellets in the apparatus compared to non-treated animals as revealed by one way 
ANOVA (F2,29=3.55, p=0.042; Panel A). Bonferroni post-test revealed no significant 
difference between individual treatments. One-way ANOVA revealed no significant effects 
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of drug treatment on latency to enter the dark chamber (F2,29=1.96, p=0.159; Panel B), time 
spent in the light (F2,29=0.11, p=0.89; Panel C) or total number of light-dark transitions 
(F2,29=0.86, p=0.43; Panel D). 
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Figure 1 - Behavioural phenotype of mice treated in early life with fluoxetine on behaviour 
in the light-dark box paradigm. A) Faecal pellet production, B) latency from entry into the 
box until entry into the dark compartment, C) time spent in the light side of the 
compartment and D) number of transitions from light to dark chamber and vise-versa. 
Data displayed in panels A,B and D as mean +/- SEM. Data displayed in panel B as mean 
with individual data points. 
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3.3.2 Baclofen challenge 
The hypothermic and ataxic effects of baclofen in mice treated in early life with fluoxetine 
are shown in Figure 2. Mice treated with baclofen from all groups displayed transient 
hypothermia (Panel A) coupled with transient ataxia (Panel B) subsequent to baclofen 
administration. Two-way ANOVA revealed no effect of early life fluoxetine treatment on 
sensitivity to the hypothermic (F2,29= 0.2703, p= 0.76) or ataxic (F2,29=0.11, p=0.89) 
effects of baclofen. 
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Figure 2- Physiological sensitivity of mice treated in early life with fluoxetine. A) Effects of 
baclofen (4mg/kg IP) on rectal temperature of mice. Data is displayed as difference in 
temperature from baseline (T0). Data represented as mean +/-SEM. B) Effects of 4 mg/kg 
baclofen on rotarod endurance in mice over 300 seconds. Data represented as mean +/-
SEM. 
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3.3.3 OH-DPAT challenge 
The hypothermic effects of 8-OH-DPAT in mice treated in early life with fluoxetine are 
shown in Figure 3. Mice treated with 8-OH-DPAT all displayed transient decreases in 
body temperatures from baseline subsequent to 8-OH-DPAT treatment. A trend was 
observed towards a significant effect of treatment on sensitivity to the hypothermic effects 
of 8-OH-DPAT (F2,29= 3.10, p= 0.06) suggesting that animals treated with fluoxetine in 
early life were more sensitive to the hypothermic effects of 8-OH-DPAT. 
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Figure 3 -Effects of 8-OH-DPAT (1 mg/kg, IP) on rectal temperature of mice treated in 
early life with fluoxetine. Data is displayed as difference in temperature from baseline 
(T0). Data represented as mean +/-SEM. 
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3.3.4 Novelty suppressed feeding (NSF) test 
Latency for animals to eat in the novelty suppressed feeding test is shown in Figure 4. 
Treatment in early life with fluoxetine had no effect of latency to eat in the novelty 
suppressed feeding test (F2,23=0.24, p=0.79). 
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Figure 4- Latency to eat of mice treated with fluoxetine in early life in a novelty 
suppressed feeding paradigm. Data is expressed as mean +/-SEM. 
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3.4 Discussion 
While treatment with fluoxetine from P14-28 produced mild anxiogenic effects in the 
light-dark box paradigm, but not in the novelty suppressed feeding test, no alterations in 
sensitivity to the hypothermic effects of baclofen were observed. Animals treated with 
fluoxetine in early life did, however, display enhanced sensitivity to the hypothermic 
effects of the 5HT1A receptor agonist 8-OH-DPAT. Our results, thus, suggest that the 
anxiogenic effects of early life SSRI treatment are not due to alterations in GABAB 
receptor function, but that enhanced 5-HT1A receptor function may play a role in this 
phenotype.  
 
The lack of alterations in GABAB receptor sensitivity seen in this study is in some ways 
unsurprising given the crucial role played by the GABAB receptor in maintaining general 
inhibitory control in the brain. Indeed in the vast majority of inbred mouse strains, 
knockout of functional GABAB receptors results in inevitable mortality due to 
uncontrollable seizures (Prosser et al., 2001; Schuler et al., 2001). It is also of note that 
GABAB receptor function is regulated by a vast number of regulatory pathways including 
kinase mediated phosphorylation and varying patterns of subunit composition (Terunuma 
et al., 2010a; Pinard et al., 2010; Gassmann & Bettler, 2012). This plethora of regulatory 
mechanisms, taken with the crucial importance of the GABAB receptor to normal brain 
function suggests a high level of redundancy leading to relatively stable levels of function 
in vivo. 
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While measurement of the ataxic and hypothermic effects of baclofen is a useful tool for 
demonstrating broad disparities GABAB receptor sensitivity (Jacobson & Cryan, 2005), it 
ultimately remains a crude tool. Evidence is growing to suggest that GABAB receptor 
function differs throughout the brain, with different regions displaying markedly different 
receptor kinetics (Pinard et al., 2010). Investigation of levels of baclofen induced γGTP 
recruitment in various brain regions in vitro may give a more detailed insight into the 
effects of early life SSRI treatment on adult life GABAB receptor function. Moreover, the 
discovery that GABAB receptor function is markedly altered by not only phosphorylation 
states but by association with a broad range of effector components (Gassmann & Bettler, 
2012) suggests that in order to thoroughly investigate the effects of any intervention on 
GABAB receptor function, detailed analysis of all these factor is required.  
 
The inbred mouse strain used in our experiment may also have influenced our results. 
C57BL/6 mice were chosen for our study, as other groups have demonstrated repeatedly 
that this strain is vulnerable to the anxiety provoking effects of early life SSRI treatment 
(Karpova et al., 2009), however given that baclofen sensitivity differs markedly between 
inbred mouse strains (Jacobson & Cryan, 2005), it is impossible to rule out the possibility 
that were other strains treated with fluoxetine in early life, alterations in baclofen 
sensitivity would be observed. 
 
A longstanding hypothesis regarding the actions of SSRI antidepressants at a molecular 
level, is that they induce a downregulation of 5-HT1A receptor function (Stahl, 1998). 
Furthermore, the 5-HT1A receptor has been shown to critically modulate the development 
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of normal anxiety behaviour in mice (Gross et al., 2002). It is thus intriguing that in our 
study, animals treated with fluoxetine in early life displayed enhanced sensitivity to the 
hypothermic effects of 8-OH-DPAT, which suggests enhanced levels of 5-HT1A receptor 
function. Reduced levels of 5-HT1A receptor expression has been observed in animals 
treated in early life with clomipramine (Kim et al., 2012), interestingly, this alteration was 
reversed by social defeat stress in this study. Animals with constitutionally downregulated 
5-HTT expression display no alterations to 5HT1Areceptor function (Bordukalo-Niksic et 
al., 2010). 
 
The interactions observed between the serotonin transporter, 5HT1A receptor and the 
GABAB receptor make it interesting to speculate as to the potential molecular links that 
underlie the changes in 5HT1A receptor function. Although the GABAB receptor and 5-
HT1A receptor share a transduction pathway that can be regulated by SSRI administration 
(Cornelisse et al., 2007), in our study fluoxetine treatment had specific effects of 
fluoxetine on OH-DPAT as opposed to baclofen sensitivity. This suggests that early life 
fluoxetine treatment affects 5HT1A receptor function at the level of receptor expression or 
serotonergic tone rather than at the level of an effector pathway. 
 
Early life treatment with fluoxetine produced a mild anxiogenic effect in the light dark box 
in terms of faecal pellet production, but not in terms of any of the exploratory outputs 
measured. Treatment did not produce any alterations in behaviour in the hyponeophagia 
paradigm. These mild effects are somewhat unexpected given the robustly anxiogenic 
effects of early life fluoxetine treatment seen in the literature. Previously deficits in 
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exploratory behaviour in mice subsequent to early life fluoxetine treatment have been 
observed in the open field test, the elevated plus maze and the light-dark box (Ansorge et 
al., 2004, 2008; Karpova et al., 2009). Enhanced latency to eat in a novel environment has 
also been observed in animals treated with fluoxetine in early life (Ansorge et al., 2004, 
2008), but was not observed in our study. It must be borne in mind here that alterations in 
the nature of the food used (novel palatable food vs normal chow) and environment can 
alter the levels of stress and anxiety generated in a novelty suppressed feeding paradigm 
(Cryan & Sweeney, 2011). Subtle changes to our protocol from those used by other groups 
may have contributed to our failure to see changes. It is also of note that our treatment was 
administered daily via IP injection as opposed to administration orally via water supply 
(Ansorge et al., 2004, 2008; Karpova et al., 2009). Pharmacokinetic variation between the 
two administration protocols may have thus resulted in a less robust phenotype being 
generated. Taken together our data suggests that early life SSRI treatment does not exert 
its anxiogenic effectsm via alterations in GABAB receptor function. 
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Abstract 
The GABAB receptor has been well-characterised as a substrate of unconditioned anxiety 
behaviour. Indeed, the anxiolytic effects of positive modulators of the GABAB receptor 
have been demonstrated across a range of behavioural tests of innate anxiety, whereas 
functional deactivation of the GABAB receptor using genetic techniques generates a 
phenotype of pronounced anxiety behaviour. However, the role of the GABAB receptor in 
regulating conditioned anxiety behaviour, an important facet of the preclinical study of 
anxiety disorders such as post-traumatic stress disorder, is less well understood. In vitro 
data suggests that the GABAB receptor plays an important role in regulating the neural 
circuitry that underpins conditioned fear-learning and extinction, but whether these effects 
translate into alterations in conditioned anxiety behaviour has not been widely 
investigated. This represents a crucial deficit in the preclinical characterisation of these 
drugs as putative anxiolytic agents. Using the highly anxious mouse strain, BALB/C and 
an auditory fear conditioning protocol, we sought to characterise the GABAB receptor 
positive modulator GS39783 and GABAB receptor antagonist CGP52432, two compounds 
not previously evaluated for their effects on conditioned fear in this regard. Neither 
GS39783 nor CGP52432 altered freezing behaviour irrespective of whether drugs were 
administered before the acquisition, recall or extinction training sessions. These findings 
suggest limitations to the potential role of GABAB receptor-active drugs as clinical agents 
in the treatment of anxiety. 
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4.1 Introduction 
Current data has suggested a role for the GABAB receptor as a crucial regulator of anxiety-
like behaviour in rodents and highlighted the GABAB receptor as potential therapeutic 
target in anxiety disorders and depression (Cryan & Kaupmann, 2005). 
Indeed, animals deficient in functional GABAB receptors display marked increases in 
anxiety behaviour across a range of tests of unconditioned anxiety such as the light-dark 
box, the staircase test and the elevated zero maze with an apparent resistance the 
behavioural anxiolytic effects of benzodiazepines (Mombereau et al., 2004a, 2004b, 2005). 
The anxiolytic effects of GABAB receptor positive modulators in tests of unconditioned 
anxiety have also been well-characterised (Cryan & Kaupmann, 2005) with some studies 
suggesting that GABAB receptor antagonists have anxiolytic effects in some exploratory 
and conflict based tests of anxiety (Partyka et al., 2007; Frankowska et al., 2007). 
 
Although behavioural tests of unconditioned anxiety play a crucial role in the screening 
and development of novel anxiolytic compounds, it is increasingly clear that models of 
conditioned and learned fear also represent an important tool in this process (Cryan & 
Holmes, 2005; Cryan & Sweeney, 2011). The persistent salience of traumatic cue and 
memories in post-traumatic stress disorder and disordered processing of potentially 
threatening stimuli seen in generalised anxiety disorder patients suggest that cognitive 
deficits and in particular altered conditioned fear-learning is a key facet of the pathology of 
anxiety disorders (American Psychiatric Association, 2000; Lang et al., 2000). 
Behavioural tests designed to model these aspects of anxiety disorders are based on the 
Pavlovian principles of associating a neutral cue, such as a tone or light, (conditioned 
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stimulus) with a painful or aversive stimulus such as an electrical foot-shock (conditioned 
stimulus). Conditioned fear responses can then be indexed through a wide variety of 
outputs such as conditioned freezing (Fendt & Fanselow, 1999; Cryan & Holmes, 2005). 
 
The neuronal basis for the development of conditioned fear revolves around the onset of 
molecular plasticity in the lateral amygdala (LA). Auditory and nociceptive sensory 
afferents converge in the LA, which in turn innervates the central nucleus of the amygdala. 
Molecular plasticity in the LA results in increased input to the central nucleus in response 
to auditory conditioned stimuli, and corresponding increases in central nuclei mediated 
fear responses (Phelps & LeDoux, 2005; Johansen et al., 2011). GABA plays a crucial role 
in this process, with GABAergic interneurons in the amydala regulating neuronal activity 
and LTP generation (Johansen et al., 2011). In particular GABAA receptor antagonists, 
when applied to the LA can inhibit the acquisition of conditioned fear (Muller et al., 1997; 
Wilensky et al., 1999). The GABAB receptor agonist baclofen has been demonstrated to 
inhibit the extinction of conditioned fear when given before fear training or before recall 
testing (Heaney et al., 2012). This study also demonstrated that the GABAB receptor 
antagonist phaclofen had no effect on fear-learning or extinction (Heaney et al., 2012). 
However, recent years have seen a proliferation of novel GABAB receptor ligands, most 
importantly GABAB receptor positive allosteric modulators such as GS39783 and highly 
selective and potent GABAB receptor antagonists such as CGP52432 (Froestl, 2010). 
Drugs from these novel pharmacological classes have yet to be thoroughly evaluated in 
terms of their effects in conditioned fear paradigms and in particular the effects of the 
aforementioned compounds have not yet been assessed in conditioned fear. Therefore, we 
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examined whether GS39783 or CGP52432 impact the acquisition, expression and 
extinction of such fear responses using an auditory conditioned fear paradigm and the 
highly anxious BALB/c mouse (Belzung & Griebel, 2001). 
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4.2 Methods 
4.2.1 Animals 
Male BALB/cOlaHsd aged 6-8 weeks were acquired from Harlan and given at least seven 
days acclimatisation to laboratory conditions prior to testing. Mice were housed in cages of 
10 with food and water available ad-libitum. Animals were maintained on a 12h light/dark 
cycle with lights on at 7.00am.  All experiments were conducted in accordance with the 
European Directive 86/609/EEC, the Recommendation 2007/526/65/EC and approved by 
the Animal Experimentation Ethics Committee of University College Cork. All efforts were 
made to minimize animal suffering and to reduce the number of animals used. 
 
4.2.2 Auditory fear-conditioning protocol 
Auditory fear conditioning was conducted as previously described by our lab (Bravo et al., 
2011) based on a protocol developed by Brinks and colleagues (Brinks et al., 2009). On day 
1, mice were placed in conditioning chambers (21.6 cm x 17.8 cm x 12.7 cm), with 
transparent walls in the front and back, stainless-steel bars, and a metal-grid floor connected 
to a shock scrambled and generator in sound-attenuating box. After180 s acclimatisation 
mice received 6 pairings (60s interpairing interval) of a conditioned stimulus (CS; 20 s, 
light, 10 dB, 10kHz tone) and a unconditioned stimulus (US; 2 s, scrambled foot shock; 60 
mA). The US was presented during the last 2 s of the CS. After a 60 s no-stimulus 
consolidation period after the final CS–US pairing, mice were returned to the home cage. 
Chambers were cleaned with 70% ethanol between each mouse. On days 2 and 3 mice were 
returned to the same chamber as day one and the procedure repeated, with the absence of 
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electrical footshocks. Activity of mice was monitored by Video Freeze (Med Associates, 
USA). Animals were filmed at rate of 15 frames per second, with a freezing behaviour 
represented by movement of less than 255 pixels (to accommodate breathing) over 7 frames. 
This paradigm allows for the measurement of the acquisition and extinction of conditioned 
fear. The design of the procedure additionally allows us to measure both context and cue 
induced freezing which are measures of hippocampus and amygdala dependent fear 
behaviours, respectively. An outline of the experimental procedure is given in Figure 1. 
 
The GABAB receptor positive modulator GS39783 (Discovery Fine Chemicals, Dorset, 
UK) was administered via oral gavage suspended in 0.5% methylcellulose (0, 10, 30 
mg/kg). The GABAB receptor antagonist CGP52432 (Tocris Bioscience, Bristol, UK) was 
delivered via intraperitoneal injection in phosphate buffered saline (0, 10, 30 mg/kg). 
Doses and routes of administration were based on those shown to produce behavioural 
effects in the literature (Mombereau et al., 2004a; Felice et al., 2012b).  In order to dissect 
specific effects of the GABAB receptor-active drugs on the acquisition, expression and 
extinction of conditioned fear, animals were received drugs either prior to acquisition, 
recall testing or extinction training. GS39783 or its vehicle were administered 60 minutes 
prior to the start of the trial for the specific day, with CGP52432 being administered 30 
minutes prior to each trial. To obviate the effects of injection stress all groups received an 
injection with drug or vehicle on each day.  
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Figure 1 –Schematic of the auditory fear conditioning protocol. On day one (acquisition 
training) mice are given 180 seconds  acclimatisation to the novel test chamber before 
presentation of the CS (light, 10 dB, 10kHz tone) for 20 seconds (Black rectangles) with 
the US (60 mAmp scrambled footshock) presented for the final 2  seconds (yellow arrow). 
The US-CS pairing was repeated six times with a 60 second inter-pairing interval and a 
final 60 second consolidation period. On day two (recall testing) and three (extinction 
testing) an identical protocol in the same contextual environment, was used with the 
absence of the footshock. 
 
4.2.3 Statistical analyses 
The effect of drug administration on each day was examined by two-way repeated 
measures ANOVA followed by Bonferonni post-hoc tests. Statistical analyses were carried 
out using the Statistical Package for Social Sciences (SPSS) 20. P values of less than 0.05 
were considered significant.
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4.3 Results 
4.3.1 The effects of GS39783 on conditioned fear in BALB/c mice 
The effects of GS39783 administration on conditioned fear behaviour in BALB/c mice are 
shown in Figure 1. All groups were observed to acquire, retain and extinguish conditioned 
fear as measured by freezing responses to both the conditioning chamber context and the 
light/sound cue. When drugs were administered prior to acquisition training, two-way 
ANOVA revealed no effect of drug treatment on freezing behaviour on the acquisition 
(F2,25=0.07, p=0.93), recall (F2,25=0.84, p=0.44) or extinction of conditioned fear 
(F2,25=0.55, p=0.58).  
 
When GS39783 was administered prior the recall phase, no difference in the acquisition of 
conditioned fear was observed between treatment groups (F2,27=0.001, p=0.99). Two-way 
ANOVA revealed no effect of drug treatment on the recall (F2,27=0.99, p=0.39) or extinction 
(F2,27=0.25, p=0.78) of conditioned fear. 
 
When GS39783 was administered prior to the extinction phase no overall effect of group 
was observed on fear acquisition (F2,27=0.22 p=0.81) or fear recall (F2,27=2.09, p=0.14). 
Likewise, drug treatment had no significant effect on the extinction of conditioned fear 
(F2,27=1.9, p=0.17). 
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Figure 2 – Effects of GS39783 on freezing behaviour in a paradigm of conditioned fear. 
Black arrows indicate the point of drug dosing (30 minutes prior to testing. White boxes on 
the x-axis represent context components and black boxes signify cue. Drug was 
administered at three different timepoints A) before the acquisition phase, B) before the 
recall phase and C) before the extinction phase 
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4.3.2 The effects of CGP52432 on fear conditioning behaviour in BALB/c mice 
The effects of CGP52432 administration on conditioned fear behaviour in BALB/c mice are 
shown in Figure 2. All groups were observed to acquire, retain and extinguish conditioned 
fear as measured by freezing responses to both the conditioning chamber context and the 
light/sound cue. When drugs were administered prior to acquisition training, two-way 
ANOVA revealed no effect of drug treatment on freezing behaviour on the acquisition 
(F2,54=1.13, p= 0.33), recall (F2,54=0.21, p=0.8) or extinction of conditioned fear (F2,56=0.86, 
p=0.43).  
 
When CGP52432 was administered prior the recall phase, no difference in the acquisition of 
conditioned fear was observed between treatment groups (F2,54=0.61, p=0.68). Two-way 
ANOVA revealed no effect of drug treatment on the recall (F2,54=1.5, p=0.89) or extinction 
(F2,54=1.2, p=0.33) of conditioned fear. 
 
When CGP52432 was administered prior to the extinction phase no effect of group was 
observed on fear acquisition (F2,54=1.4, p=0.26) or fear recall (F2,54=0.07, p=0.93). Drug 
treatment had no significant effect on the extinction of conditioned fear (F2,54=1.08, p=0.35). 
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Figure 3 – Effects of CGP52432 on freezing behaviour in a paradigm of conditioned fear. 
Black arrows indicate the point of drug dosing (30 minutes prior to testing. White boxes on 
the x-axis represent context components and black boxes signify cue. Drug was 
administered at three difference time points, A) before the acquisition phase, B) before the 
recall phase and C) before the extinction phase 
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4.4 Discussion 
The current results demonstrate that GABAB receptor positive modulators and antagonists 
have no effect on the acquisition, recall or extinction of conditioned fear. This is somewhat 
surprising given that current data suggests the GABAB receptor is a substrate in the 
molecular pathways that underlie conditioned fear. Genetic ablation of the GABAB(1A) 
subunit results in generalisation of LTP in the amygdala and results in generalisation of 
conditioned fear in mice (Shaban et al., 2006). GABAB receptors furthermore inhibit 
excitatory input to the primary neurons of the amygdala suggesting a crucial role in the 
regulation of normal fear-learning behaviour (Pan et al., 2009). The absence of effects on 
auditory fear conditioning associated with GS39783 and CGP52432 administration 
suggests that the role the GABAB receptor plays in conditioned fear is not absolutely 
crucial.  
 
Similar studies to ours have recently examined the effects of other GABAB receptor 
ligands in tests of contextual and cued conditioned fear. In these studies neither the PAM 
BHF117 nor the antagonist  phaclofen were shown to alter the processes of acquiring, 
retaining or extinguishing conditioned fear  (Heaney et al., 2012; Li et al., 2013).  In 
contrast, conflicting reports of the effects of the agonist baclofen, on fear conditioning 
have been reported. Specifically, one study reported that baclofen  impaired the extinction 
of trace cue and context fear conditioning (Heaney et al., 2012) while another reported no 
effect on fear behaviour (Li et al., 2013). The experimental design of the aforementioned 
studies differed from the present study in that difference species, strains and fear 
conditioning protocols were used specifically,  Li and colleagues (Li et al., 2013) used 
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C57/BL6 mice while Heaney and colleagues (Heaney et al., 2012) used Sprague-Dawley 
rats. Another major methodological difference was that those studies  the used of a fear-
conditioning protocol which examines contextual and cue-induced fear conditioning in 
different sessions, i.e. cue exposure in a novel environment, context exposure in the 
absence of cue, as opposed to our procedure that tests both contextual and cued fear 
recall/extinction in the same session (Brinks et al., 2009). The fact that the results from our 
experiment using a PAM and and antagonist are in agreement with the aforementioned 
studies despite methodological differences, strongly suggest that neither GABAB receptor 
positive modulators nor antagonists affect conditioned anxiety. 
 
Auditory fear conditioning is a cognitive process underpinned by neuronal circuitry 
overlapping to other aspects of learning and memory (Fendt & Fanselow, 1999). Thus, the 
lack of effect of PAMs and antagonists on learned fear is somewhat surprising given the 
role of the GABAB receptor in cognitive function. For example, GABAB receptor 
antagonists have been shown to enhance cognitive function across several species in a 
broad range of functional tests (Mondadori et al., 1993) and enhance hippocampus 
dependant memory function in particular (Helm et al., 2005). Interestingly, the GABAB 
receptor agonist baclofen has recently been shown to ameliorate cognitive deficits seen in 
methamphetamine-treated mice (Arai et al., 2009). In contrast, positive allosteric 
modulators of the GABAB receptor appear to be devoid of effects on cognitive function 
(Cryan et al., 2004), while evidence from genetic models suggest that GABAB1 receptor 
subunit isoforms play different yet important roles in regulating cognition (Jacobson et al., 
2007b). The fact that GABAB receptor ligands can have such an influence over cognitive 
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function, but not over auditory fear conditioning, suggests that GABAB receptors do play a 
role in cognition but via neuronal populations other than those that underpin auditory fear 
conditioning. 
 
Despite the status of positive modulators of the GABAB receptor as promising anxiolytic 
drugs, GS39783 failed to alter learned fear behaviour in the present study. GS39783 has 
previously been demonstrated to generate anxiolytic effects in mice in many tests of innate 
anxiety including the elevated plus maze, elevated zero maze, stress induced hypothermia 
paradigm and the light dark box (Cryan & Kaupmann, 2005), as have other positive 
modulators (Cryan & Kaupmann, 2005; Frankowska et al., 2007) although it has been 
shown to lack anxiolytic activity in the modified Geller-Seifter test (Paterson & Hanania, 
2010). Taken with our current data, a pre-clinical profile of the GABAB receptor positive 
allosteric modulators as having anxiolytic effects in exploratory and autonomic measures 
of anxiety behaviour, but lacking these effects in learning based models of anxiety 
emerges. This suggests a potential clinical limitation for these compounds when 
attempting to modify certain symptoms of anxiety disorders especially those of a cognitive 
nature. 
 
The current literature has provided limited behavioural evidence for GABAB receptor 
antagonists as anxiolytic agents. Although some studies have demonstrated anxiolytic 
effects for the GABAB receptor antagonists in the elevated plus maze, elevated zero maze, 
conflict drinking test and the four plate test (Partyka et al., 2007; Frankowska et al., 2007) 
others have shown GABAB receptor antagonists to have no effects on anxiety behaviour in 
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these tests as well as the Geller-Seifter test (Partyka et al., 2007; Mombereau et al., 2004a; 
Paterson & Hanania, 2010). Our data appears to further suggest that the anxiolytic effects of 
GABAB receptor antagonist are limited. The antidepressant like effects of the GABAB 
receptor antagonists are well-characterised (Cryan & Kaupmann, 2005), however given the 
frequent comorbidity of anxiety and depression, a failure to generate anxiolytic effects in 
these tests makes the GABAB receptor a less promising therapeutic avenue. Taken together 
this data does not support a specific role of GABAB receptor allosteric modulators and 
antagonists in the modulation of conditioned fear which is a cognitive facet of some anxiety 
disorders. 
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Abstract 
Although the GABAB receptor has been suggested as a potential drug target in the treatment 
of both anxiety disorders and depression, development of novel GABAB receptor-active 
therapeutic drugs is hampered by our poor understanding of the molecular basis of the 
heterogeneity of this receptor in vivo. In vitro studies have suggested that a key process 
underlying the functional modulation of the receptor is phosphorylation of the Ser892 
residue of the GABAB(2) receptor subunit. In an effort to assess the role played by this 
phosphorylation process in vivo we have developed a mouse model wherein a point 
mutation in the GABAB(2) subunit has converted the Ser892 residue to an alanine residue, 
thus ablating phosphorylation. This mouse was assessed in terms of its sensitivity to both 
acute and chronic baclofen treatment as well as its behaviour in tests of anxiety and 
antidepressant like activity. Our results revealed that the GABAB(2)-S892A mouse displays a 
sensitivity to acute and chronic baclofen treatment which is indistinguishable from wildtype 
controls. We also demonstrated that the GABAB(2)-S892A mouse behaves identically to 
wildtype controls in a battery of commonly used behavioural tests of anxiety and anti-
depressant like behaviour. The overall lack of alteration in behaviour displayed by this 
mouse suggests that Ser892 phosphorylation plays a limited role in regulating GABAB 
receptor function in vivo. A variety of factors including the presence of a plethora of other 
GABAB receptor regulatory mechanisms as well as the unique GABAB receptor sensitivity 
profile of the BALB/c background strain may underlie these results. 
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5.1 Introduction 
The GABAB receptor is currently postulated as a potential therapeutic target in a variety of 
psychiatric disorders including depression, anxiety and drug addiction (Cryan & Kaupmann, 
2005; Tyacke et al., 2010). However, a major barrier to our understanding the function of 
the GABAB receptor in vivo is heterogeneity of agonist potency observed between different 
neuronal populations (Pinard et al., 2010). Among other processes, GABAB receptor 
functionality is critically controlled by the phosphorylation of the receptor heterodimer 
complex by protein kinases in vivo, with both the GABAB(1) and GABAB(2) receptor 
subunits possessing multiple phosphorylation sites (Terunuma et al., 2010a). 
 
cAMP-dependent protein kinase (PKA) was first suggested to have a role in regulating 
GABAB receptor function when it was demonstrated that administration of dibutyric cAMP 
could suppress GABAB receptor function in active receptor expressing Xenopus oocytes 
(Yoshimura et al., 1995). This role for PKA in the modulation of the GABAB receptor was 
confirmed with the discovery of the sole site for PKA mediated phosphorylation of the 
GABAB receptor at the serine 892 (S892) residue of the GABAB(2) receptor subunit (Couve 
et al., 2002).  Using phospho-GABAB specific antibodies it has been shown that the S892 
residue undergoes significant basal PKA dependent phosphorylation in vivo. PKA 
dependent phosphorylation of the S892 residue plays a crucial role in inhibiting agonist 
induced receptor desensitisation in both HEK cells and cultured hippocampal neurons 
(Couve et al., 2002).  
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Although chronic exposure to the GABAB receptor agonist baclofen promotes GABAB 
receptor degradation, this effect can be attenuated by concurrent activation of PKA or 
treatment with a β-adrenergic receptor agonist. Furthermore, the rate of GABAB receptor 
degradation is directly correlated to S892 residue phosphorylation (Fairfax et al., 2004). 
This data strongly suggests that S892 phosphorylation plays a crucial role in maintaining the 
cell surface stability of the GABAB receptor and promoting receptor function. It must also 
be noted that data obtained from Xenopus oocytes conversely suggests that PKA mediated 
phosphorylation can effectively desensitise the receptor (Yoshimura et al., 1995). The 
precise role played by S892 phosphorylation in the regulation of GABAB receptor function 
thus remains elusive. 
 
As an investigational tool designed to further characterise the effect of PKA dependent 
phosphorylation on GABAB receptor function, a mouse model has been developed wherein 
the serine 892 residue in the GABAB(2) subunit is substituted for an alanine residue which is 
not subject to PKA- mediated phosphorylation; the GABAB(2)-S892A mouse. This mutation 
appears to results in cell and region specific enhancements of ligand potency and membrane 
stability suggestive of receptors being in a tonically active state (Bettler et al. unpublished 
data). The development of this model offers the opportunity to determine the role of PKA 
mediated phosphorylation of the GABAB receptor in vivo, in particular on the sensitivity of 
the animal to the effects of both acute and chronic GABAB receptor agonist treatment. In 
addition, it is of interest to note that the in vitro effects of serine 892 to alanine substitution 
on both ligand potency and receptor membrane stability appear to be analogous to the 
molecular effects of positive modulators of the GABAB receptor (Urwyler et al., 2001a). 
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Thus, given the pronounced anxiolytic activity of GABAB receptor modulators in a host of 
behavioural measures of unconditioned anxiety in rodents (Cryan & Kaupmann, 2005), it is 
possible that the GABAB(2)-S892A mutation may modulate anxiety behaviour in animal 
models.  To this end, we compared the response of GABAB(2)-S892A mice with their 
wildtype littermate controls in the physiological responses to GABAB receptor agonist 
baclofen.  Moreover, the behaviour of the animals in tests of anxiety and antidepressant 
action was also assessed. 
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5.2 Methods 
5.2.1 Generation and analysis of GABAB(2)-S892A knock-in mice 
The gene targeting construct contained a neomycin resistance cassette (pRay-2; Genbank 
accession number U63120) flanked by two arms of BALB/c GABAB(2) genomic DNA. 
The S892A mutation in exon 19 was introduced into the 3’ arm along with a diagnostic 
silent NheI restriction site (Fig. 1A). The targeting construct was electroporated into 
Balb/c embryonic stem cells. Neomycin resistant colonies were screened for homologous 
recombination by PCR, and positive clones confirmed by Southern blot (Fig. 1b). Positive 
ES cells were microinjected into C57BL/6 blastocysts. Chimeric males were crossed with 
female BALB/c mice resulting in a F1 of inbred BALB/c mice heterozygous for the 
S892A+neo allele. The neomycin cassette in the S892A+neo allele was excised by mating 
heterozygous F1 mice with BALB/c Cre-deleter mice (Vigot et al., 2006). Deletion of the 
neomycin cassette in the S892A allele was confirmed by Southern blot analysis. GABAB(2) 
immunoblot analysis was performed as described (Gassmann et al., 2004). All animal 
experiments were subjected to institutional review and approved by the Veterinary Office 
of Basel-Stadt. 
 
GABAB(2)-S892A mice were bred from heterozygous breeding pairs. Genotyping was 
performed on offspring on tail clip samples taken from animals as described in Appendix 1. 
Male mice homozygous for the GABAB(2)-S892A mutation were used for all experiments, 
with age matched homozygous wildtype littermates used for controls. 
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All experiments were conducted in accordance with the European Directive 86/609/EEC, 
the Recommendation 2007/526/65/EC and approved by the Animal Experimentation 
Ethics Committee of University College Cork and in accordance with methods approved 
by the Veterinary Authority of the City of Basel. All efforts were made to minimize animal 
suffering and to reduce the number of animals used. 
 
5.2.2 Sensitivity of the GABAB(2)-S892A mouse to the physiological effects of baclofen 
In order to determine the effects of the GABAB(2)-S892A mutation on GABAB receptor 
activity in vivo a cohort of GABAB(2)-S892A mice were assessed for their sensitivity to the 
ataxic and hypothermic effects of the GABAB receptor agonist baclofen.  
 
Baclofen treatment and measurement of physiological effects 
Wildtype and GABAB(2)-S892A mice were dosed once daily with baclofen [(10mg/kg, IP 
enantiomeric baclofen (Tocris)] for 14 days. The sensitivity of the mice to the hypothermic 
and ataxic effects of the baclofen dose was assessed on days 1, 7, and 14. The baclofen 
doses and experimental procedures were selected based on work previously conducted in 
our lab (Jacobson & Cryan, 2005) 
Apparatus 
Temperature was measured using a thermistor probe of 2mm in diameter (Ellab, Denmark 
– Model DM852). The thermistor probe was lubricated with petroleum jelly and inserted 
roughly 20mm into the rectum until a stable temperature was achieved (10-15s).  
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Measurement of the ataxic effects of baclofen was assessed via rotarod endurance. The 
rotarod (Ugo Basile, Italy - Model 47600) was set at 12RPM and each trial lasted for a 
maximum of 300 seconds. Endurance was determined by the time taken before mice fell 
off the rotarod. Mice clinging to the rotarod for more than 80% of the 300 seconds test 
time were given a score of 0. Mice clinging to the rotarod for less than 80% of the 300 
seconds only had their time spent actively walking on the rotarod measured. 
 
Procedure 
One day prior to the first baclofen dose, mice were injected with saline and rectal 
measurements of temperature were taken in order to ensure that mice were acclimatised to 
both injection and temperature measurement stress. Animals were then trained to walk on 
the rotarod apparatus (Ugo Basile, Italy - Model 47600) for 300s over a series of 8 trials 
each 30 minutes apart. The number of falls during training was recorded for each mouse.  
 
Prior to each testing day, mice were singly housed overnight to limit levels of variability in 
rectal temperature between animals. The morning of testing, animals were moved to the 
experimental room 2 hours prior to the baclofen dose, with the first measurement of rotarod 
endurance and temperature measurement being taken 1 hour later (T-60) in order to re-
establish endurance. A second measurement was taken immediately prior to the baclofen 
injection (T0), with subsequent measurements 30, 60, 120, 180 and 240 minutes after the 
baclofen dose. Animals remained singly housed in their holding cages between each 
temperature/endurance measurement and were returned to their home cages subsequent to 
the final measurement. 
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Statistical analyses 
Wildtype and GABAB(2)-S892A endurance on the rotarod and rectal temperature subsequent 
to baclofen treatment was compared for each day by repeated measures two-way ANOVA. 
Each timepoint was then assessed by Bonferonni’s post-hoc test. All statistical analyses 
were conducted in statistical package for social sciences (SPSS, ver 20.1). 
5.2.3 Anxiety behaviour of the GABAB(2)-S892A mouse 
A separate cohort of mice (n=11) were tested in a battery of tests of anxiety behaviour 
consisting of the light dark box, defensive marble burying, stress-induced hyperthermia, a 
conditioned fear acquisition/extinction paradigm and a forced swim test. Three recovery 
days were given between each of the first four tests with a seven day break between the 
conditioned fear paradigm and the forced swim test. A schematic depicting the timeline of 
behavioural experiments is shown in Figure 2. 
 
 
Light Dark Box Stress-Induced 
Hyperthermia
Defensive 
Marble Burying
Forced Swim 
Test
Fear 
Conditioning    
(3 Days)
3 Days 3 Days 3 Days 7 Days
 
Figure 1 –Timeline illustrating the sequence of behavioural testing 
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Light-Dark box 
The light dark box is a behavioural test used to assess levels of unconditioned anxiety in 
rodents based on levels of passive avoidance behaviour and was conducted a previously 
described (Finger et al., 2011). The apparatus consisted of a Plexiglas enclosure 
(44 × 21 × 21 cm) comprised of two adjoining compartments (one light and one dark). The 
light compartment had transparent Plexiglas walls and had an open top. Bright lighting 
(approximately 1,000 lx) was used to generate aversive conditions in this compartment. The 
dark compartment (14 cm width) consisted of a black Plexiglas wall and roof. The 
compartments were connected by a small opening (12 × 5 cm) at floor level. Animals were 
placed in the light compartment facing away from the dark compartment and were allowed 
to freely explore the apparatus for 10 minutes. During this period the behaviour of the 
animals was recorded. The latency of the animal to enter the dark compartment of the 
apparatus, the number of transitions between the two compartments and the total time spent 
in the light compartment were measured. An animal was adjudged to have entered a 
compartment when all four paws had crossed the threshold. The number of faecal pellets 
produced by each animal during the test period was also recorded as a measure of the 
physiological response to a stressful stimulus. 
 
Defensive Marble Burying 
The test was adapted from a protocol previously described (Jacobson et al., 2007a). Briefly, 
mice were placed in the centre of a cage (38x25x18cm) containing 4cm of bedding with 20 
blue glass marbles (1.5cm diameter) on top, arranged in 4 rows of 5 marbles (2cm apart). 
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The lid of the cage was used to prevent mice from escaping the test chamber. Mice were 
allowed to explore the chamber for 30 minutes and then returned to their home cage.  
Following removal of the mouse, the number of marbles that were covered in bedding by at 
least two thirds was counted. 
 
Stress-Induced Hyperthermia (SIH) 
Testing was conducted in a similar manner to that previously described (Jacobson & Cryan, 
2008). Briefly, mice were singly housed 24 hours prior to testing. The rectal temperatures 
were then taken using a thermistor probe ca. 2mm in diameter inserted 20mm into the 
rectum (T1) for 15 seconds. The temperature was measured again 15 minutes later (T2). The 
increase in temperature due to the stress of the initial temperature measurement (T2 value 
minus T1 value) was taken as a measure of the physiological response to an acute stressor. 
Mice were returned to their home cage immediately after testing. 
 
Conditioned fear/extinction paradigm 
Conditioned fear testing was conducted according to a protocol previously described by our 
lab (Bravo et al., 2011; Sweeney et al., 2013). On day 1, mice were placed in conditioning 
chambers (21.6 cm x 17.8 cm x 12.7 cm), with transparent walls in the front and back, 
stainless-steel bars, and a metal-grid floor connected to a shock scrambled and generator in 
sound-attenuating box. After180 s acclimatisation mice received 6 pairings (60s interpairing 
interval) of a conditioned stimulus (CS; 20 s, 10 dB, 10kHz tone) and a unconditioned 
stimulus (US; 2 s, scrambled footshock; 60 mA). The US was presented during the last 2 s 
of the CS. After a 60 s no-stimulus consolidation period after the final CS–US pairing, mice 
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were returned to the home cage. Chambers were cleaned with 70% ethanol between each 
mouse. On days 2 and 3 mice were returned to the same chamber as day one and the 
procedure repeated, with the absence of electrical footshocks. Activity of mice was 
monitored by Video Freeze (Med Associates, USA). Animals were filmed at rate of 15 
frames per second, with a freezing behaviour represented by movement of less than 255 
pixels (to accommodate breathing) over 7 frames. This paradigm allows for the 
measurement of the acquisition and extinction of conditioned fear. The design of the 
procedure additionally allows us to measure both context and cue induced freezing which 
are measures of hippocampus and amygdala dependent fear behaviours respectively. 
 
 
Forced Swim Test 
The forced swim test is a behavioural test commonly used to assess levels of antidepressant-
like behavioural activity in mice (Cryan & Mombereau, 2004). Mice are placed in glass 
cylindrical tank containing 17cm of water at 23-25°C for 6 minutes and their behaviour is 
recorded. The length of time the mouse spends immobile, i.e. not actively swimming, during 
the last 4 minutes of the test is scored manually by a trained observer blinded to the 
treatment group.  
 
Statistical analyses 
Data from the light-dark box, defensive marble burying, and Stress-Induced Hyperthermia 
paradigm were analysed by student’s t-test. Data from the conditioned fear experiment was 
analysed by two-way ANOVA followed by Bonferonni’s post-hoc test where appropriate. 
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Significance was accepted at p>0.05. Data were analysed using the statistical package for 
social sciences (SPSS v.20.1). 
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5.3 Results 
5.3.1 Generation and analysis of S892A knock-in mice 
S892A knock-in mice carrying a S892 to alanine mutation in the GABAB(2) gene were 
generated using standard gene targeting techniques (Fig. 1a,b). Homozygous S892A mice 
were kept on a pure inbred Balb/c genetic background and exhibited no overt phenotypic 
abnormalities. Immunoblot analysis revealed similar levels of GABAB1a, GABAB1b and 
GABAB2 protein in S892A and wildtype (WT) brain extracts (Fig. 1c). Antibodies specific 
for pS892 detected basal phosphorylation in WT but not in S892A brain extracts (Fig. 1c), 
confirming the absence of S892 phosphorylation in the knock-in mice.  
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Figure 1. Generation of S892A knock-in mice. (a) WT and mutated GABAB(2) alleles. The 
S892 to alanine mutation (tcc→gcc) and a silent diagnostic NheI restriction site (gctagc) 
were introduced into exon 19 using homologous recombination in Balb/c embryonic stem 
(ES) cells
37
. Mutated nucleotides are shown in italic. A neomycin marker (neo) flanked by 
loxP sites (arrowheads) was used for selection of ES cells. Correctly targeted ES cells 
(S892A+neo allele) were injected into C57BL/6 blastocysts. A founder mouse was crossed 
with a Balb/c mouse expressing Cre-recombinase
35
 to excise the neomycin cassette, 
leaving one loxP site behind (S892A allele). The hybridization probe used in the Southern 
blot in (b) is indicated. N, NheI restriction sites. (b) Southern blot of NheI cut genomic 
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DNA from correctly targeted ES cells. The probe labels a 15.3 kb fragment for the WT 
allele and a 4.3 kb fragment for the S892A+neo allele. (c) Immunoblot analysis of brain 
extracts showing that S892A mice express normal levels of GABAB(2) (GB2), GABAB(1)a 
(GB1a) and GABAB(1)b (GB1b) proteins. S892 was phosphorylated in brain extracts of WT 
but not S892A mice, as shown with an antibody specific for phosphorylated S892 (pS892)
9
. 
Brain extracts of GABAB2-deficient mice (GB2-/-)
36
 confirm the specificity of the GB2 and 
pS892 antibodies. An antibody specific for tubulin controls for equal loading of samples.  
 
5.3.2 Baclofen sensitivity 
Hypothermic response to baclofen 
The hypothermic effects of 10mg/kg baclofen are shown in Figure 2 (Panels A-D). Both 
GABAB(2)-S892A and WT mice displayed a pronounced and transient drop in body 
temperature in response to treatment with baclofen; these effects were greatly diminished 
on days 7 and 14 in both groups.  One-way repeated measures ANOVA following different 
durations of treatment revealed no significant effect of genotype on treatment day 1 
(F1,15=0.97,  p=0.34), day 7 (F1,15= 0.28,  p= 0.61) or day 14 (F1,15=0.002,  p= 0.96). 
Comparing the cumulative changes in temperature from baseline across the 240 minute 
trial period for each test session revealed a significant effect of test day (F2,15=22.61, 
p>0.001). Bonferroni’s posthoc test revealed significant differences between the 
cumulative changes in temperature in wildtype animals from day 1 to day 7 ((p<0.001) and 
from day 1 to day 14 (p<0.01). Bonferroni’s posthoc test also revealed significant 
differences between the cumulative changes in temperature in wildtype animals from day 1 
to day 7 (p<0.001) and from day 1 to day 14(p<0.001).  
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Ataxic response to baclofen 
The ataxic effects of 10mg/kg baclofen are shown in Figure 2 (Panel E-H). Both 
GABAB(2)-S892A and WT mice displayed a pronounced and transient reduction rotatod 
endurance in response to treatment with baclofen, these effects were greatly diminished on 
days 7 and 14 in both groups.  Two-way ANOVA revealed no significant effect of 
genotype on treatment day 1 (F1,9=0.17,  p=0.69), day 7 (F1,9=0.95,  p=0.35) or day 14 
(F1,9=0.005,  p=0.94). 
 
 
Comparing the cumulative changes in temperature from baseline across the 240 minute 
trial period for each test session revealed a significant effect of test day (F2,9=22.9, 
p>0.001). Bonferroni’s posthoc test revealed significant differences between the 
cumulative changes in temperature in wildtype animals from day 1 to day 7 (p<0.001) and 
from day 1 to day 14 (p<0.01). Bonferroni’s posthoc test also revealed significant 
differences between the cumulative changes in endurance in GABAB(2)-S892A mice from 
dose 1 to dose 7 (p<0.001) and from dose 1 to day 14 (p<0.01).
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Figure 1- Desensitisation to the physiological effects of baclofen in wildtype and GABAB(2)-S892A mice. A) The hypothermic response of WT and GABAB(2)-
S892A on day 1 of baclofen treatment, B) the hypothermic response of WT and GABAB(2)-S892A  on day 7 of baclofen treatment, C) the hypothermic response 
of WT and GABAB(2)-S892A on day 14 of baclofen treatmen (baclofen doses given at T0) and D) the cumulative change in temperature from baseline across 
all five temperature measurements. Data is expressed as change in temperature from T0. B) E) The rotarod endurance of WT and GABAB(2)-S892A on day 1 
of baclofen treatment, F) the rotarod endurance of WT and GABAB(2)-S892A  on day 7 of baclofen treatment, G) the rotarod  endurance of WT and GABAB(2)-
S892A on day 14 of baclofen treatment (arrows indicate timing of Baclofen dose (10mg/kg IP) and H) the cumulative endurance across all measurements on 
each test day. ## represents p<0.01, ### represents p<0.001 from acute baclofen response.
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5.3.3 Anxiety behaviour 
Light dark box 
Figure 3 shows the behaviour of wildtype and GABAB(2)-S892A mice in the light dark box. 
Students T test revealed no significant effect of the GABAB(2)-S892A mutation on latency to 
enter the dark side of the apparatus (p=0.869, Panel A), total time spent in the light side of 
the box (p=0.753, Panel B), number of transitions between the two chambers (p= 0.313, 
Panel C) or number of faecal boli produced during the test session (p=0.741, Panel D). 
 
Latency
WT S892A
0
100
200
300
Genotype
T
im
e
 (
s
)
Time in Light
WT S892A
0
100
200
Genotype
T
im
e
 (
s
)
Transitions
WT S892A
0.0
2.5
5.0
7.5
10.0
Genotype
N
o
. 
T
ra
n
s
it
io
n
s
Faecal Boli
WT S892A
0
2
4
6
8
10
F
a
e
c
a
l 
B
o
li
T
im
e
 (
s
)
T
im
e
 (
s
)
N
o
. 
T
ra
n
s
it
io
n
s
F
a
e
c
a
l 
B
o
li
A
DC
B
 
Figure 3- A)Latency to enter the dark compartment, B) time in light compartment, C) 
transitions between the light and dark compartments and D)  number of faecal boli produced 
in the light-dark box by wildtype and GABAB2-S892A mice. Data are expressed as 
mean±SEM. 
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Defensive marble burying 
Figure 4 shows the behaviour of wildtype and GABAB(2)-S892A mice in the defensive 
marble burying test. No difference in the number of marbles buried in the defensive marble 
burying test were seen between wildtype and GABAB(2)-S892A mice (p=0.328). 
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Figure 4 -Number of marbles buried by wildtype and GABAB2-S892A mice in the defensive 
marble burying test. Data are expressed as mean±SEM. 
 
SIH 
Figure 5 shows the behaviour of wildtype and GABAB(2)-S892A mice in the SIH paradigm. 
No difference in either basal temperature (p=0.893) or in the increase in temperature in 
response to stress (p=0.577) was observed between wildtype and GABAB(2)-S892A mice. 
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Figure 5 - The baseline temperatures and stress induced increases in temperature (T2-T1) of 
wildtype and GABAB(2)-S892A mice observed in the Stress-Induced Hyperthermia paradigm. 
Data are expressed as mean±SEM. 
 
Conditioned fear paradigm 
Figure 6 shows the behaviour of wildtype and GABAB(2)-S892A mice in the fear 
conditioning paradigm. Both GABAB(2)-S892A and wildtype animals acquired, expressed 
and extinguished conditioned fear as measured by freezing responses to both the 
conditioning chamber context and the light/sound cue. When data was analysed in terms of 
% freezing during each component of the three testing sessions (cue and context), no 
significant effect of genotype, likewise was observed (F1,18=0.01, p=0.92) (Fig 5). 
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Figure 6 - Freezing behaviour of wildtype and GABAB(2)-S892A mice observed in the conditioned fear paradigm.White 
boxes on the x-axis represent context components and black boxes signify cue components. Data are expressed as % time 
spent immobile (freezing) during each stage of the procedure. Data are expressed as mean±SEM.
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Forced swim test 
Figure 7 shows the behaviour of wildtype and GABAB(2)-S892A mice in the forced swim 
test. No difference in immobility in the forced swim test was observed between wildtype and 
GABAB(2)-S892A mice in the forced swim test (p=0.885) 
Forced Swim Test
WT S892A
0
10
20
30
40
50
60
70
Genotype
T
im
e
 I
m
m
o
b
il
e
 (
s
)
 
Figure 7 - Time spent immobile in the final 4 minutes of the forced swim test by WT and 
GABAB2-S892A mice. Data are expressed as mean±SEM. 
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5.4 Discussion 
Treatment with baclofen produces pronounced ataxic effects in both GABAB(2)-S892A and 
wildtype mice, although after seven and fourteen days of treatment, both groups displayed 
almost complete tolerance  to these effects. This is in line with reported data in the 
literature. 
 
GABAB(2)-S892A mice did not differ in either their acute response or in their 
desensitisation rate to chronic baclofen. Given the crucial role played by PKA dependent 
phosphorylation in regulating GABAB receptor expression at the cell surface, the lack of 
difference seen between the GABAB(2)-S892A mouse and wildtype controls is interesting. 
Our data would suggest that sensitisation to the physiological effects of baclofen is 
independent of this process. It is worth noting that given the crucial role of the GABAB 
receptor in maintaining inhibitory control of the brain, it is likely that other phosphorylation 
processes may compensate in maintaining stable levels of GABAB receptor activity the 
absence of S892 phosphorylation. 
 
The current results also strongly suggest that GABAB(2)-S892A mice display a phenotype 
indistinguishable from wildtype littermates across a broad range of tests of anxiety, fear 
conditioning and depression like behaviours. This stands in stark contrasts to the 
administration of GABAB positive allosteric modulator (PAM), which has robust anxiolytic 
effects in a diverse range of behavioural tests. Indeed, the prototypical modulator CGP 
7930 and the more potent GS39783 and rac-BHFF (Froestl, 2010) have been shown to 
produce anxiolytic effects in the light dark box test and the SIH paradigm as used in this 
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experiment (Cryan et al., 2004; Mombereau et al., 2004a; Jacobson & Cryan, 2008; 
Malherbe et al., 2008), as well as in other behavioural tests such as the elevated zero maze, 
the elevated plus maze and the staircase test (Cryan et al., 2004; Mombereau et al., 2004a; 
Frankowska et al., 2007; Jacobson & Cryan, 2008). The fact that no behavioural phenotype 
is observed in the GABAB(2)-S892A mouse suggests that the GABAB(2)-S892A point 
mutation does not produce the same pharmacological effects as GABAB PAMs.  
 
GABAB receptor PAMs were initially hypothesised to interact with the helical domain of 
the GABAB(2) subunit based on discoveries relating to the action of positive modulators of 
metabotropic glutamate receptors and known interactions between the GABAB(2) subunit 
and G-proteins (Pin et al., 2001). This was confirmed using in vitro studies assessing the 
activity of the GABAB PAM CGP7930, on both wildtype and a series of chimeric GABAB 
receptor subunit dimers co-expressed with G-protein effector proteins in the HEK-293 cell 
line. These studies clearly demonstrated that CGP7930 could exert pharmacological effects 
on chimeric dimers lacking either or both extracelluar domains and the helical domains of 
the GABAB(1) subunit, but required the presence of a GABAB(2) HD (Binet et al., 2004a). 
These studies went on to demonstrate that CGP7930 is not only a partial GABAB receptor 
agonist, but that it can directly activate GABAB(2) HD domains expressed by themselves, 
with data suggesting that the compound acts by stabilising an active conformation of the 
GABAB(2) subunit (Binet et al., 2004a, 2004b). Further work on establishing the precise site 
where GABAB PAMs bind to the GABAB(2) helical domain established that GS39783 has 
its functionality radically altered by the point mutations G706T and A708P, suggesting a 
binding site in the sixth transmembrane domain of the GABAB(2) subunit (Dupuis et al., 
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2006). The current data suggests that the behavioural effects of GABAB positive allosteric 
modulators are not analogous to the ablation of PKA mediated GABAB receptor 
phosphorylation. 
 
Although phosphorylation of the GABAB(2) subunit at the S892 site has pronounced effects 
on GABAB receptor function, indeed being the only PKA dependent phosphorylation site 
on the GABAB receptor (Couve et al., 2002), other regulatory phosphorylation mechanism 
exist to regulate receptor function (Terunuma et al., 2010a; Gassmann & Bettler, 2012). 
The GABAB receptor undergoes Protein-kinase C (PKC) mediated regulation of its 
signalling efficiency (Pontier et al., 2006) as well as AMPK mediated regulatory 
phosphorylation at sites on both the GABAB1 and GABAB2 subunits (Kuramoto et al., 
2007). Furthermore CamKII mediated phosphorylation of the S867 residue of the 
GABAB(1) has been shown to regulate cell  surface receptor levels (Guetg et al., 2010).  It is 
of note that more recent discoveries have revealed even more complex mechanisms by 
which GABAB receptor function is regulated. One example is the discovery that potassium 
channel tetramerisation domains (KCTD) proteins form heteromultimers with functional 
GABAB receptors and strongly influence fast receptor desensitization and agonist potency 
(Schwenk et al., 2010). Indeed the distribution of these proteins varies greatly across brain 
regions, neuronal subpopulations and even across different periods of brain development, 
suggesting that the heterogeneity of GABAB receptor function may be heavily dependent 
on formation of different heteromultimers across the brain (Metz et al., 2011). It is thus 
increasingly clear that the functional properties of GABAB receptors are regulated by 
multiple pathways and protein interactions and as such it is possible that the effects of the 
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GABAB(2)-S892A mutation could be compensated for by changes in one or more of the 
other regulatory mechanisms. Given the high levels of cell surface stability of the GABAB 
receptor heterodimer (Fairfax et al., 2004) it seems likely that these mechanisms may exist. 
 
One caveat to the study is the use of the BALB/c mouse as a background strain for the 
GABAB(2)-S892A mutation. Mouse strains vary significantly in their sensitivity to baclofen 
(Jacobson & Cryan, 2005), with the BALB/c mouse displaying complete insensitivity to 
lower doses. It is also of note that the BALB/c mouse is the only mouse strain that appears 
to be capable of surviving GABAB receptor knockout into adulthood (Prosser et al., 2001; 
Schuler et al., 2001). This suggests that the BALB/c mouse displays slightly altered 
GABAB receptor signalling properties that may explain its insensitivity to lack of S892 
phosphorylation. 
 
In conclusion, our data appear to suggest that S892A substitution does not markedly alter 
the baclofen sensitivity in vivo, nor does it alter anxiety or antidepressant-like behaviour. 
This may be the result of compensatory changes in other phosphorylation pathways or of 
alterations in one or more of the many complement proteins that influence GABAB receptor 
activity. 
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Abstract 
The GABAB receptor has long been implicated as a potential drug target for the treatment 
of substance abuse disorders. In particular preclinical data has suggested that positive 
allosteric modulators of the GABAB receptor possess anti-addictive effects and lack the 
side effect profile of full GABAB receptor agonists such as baclofen. In vitro data has 
suggested that GABAB receptor function in the ventral tegemental area (VTA) may play a 
crucial role in regulating the dopaminergic innervation of forebrain structures such as the 
nucleus accumbens and the dorsal striatum. We have recently developed a mouse model 
wherein phosphorylation of the S892 residue of the GABAB(2) subunit is eliminated 
resulting in a tonically active receptor. This has been shown to reduce dopaminergic 
neurotransmission to reward-related structures in the forebrain in vitro. We thus attempted 
to assess in vivo the sensitivity of these mice to the acute rewarding and locomotor effects 
of cocaine using a conditioned place preference (CPP) paradigm. We then sought to 
examine the levels of ΔFosB, a molecular correlate of chronic cocaine exposure, in reward-
related brain structures subsequent to CPP testing. We found that the GABAB(2)-S892A 
mouse displayed behaviour identical to those of its wildtype littermates in the CPP 
paradigm as well as displaying an identical pattern of locomotor sensitisation to cocaine as 
wildtype animals. GABAB(2)-S892A substitution furthermore had no effect on levels of 
cocaine-induced ΔFosB accumulation in reward-related forebrain regions. Together these 
data suggests that GABAB(2)-S892A substitution does not modify the behavioural or 
molecular consequences of repeated cocaine in vivo. 
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6.1 Introduction 
Preclinical research has shown that the GABAB receptor plays a crucial role in mediating the 
behavioural and molecular effects of drugs of abuse, with activation of the GABAB receptor 
being identified as a potential anti-addictive therapeutic strategy (Roberts, 2005; Vlachou & 
Markou, 2010). Human studies have shown that the GABAB receptor agonist baclofen can 
reduce cue-associated cocaine craving as well as reduce cocaine use in a double blind 
placebo controlled trial (Vocci & Elkashef, 2005). Over the past decade, positive allosteric 
modulators of the GABAB receptor have emerged as a therapeutic strategy for targeting the 
GABAB receptor. Positive allosteric modulators stabilise the GABAB receptor in a 
conformation which increases the affinity of GABA for the receptor (Urwyler et al., 2001b, 
2005). They have been shown to share the behavioural effects of GABAB receptor agonists 
without inducing the sedation, impairment in cognitive function and hypothermic response of 
full agonists (Cryan & Kaupmann, 2005). Furthermore, positive allosteric modulators of the 
GABAB receptor have been shown to reduce the sensitivity of rats to the hyperlocomotor 
effects of acute cocaine administration and reduce the expression of the neuronal marker of 
cfos in the dorsal striatum and nucleus accumbens of these animals (Lhuillier et al., 2007). 
Similarly, the GABAB receptor positive allosteric modulator GS39783 prevents the 
acquisition of nicotine-induced conditioned place preference (CPP), coupled with a reduction 
in ΔfosB accumulation in the striatum (Mombereau et al., 2007). In addition, other positive 
allosteric modulators including  CGP7930 and GS39783 have been shown to decrease 
cocaine self-administration (Smith et al., 2004). Positive allosteric modulators of the GABAB 
receptors have futhermore been repeatedly shown to decrease the expression of cocaine 
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reinforced behaviours (Filip et al., 2007a, 2007; Filip & Frankowska, 2007; Halbout et al., 
2011). 
 
The behavioural effects of drugs of abuse such as cocaine are strongly associated with 
enhanced activation of dopaminergic projections from the ventral tegemental area (VTA) to 
forebrain targets such as the dorsal striatum and the nucleus accumbens. GABAB receptors 
have been demonstrated to influence dopaminergic neuron activity in the VTA (Kalivas et 
al., 1990; Westerink et al., 1996, 1998). Indeed, genetic ablation of the GABAB(1) subunit 
results in elevated dopamine levels in striatal regions and reduced availability of dopamine 
(Vacher et al., 2006). GABAB receptor effector coupling in the VTA is lower in dopamine 
neurons than in GABA neurons resulting in GABAB receptors exerting bidirectional control 
of dopaminergic signalling i.e. higher potency agonists decrease dopaminergic signalling, 
whereas lower potency GABAB agonists such as GHB increase dopaminergic tone (Cruz et 
al., 2004). 
 
A process vital to the regulation of GABAB receptor stability and ligand affinity is 
phosphorylation of the serine 892 (S892) residue of the GABAB2 subunit (Fairfax et al., 
2004). In order to further characterise the role of this phosphorylation process on GABAB 
receptor function in vivo, a knock-in mouse where the serine 892 residue in the GABAB(2) 
subunit is replaced with an alanine residue; the S892A knock-in mouse has been developed. 
The result of this modification is removal of this regulatory phosphorylation site. Preliminary 
research indicates that this mutation results in GABAB receptors producing high potency, 
non-desensitising responses to GABA, specifically on dopaminergic, but not GABAergic 
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neurons in the ventral tegemental area (VTA) suggesting that these GABAB receptors are 
active at tonic levels of GABA (Bettler et al., unpublished). These effects are mimicked in 
vitro by administration of positive modulators of GABAB receptors (Bettler et al. 
unpublished data). Dopaminergic projections to forebrain structures from the VTA form a 
key component of the neuronal circuitry of reward and underpins the rewarding effects of 
drugs of abuse such as cocaine (Koob & Volkow, 2010). Alterations in inhibitory signalling 
in this region can thus be hypothesised to result in alterations in sensitivity to the rewarding 
effects of drugs of abuse. 
 
The current study aims to detect whether the GABAB receptor subtypes play differing roles 
in the regulation of cocaine reward and whether the alterations in GABAergic signalling in 
the VTA of the GABAB(2)-S892A mouse can lead to changes in the behavioural and 
molecular response to cocaine. In order to examine this, we first examined the behaviour of 
the GABAB(2)-S892A mouse in a CPP paradigm. CPP is a widely employed Pavlovian 
technique wherein animals are trained to associate the rewarding effects of a drug of abuse 
such as cocaine with a specific physical context , thus developing a preference for this 
context and is regarded as an effective way of quantifying the rewarding effects of a drug of 
abuse (Cunningham et al., 2006; Tzschentke, 1998). In addition to this, we assessed the 
locomotor sensitisation profile of the GABAB(2)-S892A mouse. Locomotor sensitisation is a 
behavioural phenomenon whereby the acute hyperlocomotor effect of cocaine increases in 
magnitude with repeated cocaine dosing and is regarded as a potential model of incentive 
sensitisation seen in addicted patients (Robinson & Berridge, 2008). Subsequently, we 
examined levels of ΔFosB in the reward-related brain regions of GABAB(2)-S892A  mice. 
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ΔFosB is a protein that is increased in forebrain regions subsequent to chronic cocaine 
exposure and may underpin the neuronal changes that govern the transition from habitual 
drug use to addiction (Nestler, 2008). Finally, we assessed whether the molecular 
consequences of acute cocaine administration were altered by quantifying the levels of the 
immediate early gene cFos, a marker of neuronal activity (Lhuillier et al., 2007; O’Mahony 
et al., 2010), in reward-related brain regions in a separate cohort of GABAB(2)-S892A mice. 
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6.2 Methods 
6.2.1 Mice 
The gene targeting construct contained a neomycin resistance cassette (pRay-2; Genbank 
accession number U63120) flanked by two arms of BALB/c GABAB(2) genomic DNA. The 
S892A mutation in exon 19 was introduced into the 3’ arm along with a diagnostic silent 
NheI restriction site. The targeting construct was electroporated into BALB/c embryonic 
stem cells. Neomycin resistant colonies were screened for homologous recombination by 
PCR, and positive clones confirmed by Southern blot. Positive ES cells were microinjected 
into C57BL/6 blastocysts. Chimeric males were crossed with female BALB/c mice resulting 
in an F1 of inbred Balb/c mice heterozygous for the S892A+neo allele. The neomycin 
cassette in the S892A+neo allele was excised by mating heterozygous F1 mice with BALB/c 
Cre-deleter mice (Vigot et al., 2006). Deletion of the neomycin cassette in the S892A allele 
was confirmed by Southern blot analysis. GABAB(2) immunoblot analysis was performed as 
described previously in the literature (Gassmann et al., 2004). 
 
Male mice homozygous for the GABAB2-S892A mutation were used for all experiments, 
with age match homozygous wildtype littermates used for controls. Genotyping was 
performed on offspring on tail clip samples taken from animals as described in Appendix 1. 
Mice homozygous for the GABAB2-S892A mutation were used for the experiment, with 
wildtype aged match homozygous wildtype mice obtained from the same breeding pairs used 
for controls. 
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Animals were maintained on a 12 hour light dark cycle with lights on 7AM. Food pellets 
and tap water were available ad-libitum.  
 
All experiments were conducted in accordance with the European Directive 86/609/EEC, 
the Recommendation 2007/526/65/EC and approved by the Animal Experimentation Ethics 
Committee of University College Cork and in accordance with methods approved by the 
Veterinary Authority of the City of Basel. All efforts were made to minimize animal 
suffering and to reduce the number of animals used. 
 
 
6.2.2 CPP 
Drug induced CPP is a behavioural paradigm used to determine the acute rewarding effects 
of drugs of abuse in rodents. It consists of an initial habituation phase, a conditioning phase 
where administration of a drug of abuse is repeatedly paired with a specific tactile, visual and 
olfactory context and finally a test phase where the animal is given a choice between the 
drug-paired (CS+) and a non-drug paired (CS-) context. The acute rewarding effects of the 
drug can then be assessed in terms of animal’s preference for the CS+ context (Cunningham 
et al., 2006). The acute rewarding effects of cocaine in this paradigm are well established, 
with cocaine producing robust conditioned place preference across a number of species and 
experimental conditions (Tzschentke, 1998).  
 
To ensure the development of place preference in control mice a protocol based on one 
previously described in the literature (Medvedev et al., 2005) was utilised with slight 
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modifications to the apparatus and an extended period of conditioning to accommodate the 
apparent resistance of the BALB/c strain to the acquisition of place preference. Place 
preference was assessed using a 3-compartment place preference apparatus for mouse (Med 
Associates, VA, USA). The apparatus consisted of a central compartment (7.2cm x 12.7cm x 
12.7cm) flanked on either side by two “choice” compartments (16.8cm x 12.7cm x 12.7cm). 
Compartments were connected via manual guillotine doors. The two choice compartments 
were differentiated by visual, tactile and olfactory cues. One chamber had white walls, a fine 
stainless steel mesh floor (6.35 mm x 6.35 mm grid) and a lemon and ginger teabag (Lipton) 
placed in a stainless steel pan beneath the floor out of physical contact. The other chamber 
had black walls, a floor consisting of 3.2mm diameter bars at intervals of 7.8mm and no 
specific olfactory stimulus. Preliminary experiments were performed on normal BALB/c 
mice to determine conditions (light intensity/ olfactory stimuli) which did not elicit any 
baseline preference (Appendix 2). All chambers were wiped down with 70% ethanol and 
dried with paper towels between each mouse. 
 
Animals were group-housed throughout the experiment and returned to their home cages 
subsequent to each testing session. All sessions were carried out at the same time each day 
for each animal during the light part of the light dark cycle. Behaviour was monitored using 
beam-break detection (13 beams) and analysed using Med-PC® IV (Med Associates, USA) 
software.  
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The conditioned place preference procedure consisted of three phases; an initial habituation/ 
pre-test phase, a conditioning phase and a test phase. The conditioning and test phases were 
then repeated. 
 
Habituation and Pretest 
In the initial habituation phase mice received a single IP injection of 0.9% saline prior to 
being introduced to the central compartment the apparatus and being allowed to explore the 
apparatus freely for 30 minutes. 24 hours later this was repeated and the time spent in each 
chamber was recorded to determine baseline preference.  
 
Conditioning phase 
Mice were randomly allocated a cocaine-context pairing. Conditioning consisted of 4 
alternating pairings of drug with the CS+ chamber and saline with the CS- chamber. 
Conditioning sessions consisted of intraperitoneal injections of either vehicle or cocaine (10 
mg/kg) and then placed in the appropriate chamber for 30 minutes. Locomotor activity was 
recorded for each conditioning session. 
 
Test Phase 
Animals were allowed to explore the apparatus freely for 30 minutes, with the amount of 
time spent in each compartment recorded. 
 
Tissue Collection 
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Animals were killed by cervical dislocation followed by decapitation 24 hours subsequent to 
the second testing session. Brains were removed, briefly immersed in ice cold phosphate-
buffered saline and 1mm slices taken using a mouse brain matrix (RBM 2000C, Asi 
Instruments). Dorsal striata and nuclei accumbens were then dissected out over ice as 
previously described in our lab (Lhuillier et al., 2007). 
 
6.2.3 Acute cocaine treatment 
Mice were singly housed overnight to minimise variability between animals before 
recieviing a single IP injection of either 0.9% saline or 10 mg/kg cocaine Animals were 
killed by cervical dislocation followed by decapitation 2 hours subsequent to cocaine 
injection to ensure maximal expression of the immediate early gene cFos. Brains were 
removed, briefly immersed in ice cold phosphate buffered saline and 1mm slices taken 
using a mouse brain matrix (RBM 2000C, Asi Instruments). Dorsal striata and nuclei 
accumbens were then dissected out over ice. 
 
6.2.4 Western blot 
Western blotting for cFos and ΔFosB were performed using a technique modified from one 
previously described by our lab (Lhuillier et al., 2007). Nuclear fractions were extracted 
from the dorsal striatum and nucleus accumbens of mice from both the locomotor 
monitoring and CPP experiments using a commercially available extraction kit (Active 
Motif, 40010). Extracts were then separated in via SDS-PAGE, with proteins then 
transferred to PVDF membranes. In order to confirm that our extraction had generated a 
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pure nuclear extract, expression levels of histone deacetylase (HDAC-1) was also measured 
with samples not expressing single band expression of HDAC were excluded from analyses 
(Galbán et al., 2003). Briefly, 16-18mg of protein from each sample was separated via 
SDS-PAGE, before proteins were transferred to a polyvinylidene fluoride membrane. 
Membranes were blocked in 5% milk in 1% TBS-Tween 20, prior to overnight incubation 
with primary antibody. Primary antibodies used were sc-253 rabbit anti-cFos (sc-253, Santa 
Cruz, CA, USA, 1:1000), rabbit anti-ΔFosB (sc-48, Santa Cruz, CA, USA, 1:1000) and 
rabbit anti-HDAC-1 (#2062, Cell Signalling, MA, USA, 1:1000) . Membranes were 
subsequently incubated with horseradish peroxidase–conjugated goat anti-rabbit (111-035-
003, Jackson Immunoresearch, Suffolk, UK 1:5000) prior to visualisation using 
Westernbright quantum HRP substrate (K-12042, Advansta, CA, USA). (Densiometric 
analysis of blot images was performed using MultiGauge (v.2.2) software (Fujifilm). 
Expression levels of cFos were measured in extracts from animals treated acutely with 
cocaine, whereas ΔFosB levels were examined in extracts from animals in the CPP study. 
 
6.2.5 Drug treatment 
Animals were treated with 10mg/kg of cocaine (Sigma, UK) in sterile 0.9% (10ml/kg) 
saline. A 10mg/kg dose of cocaine was selected as this is a dose shown in the literature to 
robustly generate behavioural effects and molecular responses in mice (Lhuillier et al., 
2007; Medvedev et al., 2005). 
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6.2.6 Statistical analyses 
Conditioned place preference 
Preference for the CS+ chamber i.e. Time in CS+ chamber minus Time in CS- chamber) at 
the pretest session and the two preference testing sessions, was analysed via two-way 
repeated measures ANOVA with the two factors being genotype and time. The Fisher Least 
Significant Difference (LSD) method was used for post hoc comparisons where indicated 
by significant ANOVA factors.  
 
The number of beam breaks made by animals during each conditioning session was 
recorded across the conditioned place preference experiment i.e. 8 cocaine paired and 8 
saline paired sessions. A two-way repeated measures ANOVA was performed to examine 
the effects of genotype and time. Data from cocaine paired and saline paired sessions was 
analysed separately. The Fisher Least Significant Difference (LSD) method was used for 
post hoc comparisons where indicated by significant ANOVA factors. 
 
Molecular Data 
Relative levels of ΔFosB expression were analyses via students t-test Relative levels of 
cFos expression subsequent to acute cocaine treatment were analysed via two-way 
ANOVA with genotype and cocaine dose as factors, followed by a bonferroni post-hoc test 
where appropriate. 
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6.3 Results 
6.3.1 Conditioned place preference in GABAB(2) -S892A mice 
Both WT and GABAB(2)-S892A mice displayed no preference for either the CS+ or CS- 
chambers of the CPP apparatus at baseline, apart from one WT animal that displayed a 
preference to the drug paired chamber at baseline (greater than 2 standard deviations from 
mean preference) and was excluded from the study. Both WT and GABAB(2)-S892A mice 
developed a clear preference for the drug paired chamber at trials one and two, with Two-
way ANOVA detecting a significant effect of time on levels of preference (F(2,52) = 9.67, p 
< 0.005). Two-way ANOVA revealed no effect genotype on preference (F(1,52) =  0.01, p = 
0.92) nor a time vs genotype interaction (F(2,52) =  1.16, p = 0.3205) (Fig 1.). 
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Figure 1 – Preference of Wildtype and GABAB2- S892A mice across the CPP paradigm. 
Preference data is measured as the time in seconds spent in the drug paired chamber minus 
time spent in the saline paired chamber. Data is expressed as mean +/- SEM. 
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6.3.2 Locomotor sensitization to cocaine in GABAB(2) -S892A mice 
The locomotor response of WT and GABAB2-S892A mice in response to cocaine is shown 
in Figure 2. Interestingly, when the locomotor activity of the animals in the CPP paradigm 
was analysed it was revealed that cocaine administration did not cause any locomotor 
activity following the first doses. Both strains however displayed a locomotor sensitisation 
to cocaine, displaying markedly increased locomotor activity after the 8
th
 cocaine dose. 
Two-way ANOVA of the total number of beam breaks revealed no effect of time 
(F7,126=0.96, p=0.46)or of genotype (F1,126=0.004, p=0.95) on locomotor activity across 
saline paired training sessions as well as detecting no genotype-time interaction 
(F7,126=0.79, p=0.60) (Fig 2A). Analyses of cocaine paired training sessions revealed a 
significant effect of time on beam break frequency indicating locomotor sensitisation effect 
(F7,112=13.81, p<0.0001). No effect of genotype (F1,112=0.30, p=0.59) and no genotype x 
time interaction (F7,112=0.38, p=0.91)was observed (Fig 2B). 
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Figure 2 – Cocaine induced hyperlocomotor response of Wildtype and GABAB2- S892A 
mice across the conditioning days of the CPP experiment. A) Locomotor response to 
cocaine across the conditioning period. B) Locomotor response to saline across the 
conditioning period. Data is measured as no. of beam breaks per 30 minute conditioning 
session and expressed as mean +/- SEM 
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6.3.3 Western blot analyses 
Once samples failing to express pure HDAC-1 and samples displaying low levels of overall 
protein content were excluded from our study an n of 7-9 samples remained in each group 
for the dorsal striatum and nucleus accumbens. A Student’s T-test of our western blot 
analyses revealed no significant difference was observed between GABAB2-S892A and WT 
animals in terms of dorsal striatum ΔFosB accumulation (p= 0.47) (Fig 3A) or in terms of 
nucleus accumbens ΔFosB accumulation (p=0.46) (n=7-9 samples per group) (Fig 3B). 
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Figure 3 – Levels of ΔFosB protein in the A) dorsal striatum and B) nucleus accumbens 
subsequent to the CPP experiment as measured by western blot. Protein levels are 
expressed in terms of densitometry of band relative to β-actin expression. Data is expressed 
in terms of mean +/- SEM. 
 
Once samples failing to express pure HDAC-1 and samples displaying low levels of overall 
protein content were excluded from our study an n of 5-6 samples remained in each group 
for the dorsal striatum and nucleus accumbens. In samples from the dorsal striatum of 
animals treated acutely with cocaine (n=5-6), two-way ANOVA revealed no significant 
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effects of cocaine treatment (F1,18=0.77, p=0.39) or of genotype (F1,18=0.43, p=0.52) on 
cFos expression. No interaction was detected between cocaine and genotype (F1,18=0.09, 
p=0.76). An inadequate number of samples from the nucleus accumbens were shown to 
contain pure HDAC protein via western blot for any meaningful statistical analysis. This 
may be due to difficulties in obtaining a pure nuclear fraction due to difficulties in 
extracting protein from a small sample of tissue such as the tissue collected for our studies. 
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Figure 4 – Levels of cFos protein in the dorsal striatum 2 hours subsequent to acute 
cocaine injection (0/10 mg/kg) as measured by western blot. Protein levels are expressed in 
terms of densitometry of band relative to β-actin expression. Data is expressed in terms of 
mean +/- SEM. 
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6.4 Discussion 
Increasing evidence points to a role for the GABAB receptor in the pathophysiology and 
treatment of cocaine dependence. In these studies, to the best of our knowledge for the first 
time, investigated the role of the S892 residue phosphorylation site of the GABAB(2) subunit 
in the manifestation of the acute and chronic behavioural and molecular effects of cocaine 
using a transgenic mouse model whereby the phosphorylation of the S892 residue of the 
GABAB(2) subunit is eliminated resulting in a tonically active receptor. Interestingly, the 
GABAB(2)-S892A mouse did not display any altered preference behaviour compared to 
wildtype and no difference in locomotor activity compared to wildtype mouse at baseline as 
well as with exposure to acute and chronic cocaine. This appears to conflict with 
preliminary evidence that the GABAB(2)-S892A mouse displays considerably enhanced 
GABAB receptor function in dopaminergic neurons projecting from the VTA to forebrain 
(Bettler et al. unpublished data). Furthermore, several studies have clearly shown that like 
other GPCRs, GABAB receptor activity is potently modulated by the phosphorylation status 
of the receptor (Terunuma et al., 2010a), with the S892 site on the GABAB(2) subunit being 
a target of particular importance (Couve et al., 2002; Fairfax et al., 2004). In addition, we 
did not observe reduced levels of ΔFosB expression in the nucleus accumbens or dorsal 
striatum of GABAB(2)-S892A mice subsequent to CPP treatment which suggests that these 
mice do not differ in susceptibility to the molecular effects of chronic cocaine. Overall, 
current data on the GABAB(2)-S892A mouse suggest that although they display reduced 
sensitivity to cocaine at a neuronal level, this does not translate to the levels of reward 
system function or behavioural sensitivity. 
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Recent findings have also shown that GABAB(1)-S867 phosphorylation dependant receptor 
internalisation of GABAB receptors is governed by NMDA receptor activation and 
subsequent CaMKII activity (Guetg et al., 2010). Indeed, evidence has suggested a much 
more complex regulation of GABAB receptor activity dependant not only on 
phosphorylation status but on the formation of complexes with potassium channel tetramer 
domains (KCTDs) (Schwenk et al., 2010). Thus, the picture that emerges is that of a 
complex situation involving numerous intracellular signalling pathways and molecules and 
indeed several phosphorylation sites on the GABAB receptor itself. Compensatory changes 
in the expression or function of other elements of these regulatory mechanisms cannot be 
excluded. It should also be noted that current unpublished in vitro data from the GABAB(2)-
S892A mouse has solely examined levels of S892 phosphorylation and GABAB receptor 
function in a subset of neurons in the VTA. Compensatory changes or indeed a lack of 
change in function in other reward-related brain regions such as the nucleus accumbens or 
dorsal striatum may underlie the maintenance of a wildtype behavioural phenotype in these 
animals.  
 
It is also important to bear in mind that cocaine administration has been demonstrated to 
alter GABAB receptor function in reward-related brain regions. Baclofen administration to 
cocaine-sensitised animals results in increased levels of glutamate in the mPFC, VTA and 
nucleus accumbens, an effect not seen in cocaine naïve animals (Jayaram & Steketee, 2004) 
and that repeated cocaine treatment results in decreased levels of baclofen-induced 35S-
GTPγS binding in the VTA, suggestive of reduced levels of receptor effector coupling 
(Kushner & Unterwald, 2001). Most importantly of all, it has also been shown that GABAB 
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receptor function is decreased in the nucleus accumbens of rats subsequent to 3 weeks of 
cocaine treatment with no reductions in GABAB(1) or GABAB(2) protein levels, suggesting 
alterations to functionality (Xi et al., 2003). The functional changes in GABAB receptor 
function seen in response to repeated cocaine administration thus appear to be dependant on 
post-translational alterations to the receptor such as S892 phosporylation or protein-protein 
interactions. Indeed, changes to cocaine-dependant regulation of GABAB receptor function 
throughout the brain may further complicate interpretation of the behavioural responses of 
the GABAB(2)-S892A mouse to cocaine. Recent data has furthermore demonstrated that 
dopaminergic neurons projecting to striatal regions release  GABAA receptor activating 
ligands, likely GABA, as a co-transporter with dopamine (Tritsch et al., 2012). In light of 
this data, the simple model of GABA mediating addiction solely in the VTA becomes 
redundant with GABA receptor activity in forebrain targets such as the nucleus accumbens, 
striatum and prefrontal cortex playing equally important role in regulating the behavioural 
effects of drugs of abuse. 
 
Our western blot experiments, in support of our behavioural data, demonstrated no 
significant differences between GABAB(2)- S892A and WT mice in terms of ΔFosB 
accumulation subsequent to the CPP paradigm, and displayed no differences in cFos 
accumulation after acute cocaine treatment. This data stands, like our behavioural data, in 
contrast to reports from our lab showing that GABAB receptor positive modulator 
administration can reduce the accumulation of ΔFosB in response to repeated cocaine 
treatment and attenuate increases in levels of cFos in response to acute cocaine treatment 
(Lhuillier et al., 2007). Our data further suggests that GABAB(2)- S892A mice are 
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indistinguishable from their WT littermates in terms of cocaine sensitivity. It must be stated 
however that the small tissue samples used in this experiment resulted in difficulties in 
generating a pure nuclear extract from our samples. As such, our molecular data must be 
interpreted with caution. 
 
The background strain of a transgenic mouse can play a significant influence on behaviour 
(Jacobson & Cryan, 2007) and a significant caveat to the use of conditioned place 
preference in examining the GABAB(2)-S892A mouse is the lack of robust place preference 
to cocaine seen in the BALB/c mouse strain (Belzung & Barreau, 2000). BALB/c mice 
have also been shown to be relatively insensitive to the locomotor effects of acute cocaine 
treatment as well as the reinforcing effects of cocaine reward (Thomsen & Caine, 2011; 
Eisener-Dorman et al., 2011). Indeed in the present study, no robust increases in cFos 
expression, a marker of neuronal activation were seen in the dorsal striatum of either 
wildtype or GABAB2-S892A mice. However, it must be said that GABAB receptor 
knockout do not survive to adulthood when generated on mouse strains other than the 
BALB/c (Schuler et al., 2001; Prosser et al., 2001). Given the vastly different levels of 
sensitivity to GABAB agonist treatment displayed by different mouse strains (Jacobson & 
Cryan, 2005), it would be unsurprising if differing effects of GABAB receptor mutation 
were seen across the spectrum of background strains. 
 
It must also be borne in mind that we have only used a few of the many animal behavioural 
models of drug abuse and indeed used techniques that model only certain facets of drug 
abuse disorders in the clinic. Further characterisation across the spectrum of behavioural 
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techniques including self-administration and intracranial self stimulation based paradigms 
(Koob & Volkow, 2010) remains to be carried out, and may indeed reveal a role for S892 
phosphorylation in determining drug of abuse sensitivity. Other molecular markers of drug 
exposure such as DARRP-32 and pCREB/CREB ratio (Lhuillier et al., 2007) should 
perhaps also be investigated. Indeed, study of the GABAB(2)-S892A mouse in terms of 
other drugs of abuse such as nicotine and alcohol may  represent a route for further 
research.  
 
In conclusion, our data suggests that the GABAB(2)-S892A mouse is indistinguishable from 
its wildtype in terms of its cocaine sensitivity. These findings highlight how the regulation 
of GABAB receptor function in vivo is a highly complex system involving multiple receptor 
phosphorylation sites and indeed several interactions with complementary proteins (Pinard 
et al., 2010). It remains difficult to predict how pharmacological and genetic interventions 
aimed at the GABAB receptor system will affect behaviour or other brain functions. The 
need for detailed in vitro studies to unravel the molecular bases of the heterogeneity of 
GABAB receptor is paramount to the development of novel GABAB directed therapeutic 
approaches.
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Abstract 
The GABAB receptor are made up of heterodimers of GABAB(1) and  GABAB(2) receptor 
subunits. In addition GABAB(1) receptors exist as two distinct isoforms based on the 
presence or absence of several sushi domains of the GABAB(1) subunit of the receptor 
heterodimer. These variants are referred to as the GABAB(1a) and GABAB(1b) receptor 
subtypes.  Development of mice wherein either subunit is selectively ablated, GABAB(1a)
-/- 
and GABAB(1b)
-/- 
mice, has revealed that the two receptor subunit isoforms differentially 
regulate several behavioural responses, including fear behaviour, learning, memory and 
stress sensitivity. However, despite the GABAB receptor being shown act as a crucial 
modulator of the behavioural effects of drugs of abuse, the GABAB(1a)
-/- 
and GABAB(1b)
-/-  
mice have not been characterised in regard to their sensitivity to drugs of abuse. We thus 
sought to characterise the behaviour of the GABAB(1) specific isoform null mice in a 
cocaine-induced conditioned place preference (CPP) paradigm as well as in terms of their 
locomotor sensitivity to acute and repeated cocaine administration. We furthermore sought 
to examine levels of neuronal activation in reward-related forebrain structures subsequent 
to acute cocaine administration and quantify levels of the FosB splice variant, ΔFosB, in 
similar regions subsequent to our CPP paradigm. ΔFosB is a neuronal marker of prolonged 
cocaine exposure and is believed to underpin the development of drug addiction.  Our data 
demonstrated enhanced locomotor activation in response to acute cocaine as well as 
enhanced locomotor sensitisation to cocaine in GABAB(1a)
-/- 
mice compared to wildtype 
(WT) mice, whereas GABAB(1b)
-/-  
mice failed to develop locomotor sensitisation despite 
displaying higher levels of basal locomotor activity. Our data furthermore suggests that 
GABAB(1a)
-/- 
mice display a heightened locomotor response to acute cocaine administration.
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7.1 Introduction 
Native GABAB receptors are obligate heterodimers of the GABAB(1) and GABAB(2) receptor 
subunits and can be divided into two specific receptor subtypes characterised by differing 
GABAB(1) isoforms; GABAB(1a) and GABAB(1b)  (Möhler & Fritschy, 1999; Bettler et al., 
2004) These isoforms are distinguished by the presence, in GABAB(1a), or the absence, in 
GABAB(1b) of two sushi domains at the n-terminus (Couve et al., 2000). With the generation 
of knockout mice with either isoform selectively ablated (Jacobson et al., 2006a) the role 
played by these isoforms in mediating fear behaviour, learning, memory and stress 
sensitivity have been extensively characterised (Jacobson et al., 2007b, 2006b, 2007a; 
Shaban et al., 2006; Moloney et al., 2012).  Characterisation of the GABAB(1a) and 
GABAB(1b) containing isoforms have revealed distinctive anatomical and functional 
differences. Although both isoforms appear to behave as presynaptic autoreceptors, 
inhibiting GABA release, the GABAB(1a) isoform also acts as a heteroreceptor modulating 
glutamate release in response to spill over of GABAB from GABAergic synapses. The 
GABAB(1b) isoform mediates inhibitory effects of GABA at post-synaptic sites (Vigot et al., 
2006; Waldmeier et al., 2008). 
 
The GABAB receptor is an emerging candidate drug target in the treatment of addiction 
(Roberts, 2005; Vlachou & Markou, 2010). Clinical data suggests that the GABAB receptor 
agonist baclofen may be an effective treatment for alcohol and cocaine addiction (Vocci & 
Elkashef, 2005; Brennan et al., 2013). Moreover, a plethora of preclinical data has shown 
that baclofen inhibits self-administration of a spectrum of drugs of abuse, including cocaine, 
as well as preventing reinstatement of drug craving in rodents (Brebner et al., 2005; Walker 
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and Koob, 2007; Spano et al., 2007; Filip et al., 2007; Fattore et al., 2009). More recently 
positive modulators of the GABAB receptors have emerged and been shown to inhibit the 
behavioural and molecular effects of cocaine (Slattery et al., 2005b; Lhuillier et al., 2007; 
Filip et al., 2007a; Filip & Frankowska, 2007; Halbout et al., 2011) 
 
The behavioural effects of drugs of abuse such as cocaine are strongly associated with 
enhanced activation of dopaminergic projections from the ventral tegemental area (VTA) to 
forebrain targets such as the dorsal striatum and the nucleus accumbens (Koob & Volkow, 
2010). The GABAB receptor acts as an important modulator of dopaminergic innervation 
from the VTA to the forebrain, with enhanced dopaminergic transmission along this pathway 
observed in GABAB receptor-deficient mice (Vacher et al., 2006). Further research has 
revealed a diversity in the GABAB receptor population in the VTA, with a low effector 
coupling population expressed in dopaminergic neurons and a population with higher 
effector coupling expressed in GABAergic neurons (Cruz et al., 2004). Given the differential 
role of GABAB(1) receptor subunit isoforms in regulating neurotransmitter release it is 
possible that they play distinct roles in mediating the rewarding effects of drugs of abuse.  
 
Interestingly, GABAB(1b)
-/-
 mice display a hyperlocomotor phenotype in response to novelty 
and during the circadian dark phase (Jacobson et al., 2006a). Given the well established role 
played by dopamine in regulating levels of locomotor activity (Kelly & Iversen, 1976), it 
may be that the GABAB receptor subtypes play differing roles on dopaminergic tone. 
However, the role played by these isoforms in regulating reward behaviour and specifically 
drug of abuse sensitivity have yet to be characterised. Using GABAB(1a)
-/- 
and GABAB(1b)
-/- 
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mice previously characterised in our lab (Jacobson et al., 2006a, 2006b, 2007a, 2007b), the 
current study aimed to determine whether GABAB receptor subtypes play differing roles in 
the regulation of cocaine and if ablation of either subunit can lead to changes in the 
behavioural and molecular response to cocaine.  To this end, we determined the levels of 
hyperlocomotor response to acute cocaine administration, the sensitivity of these mice to the 
rewarding effects of cocaine in a conditioned place preference paradigm, and the 
psychomotor sensitisation effect of cocaine in these mice. These behaviours are models of 
the acute rewarding effects of cocaine (locomotor activity, CPP) (Morgan et al., 2012; 
Tzschentke, 2007) and incentive sensitisation (psychomotor sensitisation) (Robinson & 
Berridge, 2008). We furthermore sought to characterise the molecular responses of WT, 
GABAB(1a)
-/- 
and GABAB(1b)
-/- 
 mice to repeated and acute cocaine administration. In 
particular we examined the effects of repeated cocaine injection on expression levels of 
ΔFosB in reward-related brain areas. This splice variant of FosB has been repeatedly shown 
to accumulate and persisit in forebrain regions such as the dorsal striatum subsequent to 
repeated cocaine administration and may underlie the neuronal changes that precipitate the 
development of drug addiction (Chao & Nestler, 2004; Nestler, 2008). Additionally we 
examined levels of cFos expression in the dorsal striatum and nucleus accumbens of 
GABAB(1a)
-/- 
and GABAB(1b)
-/- 
 mice subsequent to acute cocaine administration as a surrogate 
measurement of acute neuronal activation (Singewald, 2007; Lhuillier et al., 2007). 
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7.2 Methods 
7.2.1 Mice 
GABAB(1a)
-/- 
and GABAB(1b)
-/-
 mice were generated as previously described (Vigot et al., 
2006). Briefly, GABAB(1a) and GABAB(1b) initiation codons were converted to stop codons 
by targeted insertion of a floxed neo-cassette. All the mutant and WT mice were maintained 
on a pure inbred BALB/c genetic background. GABAB(1a)
−/−
 and GABAB(1b)
−/−
 mice were 
derived from homozygous breeding of siblings originating from the founding heterozygotic 
mice, while homozygous wildtype controls for the GABAB(1) isoform mutant mice were 
derived from mating together wildtype siblings generated from GABAB(1a)
+/−
 and 
GABAB(1b)
+/−
 heterozygous breeding. The breeding strategy was conducted in accordance 
with the recommendations proposed by The Jackson Laboratory to obviate genetic drift and 
the formation of substrains (http://jaxmice.jax.org/geneticquality/guidelines.html). Animals 
were maintained on a 12 hour light dark cycle. Food pellets and tap water were available 
ad-libitum. 
 
All experiments were conducted in accordance with the European Directive 86/609/EEC, 
the Recommendation 2007/526/65/EC and approved by the Animal Experimentation Ethics 
Committee of University College Cork and in accordance with methods approved by the 
Veterinary Authority of the City of Basel. All efforts were made to minimize animal 
suffering and to reduce the number of animals used. 
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7.2.2 Cocaine-induced hyperlocomotion 
Locomotor activity was assessed in transparent plexiglas boxes (dimensions: 19 x 31 x 16 
cm) by quantifying infrared light beam interruptions
 
along the x- and y-axes through the 
walls of the box as described previously (Cryan et al., 2004). The distance travelled was 
automatically
 
calculated using a TSE Moti system (TSE, Bad Homburg, Germany). Mice 
were individually placed in novel locomotor activity boxes and habituated for 60 min. This 
duration was chosen to ensure complete habituation of all mutant strains, as GABAB(1b)
-/- 
mice have been previously described as showing a hyperlocomotor phenotype and slower 
habituation in novel environment compared to wildtype and GABAB(1a)
-/- 
mice (Jacobson et 
al., 2006a). All mice were then injected with cocaine (10 mg/kg) and immediately returned 
to the locomotor activity box and activity recorded for a further 60 min. The procedure and 
dose of cocaine was selected based on previous experiments in this laboratory (Lhuillier et 
al., 2007).  
 
7.2.3 Conditioned place preference 
Mice (n=7-11 per group) were tested in terms of cocaine induced place preference. A 
conditioned place preference procedure was modified from a protocol in the literature 
(Medvedev et al., 2005). Place preference was assessed using a 3-compartment place 
preference apparatus for mouse (Med Associates, VA, USA). The apparatus consisted of a 
central compartment (7.2cm x 12.7cm x 12.7cm) flanked on either side by two “choice” 
compartments (16.8cm x 12.7cm x 12.7cm). Compartments were connected via manual 
guillotine doors. The two choice compartments were differentiated by visual, tactile and 
olfactory cues. One chamber had white walls, a fine stainless steel mesh floor (6.35 mm x 
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6.35 mm grid) and a lemon and ginger teabag (Lipton) placed in a stainless steel pan beneath 
the floor out of physical contact. The other chamber had black walls, a floor consisting of 
3.2mm diameter bars at intervals of 7.8mm and no specific olfactory stimulus. Preliminary 
experiments were performed on normal BALB/c mice to determine conditions (light 
intensity/ olfactory stimuli) which did not elicit any baseline preference (Appendix 2). All 
chambers were wiped down with 70% ethanol and dried with paper towels between each 
mouse. 
 
Animals were group housed throughout the experiment and returned to their home cages 
subsequent to each testing session. All sessions were carried out at the same time each day 
for each animal during the light part of the light dark cycle. Behaviour was monitored using 
beam-break detection (13 beams) and analysed using Med-PC® IV (Med Associates, USA) 
software.  
 
The conditioned place preference procedure consisted of three phases; an initial habituation/ 
pre-test phase, a conditioning phase and a test phase. The conditioning and test phases were 
then repeated. 
 
Habituation and pretest 
In the initial habituation phase mice received a single IP injection of 0.9% saline prior to 
being introduced to the central compartment the apparatus and being allowed to explore the 
apparatus freely for 30 minutes. 24 hours later this was repeated and the time spent in each 
chamber was recorded to determine baseline preference.  
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Conditioning phase 
Mice were randomly allocated a cocaine-context pairing. Conditioning consisted of 4 
alternating pairings of drug with the CS+ chamber and saline with the CS- chamber. 
Conditioning sessions consisted of intraperitoneal injections of either vehicle or cocaine and 
then placed in the appropriate chamber for 30 minutes. Locomotor activity was recorded for 
each conditioning session. 
 
Tests phase 
Animals were allowed to explore the apparatus freely for 30 minutes, with the amount of 
time spent in each compartment recorded. 
Animals were killed by cervical dislocation followed by decapitation 24 hours subsequent to 
the second testing session. Brains were removed, briefly immersed in ice cold phosphate-
buffered saline and 1mm slices were taken using a mouse brain matrix (RBM 2000C, Asi 
Instruments). Dorsal striata and nuclei accumbens were then dissected out over ice. 
 
7.2.4 Tissue collection 
Wildtype mice were given either vehicle or cocaine (10 mg/kg, n=5) via IP injection. 
GABAB(1a)
-/- 
 (n=7) and GABAB(1b)
-/- 
 (n=12) mice received only cocaine. Two hours after 
cocaine or vehicle injection, mice were sacrificed by cervical dislocation, brains were 
removed, briefly immersed in ice cold phosphate-buffered saline and 1mm slices were 
taken using a mouse brain matrix (RBM 2000C, Asi Instruments). Dorsal striata and nuclei 
accumbens were then dissected out over ice. 
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7.2.5 Western blot  
Western blotting for cFos and ΔFosB were performed using a tehchnique modified from 
one previously described by our lab (Lhuillier et al., 2007). Nuclear fractions were 
extracted from the dorsal striatum and nucleus accumbens of mice from both the locomotor 
monitoring and CPP experiments using a commercially available extraction kit (Active 
Motif, 40010). Extracts were then separated in via SDS-PAGE, with proteins then 
transferred to PVDF membranes. In order to confirm that our extraction had generated a 
pure nuclear extract, expression levels of histone deacetylase (HDAC-1) was also measured 
with samples not expressing single band expression of HDAC were excluded from analyses 
(Galbán et al., 2003). Briefly 16-18mg of protein from each sample was separated via SDS-
PAGE, before proteins were to transfered to a polyvinylidene fluoride membrane. 
Membranes were blocked in 5% milk in 1% TBS-Tween 20, prior to overnight incubation 
with primary antibody. Primary antibodies used were sc-253 rabbit anti-cfos (sc-253, Santa 
Cruz, CA, USA, 1:1000), rabbit anti ΔFosB (sc-48, Santa Cruz, CA, USA, 1:1000) and 
rabbit anti-HDAC-1 (#2062, Cell Signalling, MA, USA, 1:1000) . Membranes were 
subsequently incubated with horseradish peroxidase–conjugated goat anti-rabbit (111-035-
003, Jackson Immunoresearch, Suffolk, UK 1:5000) prior to visualisation using 
Westernbright quantum HRP substrate (K-12042, Advansta, CA, USA). (Densiometric 
analysis of blot images was performed using MultiGauge (v.2.2) software (Fujifilm). 
Expression levels of cFos were measured in extracts from animals treated acutely with 
cocaine, whereas ΔFosB levels were examined in extracts from animals in the CPP study. 
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7.2.6 Statistical analysis 
Locomotor response to acute cocaine 
Distance travelled during the 60 min habituation period prior to cocaine administration, the 
subsequent distance travelled in the 60 min after cocaine administration, were summed into 
5 min intervals and analyzed using 2-way repeated measures analysis of variance 
(ANOVA) with factors “genotype” and “time”. Summed (within animal) pre- and post-
cocaine distance travelled were analyzed using one-way ANOVA. The Fisher Least 
Significant Difference (LSD) method was used for post hoc comparisons where indicated 
by significant ANOVA factors.  
 
Conditioned place preference 
Preference for the CS+ chamber i.e. Time in CS+ chamber minus Time in CS- chamber) at 
the pretest session and the two preference testing sessions, was analysed via two-way 
repeated measures ANOVA with the factors genotype and time. The Fisher Least 
Significant Difference (LSD) method was used for post hoc comparisons where indicated 
by significant ANOVA factors.  
 
The number of beam breaks made by animals during each conditioning session was 
recorded across the conditioned place preference experiment i.e. 8 cocaine paired and 8 
saline paired sessions. A two-way repeated measures ANOVA was performed to examine 
the effects of genotype and time. Data from cocaine paired and saline paired sessions was 
analysed separately. The Fisher Least Significant Difference (LSD) method was used for 
post hoc comparisons where indicated by significant ANOVA factors. The total number of 
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beam breaks for cocaine and saline paired sessions across the experiment were recorded. 
These were analysed via one-way ANOVA followed by a Neumann-keuls post-hoc test 
where appropriate. 
 
Molecular analyses 
Relative levels of ΔFosB expression were analysed via one-way ANOVA followed by a 
Neumann-keuls post-hoc test where appropriate. When analysing relative levels of cFos 
expression subsequent to acute cocaine treatment, initially we compared levels of cFos 
expression between WT animals treated with 0 and 10mg/kg of cocaine via Student’s t-test. 
Subsequently levels of cFos expression were compared between WT, GABAB(1a)
-/- 
and 
GABAB(1b)
-/- 
mice treated with 10 mg/kg cocaine using one-way ANOVA followed by a 
Neumann-keuls post-hoc test where appropriate. 
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7.3 Results 
7.3.1 Cocaine-induced hyperlocomotion 
The locomotor responses of WT, GABAB(1a)
-/- 
and GABAB(1b)
-/- 
mice to acute cocaine 
injection is shown in Figure 1. Distance travelled in the 1 hour preceding cocaine 
administration was significantly affected by genotype and time (genotype: F2, 371= 8.075, 
p<0.01; time: F11,371 = 19.539, p<0.001; interaction: F22,371=1.398, p=0.112). Post hoc 
analysis revealed that, overall, GABAB(1b)
-/- 
mice travelled a greater mean distance per 5 
min block than wildtype (P < 0.001) and GABAB(1a)
-/-  
mice (P = 0.01), although wildtype 
and GABAB(1a)
−/−
 mice did not differ in this regard (Least square mean m per 5 min block ± 
sem: wildtype: 5.4 ± 0.5; GABAB(1a)
−/−
 6.1 ± 0.5, GABAB(1b)
−/−
 8.1 ± 0.5 ).  Post hoc 
analysis to address the main effect of “time” demonstrated that on average, mice had 
habituated by approximately 30-35 min after entry to the novel locomotor box (p > 0.05 for 
pair-wise comparisons between 30 min and each subsequent time point, with the exception 
of time point 40 min versus 60 min (p < 0.01). LSD analysis to specifically address the 
duration of hyperlocomotor activity of  GABAB(1b)
-/- 
indicated that this strain showed higher 
locomotor activity than wildtype mice at each of the 5 min timepoints from 5 to 55 min 
(inclusive), but had habituated to a point that was not different from wildtype mice at time-
point 60 min (p > 0.05; Fig.1.).  In comparison, GABAB(1a)
-/- 
mice differed from wildtype 
mice only at the first 5 min time-point (p < 0.05; Figure 1).   
 
As expected, cocaine increased the distance travelled in all mice. Genotype and time 
significantly affected distance travelled after cocaine (genotype: F2, 371 = 5.312, P < 0.05; 
  
 197 
time: F11,371 = 23.147, P < 0.001; interaction: F22,371 = 1.217, P = 0.231). However, in 
contrast to the pre-cocaine habituation period, the GABAB(1a)
-/- 
mice travelled a greater 
distance than wildtype mice after cocaine (P < 0.001), whereas GABAB(1b)
-/- 
mice did not 
differ from GABAB(1a)
-/- 
or wildtype mice (P > 0.05; Least square mean m per 5 min block 
± sem: wildtype: 4.8 ± 0.7; GABAB(1a)
-/- 
8.3 ± 0.8, GABAB(1b)
-/- 
6.2 ± 0.7). LSD analysis to 
specifically determine the duration of the hypersensitive responses to cocaine indicated 
GABAB(1a)
-/-  
mice were more active that cocaine-treated wildtype mice for the 30 min after 
cocaine administration, but did not different from wildtype mice subsequent to this time-
point (Fig. 1).  
 
Analysis of the summed distance travelled before (0-60 min) and after (60-95 min) cocaine 
mirrored that of the time course analysis (Fig. 1A). Genotype significantly affected distance 
travelled during pre-cocaine habituation (F2, 30 = 8.075, P < 0.01), with GABAB(1b)
-/- 
mice 
travelling more distance than wildtype (P < 0.001) and GABAB(1a)
-/- 
(P = 0.01), although 
wildtype and GABAB(1a)
-/- 
mice did not differ in this regard (P > 0.05). Following cocaine 
administration, summed distance travelled from 60-95 min was significantly greater in the 
GABAB(1a)
-/- 
mice relative to both wildtype  (P < 0.01) and GABAB(1b)
-/- 
 mice (P < 0.05), 
although again, wildtype and GABAB(1b)
-/- 
mice did not differ in this regard (P > 0.05; Fig. 
1B.).  
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Figure 1 -  A) Time course showing locomotor activity of wildtype (WT), GABAB1A
-/-
 (1a
-/-
) 
and GABAB1A)
-/-
 (1b
-/-
) mice in a novel environment, and 60 min later in the same 
environment, their responses to acute cocaine administration (10 mg/kg, i.p.; Wildtype 
(WT) n = 11; 1a
-/-
 n = 9; 1b
-/-
 n = 11.;
 #
, 
# #
, 
# # #
 P < 0.05, P < 0.01, P < 0.001 1a 
-/-
 vs WT; 
*
, 
**
, 
***
 P < 0.05, P < 0.01, P < 0.001 1b
-/-
 vs WT). B). Summed distance travelled from 0-
60 min in the novel environment in the same mice (
***
 P < 0.001 1b
-/-
 vs WT; 
# #
 P < 0.01 
1b
-/-
 vs 1a
-/-
). C). Summed distance travelled during the 30 min following cocaine 
administration in the same mice (
**
 P < 0.01 1a
-/-
 vs WT; 
#
 P < 0.05 1a
-/-
 vs 1b
-/-
). 
 
7.3.2 Conditioned place preference 
Levels of preference of WT, GABAB(1a)
-/- 
and GABAB(1b)
-/- 
mice for the CS+ chamber are 
displayed in Table 1.  WT,  GABAB(1a)
-/- 
and GABAB(1b)
-/- 
mice  displayed no preference for 
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either the CS+ or CS- chambers of the CPP apparatus at baseline, however none of the 
groups mice developed a clear preference for the drug paired chamber at either trials one or 
two. Two-way ANOVA showed no significant effect of time on levels of preference (F(2,42) 
= 0.52, p=0.60). Further Two-way ANOVA revealed no effect genotype on preference 
(F(2,42) =  1.0, p = 0.38) nor a time vs genotype interaction (F(4,42) =  0.65, p = 0.63). 
 
 Preference for CS+ chamber (seconds ± SEM) 
Trial Session WT GABAB(1a)
-/-
 GABAB(1b)
-/-
 
Pretest -130.8 ± 348.5 -115.5 ± 3941.4 -152.9 ± 315.5 
Test 1 -410.4 ± 370.4 394.5 ± 307.6 93.30 ± 282.4 
Test 2 -177.3 ± 325.8 157.1 ± 168.1 289.9 ± 184.0 
 
Table 1 – Preference of Wildtype, GABAB(1a)
-/- 
and GABAB(1b)
-/- 
mice across the CPP 
paradigm. Preference data is described as the time in seconds spent in the drug paired 
chamber minus time spent in the saline paired chamber. Data is expressed as mean +/- 
SEM. 
 
7.3.3 Locomotor responses to cocaine in the CPP paradigm 
The locomotor response of WT, GABAB(1a)
-/- 
and GABAB(1b)
-/- 
mice in response to cocaine 
is shown in Figure 2. Two-way ANOVA of the total number of beam breaks revealed a 
significant effect of genotype (F2,168=4.15, p<0.05). It is of note that this effect is time 
dependant, diminishing as the experiment progresses with two way ANOVA also revealing 
a significant effect of time (F7,168=2.46, p<0.05). When total cumulative beam breaks were 
analysed using one way ANOVA, a significant effect of genotype was detected (F2,26= 
4.15, p<0.05). Post hoc analysis using the Newman-Keuls multiple comparison test 
revealed that GABAB(1b)
-/- 
mice generated more cumulative beam breaks compared to WT 
(p>0.05) mice and GABAB(1a)
-/- 
mice (p>0.05). WT mice and GABAB(1a)
-/- 
mice did not 
display significantly different numbers of beam breaks (p=0.70) (Fig 2A).  Interestingly 
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when the locomotor activity of the animals in the CPP paradigm was analysed it was 
revealed that cocaine administration did not cause any locomotor activity following the first 
doses.  Analyses of cocaine paired training sessions revealed a significant genotype-time 
interaction effect on beam break frequency (F14,168=3.26, p<0.0001) indicating a locomotor 
sensitisation effect between genotypes. Furthermore, significant effects of genotype 
(F2,168=8.54, p<0.0001) and time (F7,168=6.66, p<0.01) were observed.  When total 
cumulative beam breaks were analysed using one way ANOVA, a significant effect of 
genotype was detected (F2,26= 8.55, p<0.001). Post hoc analysis using the Newman-Keuls 
multiple comparison test revealed that GABAB(1b)
-/- 
mice generated less cumulative beam 
breaks across the cocaine paired sessions than WT mice (p<0.05) and GABAB(1a)
-/- 
mice 
(p>0.01). GABAB(1a)
-/- 
mice trended towards an increased number of cumulative beam 
breaks relative to WT mice (p=0.08) (Fig 2B). 
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Figure 2 – Cocaine induced hyperlocomotor response of Wildtype, GABAB(1a)
-/- 
and 
GABAB(1b)
-/- 
mice across the conditioning days of the CPP experiment. A) Locomotor 
response to saline across the conditioning period. B) Locomotor response to cocaine 
across the conditioning period. Data is measured as no. of beam breaks per 30 minute 
conditioning session and expressed as mean +/- SEM n=7-11 
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7.3.4 Molecular responses to acute and repeated cocaine administration 
The levels of nucleus accumbens ΔFosB accumulation observed in WT, GABAB(1a)
-/- 
and 
GABAB(1b)
-/- 
mice is shown in Figure 3. One-way ANOVA of western blot analysis 
revealed no significant difference was observed between WT, GABAB(1a)
-/- 
and GABAB(1b)
-/- 
in terms of nucleus accumbens ΔFosB accumulation (F2,23=2.5, p=0.10, n=8-9) (Fig 3) . An 
inadequate number of samples from the dorsal striatum were shown to contain pure HDAC 
protein via western blot for any meaningful statistical analyses. This may be due to 
difficulties in obtaining a pure nuclear fraction due to difficulties in extracting protein from 
a small sample of tissue such as the tissue collected for our studies. 
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Figure 3 – Levels of ΔFosB protein in the nucleus accumbens subsequent to the CPP 
experiment as measured by western blot. Protein levels are expressed in terms of 
densitometry of band relative to β-actin expression. Data is expressed in terms of mean +/- 
SEM. 
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Levels of cFos expression in the dorsal striatum and nucleus accumbens of WT, GABAB(1a)
-
/- 
and GABAB(1b)
-/- 
mice subsequent to acute cocaine injection is shown in Figure 4. In 
samples from the dorsal striatum of animals treated acutely with cocaine, students t-test 
revealed no significant effect of cocaine on cFos expression between wildtype saline and 
wildtype cocaine treated mice in either the dorsal striatum (p=0.32) or the nucleus 
accumbens (p=0.32). When cFos levels in the dorsal striatum and nucleus accumbens were 
compared between WT, GABAB(1a)
-/- 
and GABAB(1b)
-/- 
mice, one way ANOVA revealed no 
effect of genotype on cFos expression in either the dorsal striatum (F2,17=0.03, p=0.97) or 
the nucleus accumbens (F2,18=0.73, p=0.46). 
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Figure 4 – Levels of cFos protein in the A) the dorsal striatum and B) the nucleus 
accumbens 2 hours subsequent to acute cocaine injection (0/10 mg/kg) as measured by 
western blot. Protein levels are expressed in terms of densitometry of band relative to β-
actin expression. Data is expressed in terms of mean +/- SEM. 
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7.4 Discussion 
Although differing roles in regulating a variety of behaviours have been attributed to the 
GABAB receptor subunit isoforms, in this study we have, to our knowledge, for the first 
time demonstrated differing roles for the receptor subtypes in reward- and drug-related 
behaviour. In our study we clearly observed differing locomotor response patterns to 
cocaine in GABAB(1a)
-/- 
 and GABAB(1b)
-/- 
mice. GABAB(1a)
-/- 
mice showed hypersensitive 
locomotor responses to acute cocaine, whereas GABAB(1b)
-/- 
mice responded normally 
relative to wildtype controls. Additionally, different patterns of sensitisation to the 
locomotor effects of cocaine were also observed in the GABAB1 isoform null mice, with 
GABAB(1a)
-/- 
mice displaying increased levels of locomotor sensitisation relative to wildtype 
while GABAB(1b)
-/- 
mice did not exhibit any obvious sensitisation after repeated dosing. 
GABAB(1b)
-/- 
mice also displayed increased levels of basal locomotor activity than 
GABAB(1a)
-/- 
and wildtype mice at baseline, a replication of results previously seen in our 
lab (Jacobson et al., 2006a). Taken together, our results show that GABAB(1a)
 
and 
GABAB(1b) receptor subunit isoforms differentially mediate at least some of the behavioural 
responses to cocaine administration and thus suggest that the two receptor isoforms 
differentially modulate dopaminergic neurotransmission in vivo. 
 
Specifically, our data suggests that GABAB(1a) containing receptors play a crucial role in 
inhibiting the behavioural effects of cocaine, with GABAB(1a)
-/- 
  mice displaying enhanced 
cocaine-induced hyperlocomotor activity as well as displaying a trend towards enhanced 
levels of cocaine-induced psychomotor stimulant sensitisation. On the other hand, mice 
lacking the GABAB(1b) subunit fail to develop sensitisation to the locomotor effects of 
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cocaine. Locomotor sensitisation is regarded as an animal model specifically of the clinical 
phenomenon of incentive sensitisation (Sanchis-Segura & Spanagel, 2006). Incentive 
sensitisation is the process wherein enhanced salience is attached to previously neutral drug 
associated cues. This is a widely accepted element of drug abuse in the clinic which forms 
an essential part of the transition from habitual drug consumption to drug abuse 
(Vanderschuren & Pierce, 2010). Our findings suggest that drug treatments aimed 
specifically at the GABAB(1b)
 
receptor isoform may be of use in blunting or reversing this 
process in drug users. It must however be said that our data is taken from a CPP paradigm 
and that further confirmation of these findings with other chronic cocaine dosing regimens 
is required.  
 
The opposing effects of GABAB(1a)
 
and GABAB(1b)
 
subunit ablation may be due to the 
differing patterns of anatomical localisation observed between the receptors . The 
GABAB(1a) isoform acts as both a heteroreceptor that inhibits glutamate release in response 
to spillover of GABA from GABAergic synapses as well as a postsynaptic GABA receptor, 
whereas the GABAB(1b) isoform appears to exclusively mediate the post-synaptic inhibitory 
effects of GABA (Vigot et al., 2006; Waldmeier et al., 2008).  Recent evidence suggests 
that the sushi domain of the GABAB(1a)
 
isoform may act as an axonal targeting signal 
(Biermann et al., 2010) and contribute to increased stability at the cell surface in 
comparison to GABAB(1b)
 
containing receptors (Hannan et al., 2012). Enhanced cell surface 
stability of the GABAB(1a) subunit may underlie the non-sensitising phenotype of the 
GABAB(1b)
-/- 
mouse, in that the GABAB(1b)
-/- 
 mouse is left a population of more stable 
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GABAB(1a) containing receptors and indeed that converse may be true in the GABAB(1a)
-/- 
 
mouse. 
 
To our knowledge, studies designed to determine the precise anatomical location of the 
GABAB receptor isoforms in the dopaminergic system have yet to be performed. That said, 
it has been demonstrated that postsynaptic GABAB receptors couple to Kir3 channels 
(Luscher et al. 1997), and that both GABAB receptors and Kir3 channels are co-expressed 
on dopaminergic cell bodies in the VTA (Kalivas, 1993; Murer et al., 1997). We can posit 
based on our findings a model wherein the GABAB(1b) subunit inhibits tonic but not phasic 
dopaminergic tone, whereas GABAB(1a) containing receptors play a crucial role in inhibiting 
the enhanced phasic dopaminergic tone associated with acute cocaine administration. 
Indeed the failure of GABAB(1b)
-/- 
mice to sensitise to the locomotor effects of cocaine may 
be due to compensatory increases in GABAB(1a)-containing receptor heterodimers. Detailed 
electron microscopy and electrophysiological studies will be necessary to determine the 
manner in which the receptor subtypes differentially modulate dopaminergic 
neurotransmission. 
 
In contrast to our behavioural studies, our molecular studies demonstrated no significant 
differences between WT, GABAB(1a)
-/- 
and GABAB(1b)
-/-
 mice in terms of ΔFosB 
accumulation subsequent to the CPP paradigm, and cFos expression after acute cocaine 
treatment. This is surprising especially given the crucial role played by ΔFosB in mediating 
the neuronal and behavioural effects of drug of abuse exposure (Hiroi et al., 1997; Nestler, 
2008) and in particular given the crucial role of ΔFosB in the nucleus accumbens in the 
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development of locomotor sensitisation to cocaine (Robison et al., 2013). Thus, we would 
have expected to observe reduced levels of ΔFosB expression in the GABAB(1b)
-/-
 mice and 
enhanced expression in the GABAB(1a)
-/-
 mice. It must however be said that in using 
western blot experiments, we have looked at the levels of ΔFosB throughout the brain 
regions in question, where as it has been previously demonstrated that ΔFosB accumulation 
occurs in specific neuronal subpopulations (Brenhouse & Stellar, 2006; Nestler, 2008). A 
more anatomically precise approach such as immunohistochemistry may have been a more 
accurate method for this purpose. Future studies into the role of the GABAB(1) isoforms in 
reward should examine the effects of cocaine on other molecular markers of drug exposure 
such as DARRP-32 and pCREB/CREB ratio (Lhuillier et al., 2007). The broad overall 
failure of acute cocaine injection to induce increases in cFos expression may be a result of 
context in which the drugs are administered, which has been shown to exert a significant 
influence over cfos responses to drugs of abuse in reward-related areas (Hope et al., 2006) 
or as a result of a behavioural anomaly in the BALB/c mouse strain, which has been 
characterised as having unusually weak behavioural responses to cocaine (Thomsen & 
Caine, 2011; Eisener-Dorman et al., 2011). 
 
This data stands in contrast to our behavioural data. It must be stated however, that the 
small tissue samples used in this experiment resulted in difficulties in generating a pure 
nuclear extract from our samples. As such our molecular data must be interpreted with 
caution. The potential does exist that different neuronal subpopulations within the regions 
studies may underlie the behavioural differences between our genotypes. Furthermore, 
more precise molecular techniques such as immunohistochemistry for cFos (Singewald, 
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2007; O’Mahony et al., 2010) and ΔFosB (Nikulina et al., 2012) may reveal differences in 
neuronal activation patterns in a more precise manner. It must also be held in mind that 
several other molecular markers of chronic cocaine exposure such as DARRP-32 and 
pCREB/CREB ratio remain to be studied in these mice (Lhuillier et al., 2007). 
 
We must point out that we have characterised the GABAB(1a)
-/- 
and GABAB(1b)
-/-  
mice in 
only a small subset of the available preclinical models of addiction. Further characterisation 
of these mice in terms of behaviour relating to other aspects of addition such as self-
administration behaviour and behaviour in intracranial self-stimulation based paradigms 
remains an important future research direction. Likewise, further characterisation of the 
molecular responses to cocaine seen in these mice is crucial to our understanding of the role 
played by the GABAB receptor subunit isoforms in the biology underlying addiction. 
 
An important caveat in the presented data is the failure of the GABAB(1a)
-/- 
 mice, the 
GABAB(1b)
-/- 
mice and their wildtype controls to develop a place preference to cocaine. 
Similar results were also seen when animals generated in an identical manner were tested 
with 15 minute long testing and conditioning periods, using the same timeline and 
apparatus (see Appendix 3). This stands in sharp contrast to the preference developed in the 
same experimental procedure by GABAB(2)-S892A mice and their wildtype controls 
(Chapter 6).   Subtle effects of early life environment or epigenetic effects may have played 
a role in the difference between the animals. Indeed these mice differed from the mice used 
in the GABAB(2)-S892A  experiment in that they were produced via homozygous, as 
opposed to heterozygous breeding protocols. Handling issues have been highlighted as a 
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potential cause of failure in the development of conditioned place preference (Cunningham 
et al., 2006) and indeed a major difference was the levels of handling that mice were 
subjected to prior to the experiment, with the mice from the GABAB(2)-S892A being 
exclusively handled from 3 weeks old by the same experimenter who performed the CPP 
experiment, whereas the GABAB(1) receptor isoform null mice were from a colony 
maintained by different individuals.  
 
An important consideration regarding the use of conditioned place preference to examine 
cocaine reward sensitivity in the GABAB(1a)
-/- 
and GABAB(1b)
-/- 
mice is the lack of robust 
place preference to cocaine seen in the BALB/c mouse strain (Belzung & Barreau, 2000). 
The BALB/c mouse also displays lower levels of behavioural sensitivity to cocaine than 
other inbred mouse strains which may explain why our cfos western blots failed to shown 
an effect of cocaine (Thomsen & Caine, 2011; Eisener-Dorman et al., 2011). The 
background strain of a transgenic mouse can play a significant influence on behaviour 
(Jacobson & Cryan, 2007). However, it must be said that GABAB receptor knockout has 
thus far been shown to be lethal to mouse strains other than the BALB/c (Schuler et al., 
2001) and ethical and financial constraints understandably have made researchers cautious 
to further experiment with other background strains. Given the vastly different levels of 
sensitivity to GABAB agonist treatment displayed by different mouse strains (Jacobson & 
Cryan, 2005) it would be unsurprising if differing effects of GABAB receptor mutation 
were seen across the spectrum of background strains. 
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In conclusion, the present data suggests that the two prevalent GABAB receptor subtypes 
play contrasting roles in regulating behaviours relevant to reward circuitry in the brain. 
Indeed, the current data suggest that inhibition of GABAB(1b) containing receptors or 
enhancement of GABAB(1a) containing receptors may be of potential therapeutic use in the 
treatment of drug addiction. However given the impossibility in pharmacologically 
distinguishing the receptor subtypes (Bräuner-Osborne & Krogsgaard-Larsen, 1999), it may 
require genetic silencing techniques such as RNA interference to exploit this knowledge in 
the clinic (Boudreau et al., 2011). In contrast, loss of the GABAB(1a) receptor isoform 
enhanced the hyperlocomotor responses to cocaine. Thus, both GABAB(1a) and GABAB(1b) 
isoforms contribute to control of dopaminergic neurotransmission, although the nature of 
the contribution is different for each isoform. These findings show that both GABAB(1a) and 
GABAB(1b) isoforms differentially regulate neurochemical processes that underlie the 
behavioural responses to drugs of abuse. 
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Chapter 8 
 General Discussion and Conclusion 
 
  
 212 
8.1 General Discussion 
In this thesis the overarching goal was to further explore the role played by the GABAB 
receptor in modulating anxiety-like behaviour and cocaine sensitivity in mice with a 
translational perspective of anxiety and drug abuse disorders in the clinic. To this end, we 
used novel and established genetic and pharmacological techniques in combination with a 
host of preclinical behavioural assays. 
 
Our first aim in this regard was to explore to role played by the GABAB receptor in the 
developmental priming of anxiety behaviour in the mouse, using pharmacological agents. 
Mice were treated in early life (P14-28) with the GABAB receptor agonist baclofen and the 
antagonist CGP52432 and the anxiety behaviour of these mice was tested in a battery of 
behavioural paradigms in adult life. We demonstrated that treatment in early life with the 
GABAB receptor agonist baclofen but not with CGP52432 results in altered anxiety 
behaviour in adult life (Chapter 2). To further examine the role of the GABAB receptor in 
the developmental processes underlying the adult anxiety behaviour, we treated mice in 
early life with the selective serotonin reuptake inhibitor fluoxetine, a known anxiogenic 
intervention (Ansorge et al., 2004, 2008; Karpova et al., 2009). We then examined the 
sensitivity of mice in adulthood to the hypothermic and ataxic effects of the GABAB 
receptor agonist baclofen. We found that fluoxetine treatment in early life does not result in 
alterations to GABAB receptor function during the same period (Chapter 3). 
 
 A second aim of this thesis was to examine the effects of GABAB receptor ligands on 
behaviour in experimental paradigms of conditioned fear. These effects had until this point 
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been poorly characterised in the literature. Using an established fear conditioning technique 
(Brinks et al., 2009; Bravo et al., 2011),we found that the GABAB receptor positive 
modulator GS39783 and the GABAB receptor antagonist CGP52432 do not exert 
behavioural effects on the acquisition, recall or extinction of cued or contextual conditioned 
fear (Chapter 4). 
 
The next aim of the thesis was to characterise the anxiety behaviour and the cocaine 
sensitivity of a transgenic mouse line lacking the S892 phosphorylation site on the GABAB2 
subunit. GABAB receptors have been shown in vitro to display differing sensitisation and 
agonist potency properties to normal GABAB receptors (Bettler et al., unpublished 
observations). To this end, we examined the sensitivity of the GABAB(2)-S892A mouse to 
acute and chronic baclofen treatment and also tested the behaviour of these mice in a 
battery of behavioural tests. Based on preliminary observations regarding the effects of 
S892 ablation on the function of GABAB receptors in the ventral tegemental area, a key 
region in mediating the behavioural effects of drugs of abuse, we also examined the 
sensitivity of these mice to the rewarding and locomotor effects of cocaine in a conditioned 
place preference paradigm. The GABAB(2)-S892A transgenic mouse displays baclofen 
sensitivity, anxiety behaviour and cocaine sensitivity identical to those of WT littermates 
(Chapter 5, Chapter 6).  
 
Further to these experiments, we characterised the cocaine sensitivity of mice wherein one 
isoform of the GABAB1 subunit had been selectively ablated i.e. GABAB(1a)  and 
GABAB(1b)  receptor knockout mice. We demonstrated clearly that the GABAB(1) receptor 
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isoform knockout mice display markedly different locomotor sensitisation profiles in 
response to repeated cocaine treatment, with GABAB(1a) subunit knockout mice displaying 
enhanced levels of locomotor sensitisation to repeated cocaine administration, and 
GABAB(1b) subunit knockout mice displaying diminished locomotor sensitisation (Chapter 
7). 
 
8.2 The Role of the GABAB Receptor in the Development of Anxiety-Related 
Behaviour 
Prior to our studies significant amounts of preclinical data had demonstrated that the 
GABAB receptor played a crucial role in determining levels of anxiety-like behaviour in 
rodents (Cryan & Kaupmann, 2005). Furthermore some data had suggested that treatment 
with benzodiazepines in early life can result in altered anxiety behaviour in adulthood 
(Depino et al., 2008; Shen et al., 2012). It was unknown however, what role, if any, the 
GABAB receptor played in modulating the developmental processes that underlie the 
development of normal anxiety behaviour. 
 
The major finding in this thesis is the demonstration that the GABAB receptor activation 
using exogenous agonists can result in enhanced anxiety behaviour in adult life (Chapter 2). 
This data agrees with current data demonstrating that GABAB(1) subunit isoforms play a 
crucial role in mediating the long term behavioural effects of maternal care disruption 
(Felice et al., 2012a). It also agrees with other studies that have examined the behavioural 
effects of the ionotropic GABAA receptor manipulation in early life. These studies have 
shown that treating mice in early life with benzodiazepines, positive modulators of the 
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GABAA receptor, results in enhanced anxiety behaviour in adult life (Depino et al., 2008; 
Shen et al., 2012). 
 
Further research is required to elucidate the mechanism by which GABAB receptor 
activation alters adult anxiety behaviour. Indeed there are several possible mechanisms 
which may underlie this. One such mechanism by which the GABAB receptor may 
contribute to the developmental priming of anxiety behaviour is via interactions with the 
serotonergic system.  A link between the GABAB receptor and the serotonergic system has 
been established by studies of anatomical co-localisation, electrophysiological and dialysis 
studies (Abellán et al., 2000). This link has also been shown by behavioural experiments 
demonstrating that GABAB receptor antagonists lose their behavioural effects in the 
absence of serotonergic function (Slattery et al., 2005a). The serotonergic system has been 
repeatedly demonstrated to play a crucial role in the neurological events in early life that 
programme adult anxiety behaviour. This has been repeatedly shown in mice using both 
pharmacological agents such as SSRI antidepressants, as well as by using time and brain 
region selective 5-HT1A receptor knockout mice. It has also repeatedly been shown in 
humans that polymorphisms in genes associated with the serotonergic system interact with 
early life environment to predict risk for psychiatric disorders in adult life (Nugent et al., 
2011). Although the GABAB receptor has been shown to interact strongly with the 
serotonergic system, it must be noted that in this thesis, early life treatment with the SSRI 
fluoxetine has been shown to exert no effect on adult life GABAB receptor function 
(Chapter 3), suggesting that other mechanisms, such as interactions with other 
neurotransmitter systems or with the neuroendocrine system must be explored. 
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The GABAB receptor also displays robust interactions with the glutamatergic system, and 
these interactions may also underlie the developmental effects of baclofen seen in this 
study. These include interactions with the ionotropic NMDA receptors and the 
metabotropic glutamatergic receptors (mGluRs) (Tabata & Kano, 2010; Chalifoux & 
Carter, 2011). The relevance of these interactions in the neurodevelopmental processes 
underlying anxiety disorders remains unclear. 
 
Another mechanism which may underlie the behavioural changes seen in our study is via 
the influence of the GABAB receptor on the neuroendocrine system. GABAB agonism has 
indeed been shown to induce a marked increase in growth hormone (GH) levels in healthy 
humans (Koulu et al., 1979). More interesting are studies that have shown that baclofen-
induced increases in GH levels are attenuated in depressed patients, particularly in those 
with a blunted dexamethasone suppression test response (O’Flynn & Dinan, 1993). These 
data suggest a link between GABAB receptor function and hypothalamic-pituitary axis 
function. The potential thus exists for neuroendocrine alterations to underlie the anxiogenic 
effects of baclofen treatment. Examination of HPA-related hormone levels in baclofen-
treated mouse pups and a study of long-term alterations in HPA axis function as a result of 
early life GABAB receptor agonism may prove interesting directions for further research. 
 
Further studies into the developmental role of the GABAB receptor in anxiety may make 
use of genetic models where GABAB receptor function can be modulated in regionally and 
temporally selective manner. The studies would be similar in nature to studies carried out 
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on mice with a conditional knockdown of the 5-HT1A receptor (Gross et al., 2002). Based 
on preliminary findings from other groups, however, conditional knockdown of the 
GABAB2 receptor appears to be a significant technical challenge (Bettler et al., unpublished 
observations). Another possible strategy for conditional knockdown of GABAB receptor 
function would be use of short interfering RNA (siRNA). Likewise other strategies such as 
engineering mice that can transiently over express GABAB receptor subunits may prove 
useful in the future. Another important extension of the data presented is the conduct of 
studies similar to those that examine the interactions between genetic variation in genes that 
govern serotonergic function and early life environment (Nugent et al., 2011), except 
examining the effects of GABAergic gene variance. 
8.3 The Role of the GABAB Receptor in Learned Fear Responses 
Abnormal fear-learning is a clinical hallmark of anxiety disorders and although GABAB 
receptor-active ligands have been widely characterised in terms of their effects on 
unconditioned anxiety (Cryan & Kaupmann, 2005), to our knowledge, only two studies in 
the literature have examined the effects of GABAB receptor-active ligands in conditioned 
fear paradigms (Heaney et al., 2012; Li et al., 2013). Data presented in this thesis (Chapter 
4) are an advance from these papers in that we use a different positive modulator 
(GS39783) to these papers as well as being the first study to characterise a newer 
generation highly-selective and potent GABAB receptor antagonist (CGP52432) in terms of 
its effects on fear conditioning. 
 
Our finding that the highly selective and potent GABAB receptor antagonist CGP52432, is 
similar to what has been seen with the less potent GABAB receptor antagonist phaclofen 
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(Heaney et al., 2012). Likewise our finding that the GABAB receptor positive allosteric 
modulator GS39783  has no effect on conditioned fear behaviour is in agreement with 
findings regarding the similar modulator BHF117 (Li et al., 2013). Thus the collated 
finding so far relating to the utility of GABAB receptor antagonists and positive allosteric 
modulators in conditioned fear suggests that these drugs may not be efficacious in treating 
anxiety disorders characterised by pathological fear-learning.  
 
Our data, taken with that of Li, Heaney and their colleagues (Heaney et al., 2012; Li et al., 
2013), raises an interesting issue regarding the role played by GABA in the neurobiology of 
learned fear. In vitro studies have shown that GABA plays a central role in regulating 
neuronal activity and LTP development in the amygdala (Johansen et al., 2011; Wilensky et 
al., 1999). GABAB receptors do not appear to play a crucial role in these processes. 
Additionally, given the crucial role the GABAB receptor plays in cognition (Mondadori et 
al., 1993; Helm et al., 2005; Arai et al., 2009) and the fact that the neurocircuitry of fear 
conditioning overlaps with the circuitry that underlies other elements of cognition (Fendt & 
Fanselow, 1999), the absence of effect of GABAB receptor-active agents on conditioned 
fear in our studies raises the question of how the neural circuitries that underpin fear-
learning and cognition more broadly interact.  
8.4 Is There a Functional Role for the S892 Residue of GABAB(2) Receptor 
Subunit?  
Data presented in this thesis suggests that the GABAB(2)-S892A mouse line displays a 
baclofen sensitivity, anxiety behaviour and cocaine sensitivity indistinct from its wildtype 
littermates (Chapters 5 and 6). This is somewhat surprising given the role played by 
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phosphorylation at the S892 in determining levels of receptor agonist potency and 
maintenance of cell surface stability. Indeed, the S892 residue has been shown to undergo 
significant basal PKA dependent phosphorylation in vivo, and phosphorylation of the residue 
has been shown to play a crucial role in inhibiting agonist induced receptor desensitisation in 
vitro (Couve et al., 2002). Furthermore, rates of GABAB receptor degradation have been 
correlated to levels of S892 residue phosphorylation (Fairfax et al., 2004). Data obtained 
from Xenopus oocytes conversely suggests that PKA mediated phosphorylation can 
effectively desensitise the receptor (Yoshimura et al., 1995). 
 
A reason as to why no differences in behaviour were observed throughout our studies 
between the GABAB(2)-S892A mouse and its wildtype littermates may be the presence of 
compensatory changes in the function of alternative regulatory pathways for GABAB 
receptor function. These other mechanisms may include protein-kinase C mediated 
regulation of receptor function, AMPK mediated phosphorylation or indeed CamKII 
mediated phosphorylation (Pontier et al., 2006; Kuramoto et al., 2007; Guetg et al., 2010; 
Terunuma et al., 2010a).  
 
An even more intriguing mechanism by which compensatory modulation of the GABAB 
receptor could occur is via interactions with potassium channel tetramerisation domain 
(KCTD) proteins. These proteins are a relatively novel discovery and may indeed prove to 
be one of the crucial elements in determining the basis of GABAB receptor heterogeneity 
across the brain. These proteins have been shown to directly interact with the GABAB 
receptor heterodimer and have been shown to strongly influence both the processes that 
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underlie fast receptor sensitisation and play a crucial role in determining agonist potency 
for the GABAB receptor (Schwenk et al., 2010). The fact that theses proteins are 
differentially distributed in terms of both brain region and neurodevelopmental period 
(Metz et al., 2011) strongly suggests that the KCTDs play an influential role in determining 
GABAB receptor heterogeneity. It must however be stated that, as our data from the 
GABAB(2)-S892A mouse suggests, significant levels of redundancy may exist in the 
processes that govern GABAB receptor function. One regulatory pathway is unlikely to be 
the sole determinant of heterogeneity. Indeed in light of these advances it becomes apparent 
that receptor phosphorylation only forms one part of a highly complex system that 
underlies the functional regulation of the GABAB receptor. As such characterisation of the 
GABAB(2)-S892A mouse is in some ways confounded by the existence of possible 
compensatory changes in other molecular pathways. 
 
Although the GABAB(2)-S892A mouse has been extensively characterised in terms of its 
basic pharmacological sensitivity to baclofen as well as its anxiety behaviour, 
antidepressant-like behaviour and sensitivity to the rewarding effects of cocaine in this 
thesis, the potential for further characterisation of this animal remains. Indeed, as regards its 
basic pharmacology, examination via electrophysiological techniques in vivo may provide 
a more thorough picture than seen with the basic physiological responses to baclofen used 
in this thesis. Given the well-established behavioural effects of GABAB receptor positive 
modulators and antagonists in behavioural tests of anxiety, antidepressant activity and 
cocaine addiction (Cryan & Kaupmann, 2005; Lhuillier et al., 2006), it would be of interest 
to determine the behavioural response of the GABAB(2)-S892A mouse in relevant 
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behavioural assays. The GABAB receptor has additionally been shown to modulate animal 
behaviour in terms of cognition (Jacobson et al., 2007b) as well as nociception and seizures 
(Ong & Kerr, 2000). Characterisation of the GABAB2-S892A as regards these fields of 
preclinical research remains to be accomplished. The recent discovery that the GABAB(1a) 
and GABAB(1b) null mice are differentially sensitive to the effects of early life stress (Felice 
et al., 2012a) raises the further question as to whether the GABAB(2)-S892A mouse would 
differ from wildtype animals in their own sensitivity to early life deprivation and represents 
another future research direction. 
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8.5 Addiction 
8.5.1 The GABAB receptor in cocaine addiction 
 
Prior to the studies presented in this thesis, a wealth of preclinical and clinical data had 
implicated the GABAB receptor as a putative target for novel anti-addictive therapies 
(Tyacke et al., 2010), as well as being a crucial substrate in the reward circuitry of the brain 
(Vlachou & Markou, 2010). The main finding as regards the role of the GABAB receptor in 
cocaine addiction is our data demonstrating altered locomotor sensitisation patterns for the 
GABAB(1a) and GABAB(1b) mice compared to WT mice. Our data suggests that the 
GABAB(1b) subunit is a crucial mediator in the development of the locomotor sensitisation 
to cocaine. Locomotor sensitisation is regarded as an animal model specifically of the 
clinical phenomenon of incentive sensitisation (Sanchis-Segura & Spanagel, 2006). 
Incentive sensitisation is the process wherein enhanced salience is attached to previously 
neutral drug associated cues. This is a widely accepted element of drug abuse in the clinic 
which forms an essential part of the transition from habitual drug consumption to dug abuse 
(Vanderschuren & Pierce, 2010). Our findings suggest that drug treatments aimed 
specifically at the GABAB(1b) receptor isoform may be of use in blunting or reversing this 
process in drug users. It must however be said that our data is taken from a CPP paradigm 
and that further confirmation of these findings with other chronic cocaine dosing regimens 
is required. 
 
It must be acknowledged that in our studies we have only investigated the behavioural 
effects of our three transgenic mice lines in but a few of the many behavioural paradigms of 
drug addiction available (see Introduction, Table 7). The most obvious continuation from 
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the studies in this thesis is an examination of the GABAB(2)-S892A and the GABAB(1) 
isoform specific knockout mice in other commonly used animal models of addiction such 
as the self-administration and intracranial self stimulation based procedures. Microdialysis 
studies assessing the release of dopamine in reward-related forebrain structures such as the 
nucleus accumbens and dorsal striatum in response to drugs of abuse in these animals may 
also be of interest.  
 
It must also be borne in mind that this thesis has focussed exclusively on cocaine, which is 
but one of a plethora of commonly abused drugs. The GABAB receptor has also been 
particularly of interest as a putative drug target in the treatment of alcohol use disorders 
(Agabio et al., 2012). Indeed significant preclinical evidence has also suggested that the 
GABAB may represent a potential therapeutic avenue in smoking cessation therapy, with 
GABAB receptor antagonist displaying anti-addictive effects in several animal models 
(Paterson et al., 2008; Mombereau et al., 2007; Vlachou et al., 2011a). Assessment of the 
sensitivity of the transgenic mouse lines characterised in this thesis in terms of their 
sensitivity to the behavioural effects of alcohol represents another important future research 
direction. 
8.6 Genetic Models of Altered GABAB Receptor Function – General Caveats 
8.6.1 Transgenic mouse models 
Certain qualifications are always associated with the use of transgenic mice in GABAB2-
S892A, GABAB(1a) and GABAB(1b)  null mice, can have developmental effects not readily 
distinguishable from the effects of the genetic alteration in adult life. This is all the more an 
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important reservation in the interpretation of the findings of this thesis given the now-
known developmental role of the GABAB receptor in determining adult behaviour (Felice 
et al., 2012a). A possible solution to this caveat is the development of siRNA and viral over 
expression based techniques as well as Tet-on/off conditional knockdown models allowing 
for a temporally control of GABAB receptor modulation. 
 
A recurring issue in the use of genetic models of altered GABAB receptor function is that of 
background strain. The simple fact that GABAB receptor knockout is only achievable using 
the BALB/c mouse strain as a background (Schuler et al., 2001), presents significant 
caveats to the interpretation of data from this strain. Inbred mice strains vary significantly 
in their responses to common behavioural tests and the effects of an intervention in one 
mouse strain do not necessarily occur in others. Indeed the BALB/c mouse strain displays 
in some ways an unusual behavioural repertoire in tests of anxiety and depression, with 
some researchers going as far as to utilise them as an animal model of anxiety (O’Mahony 
et al., 2010). The behavioural effects of genetic and pharmacological interventions must 
thus be interpreted with caution. A further caveat to the use of inbred mouse strains in 
studying the role of the GABAB receptor in behavioural tests is the presence of significant 
variance as regards GABAB receptor function between mouse strains (Jacobson & Cryan, 
2005). 
 
8.6.2 Optogenetic mouse models 
Another crucial technology in unravelling the role played by the GABAB receptor in 
psychiatric illness form a preclinical perspective is the advent of optogenetic technologies. 
  
 225 
This technology is based on the use of transgenic mice expressing light activated channel-
rhodopsins in which can be targeted to neuronal populations using cell type specific 
promoters allowing for their activation or inhibition by direct light exposure (Deisseroth, 
2011). Optogenetics provides an opportunity for unprecedented levels of temporal and 
spatial specificity for intervention in the mammalian brain and is already providing 
important insights into the neural circuitry of sleep and arousal, affective states and 
addiction (Touriño et al., 2013). Most recently optogenetic technology has been used to 
demonstrate a crucial role for GABAergic neurons in the VTA in signalling expected 
reward (Cohen et al., 2012), as well as a crucial role for GABAergic neurons in the raphe in 
mediating social avoidance behaviour (Challis et al., 2013). Further characterisation of the 
GABAergic neuronal populations in the brain via optogenetics, in particular GABAB 
receptor expressing populations will no doubt lead to further unravelling of the role played 
by the GABAB receptor in anxiety and substance abuse disorders. 
 
8.6.3 Behavioural models of psychiatric illness 
In these studies we have made extensive use of animal models of psychiatric disease. It 
must be remembered that the use of these paradigms is not without their own limitations. 
These include questions as to the pharmacological sensitivity of these tests i.e. whether they 
are merely assays of benzodiazepine-like pharmacological effect as opposed to actual 
models of human disease (Rodgers, 2010; Cryan & Sweeney, 2011). The battery style 
approach employed in the studies presented provides several advantages in terms of 
reducing total numbers of animals used in our studies and increasing the likelihood of 
detecting subtle behavioural differences between treatment groups or genotypes, but does 
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come with the caveat that prior test experience can profoundly alter animal behaviour in 
subsequent tests (Cryan & Holmes, 2005). Like animal models of anxiety, animal models 
of cocaine addiction such as the CPP paradigm and locomotor sensitisation come with their 
own caveats (Sanchis-Segura & Spanagel, 2006). 
 
8.6.4 Baclofen challenge as an output of GABAB receptor function 
Another major caveat to our study is the relative crudeness of the in vivo baclofen challenge 
as an output for measuring GABAB receptor function. Although treatment with baclofen 
produces robust and easily measurable physiological effects such as hypothermia and ataxia 
(Chapter 3, Chapter 5), considerably more sophisticated techniques exist to elucidate 
GABAB receptor function. This is especially important given that the GABAB receptors 
present in different brain regions, and even in different neuronal subpopulations, can differ 
in their pharmacological properties (Pinard et al., 2010).  It must however be said that 
measuring the hypothermic effects of baclofen has proved an important clinical output for 
assessing levels of GABAB sensitivity. More sophisticated and sensitive techniques may 
include electrophysiology (Abellán et al., 2000), iGTP activity assays (Germany, 1993), 
and baclofen binding studies across the whole brain (Chu et al., 1990). 
 
8.7 Perspectives and Conclusion 
The data presented in this thesis advances our understanding of the GABAB receptor as a 
moderator of the disease processes associated with anxiety disorders and cocaine addiction. 
In particular, our data suggests a role for the GABAB receptor in the developmental 
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processes that underlie adult anxiety behaviour and that the GABAB receptor isoforms may 
indeed play differential roles in the development of incentive salience, an important aspect 
of drug addiction. Our data furthermore suggests a limited role for GABAB receptor pS892 
levels in regulating behaviour and a limited effectiveness for GABAB receptor-active 
ligands in modulating conditioned fear behaviour. 
 
Recent years have seen a paradigm shift in our understanding of GABAB receptor 
pharmacology. The discovery of the KCTDs has transformed our understanding of the 
nature of GABAB receptor function in vivo and revealed that the classical heterodimer 
structure of the GABAB receptor is better understood as a multimeric complex of several 
associated proteins which exert significant influence over GABAB receptor function and 
may indeed underlie to a significant degree the heterogeneity of the GABAB receptor across 
the brain (Schwenk et al., 2010; Metz et al., 2011). Further probing of this and similar 
phenomena may represent the direction for future behavioural pharmacology regarding the 
GABAB receptor with characterisation of KCTD family knockout mice representing an 
obviously tempting avenue. 
 
It must be remembered, however, that advances in preclinical behavioural pharmacology 
must be paralleled by advances in clinical understanding of psychiatric illness (Cryan & 
Sweeney, 2011). This must not only include more accurate, biomarker-based diagnostic 
systems, but also based development of our knowledge of GABAB receptor and other 
GABAergic gene polymorphisms in the population and how these contribute to the risk of 
anxiety disorders and drug dependence. It is only with a multidisciplinary approach 
involving both in vitro and behavioural pharmacologists, pharmaceutical chemists and 
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clinicians that will allow our current understanding of the GABAB receptor to bring benefit 
to patients. 
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Appendices 
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Appendix 1 - Genotyping of GABAB(2)-S892A Mice 
Genotyping was performed on offspring on tail clip samples taken from animal at ages 6-8 
weeks. Tail clips were digested in 200μl non-ionic detergent (NID) buffer (50mM KCl; 
10mM Tris-HCl, pH 8.3; 2mM MgCl2; 0.1 mg/ml gelatin; 0.45% NP40; 0.45% Tween-
20)overnight at 56°C with addition of 3µl Proteinase K (sigma) solution 10 mg/ml. The 
digestion mix was then heated to 96° for 10 minutes, prior to centrifugation at 14800 rpm at 
room temperature for 5 minutes. The resulting supernatant was stored at -20°C prior to 
Polymerase Chain Reaction targeted at Exon 19 of the GABAB2 gene. Primer sequences 
used were: 
 
Sense - 5’-CAC TCG GAG GCT TGT GTA AC-3’ 
Antisense - 5’-TCC AAT GGA CGG GAG GTA GG-3’ 
 
PCR on the samples was carried out using the reaction mixture: 
Jumpstart buffer       2.0μl 
Forward primers (10mM)     1.0μl 
Reverse primers (10mM)     1.0μl 
10x dNTPs (each dNTP at 2.5 mM)    0.5μl 
Jumpstart polymerase (Dq307 sigma)   0.5μl 
dH2O        14μl 
 
Cycling parameters: 
 
Step 1  94 2 min 
Step 2  94 1 min 
Step 3  55 1 min 
Step 4  72 1 min 
Step 5  Go to step 2 for 34 cycles 
Step 6  72 5 min 
Step 7  8 pause 
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The products from the PCR reaction were stored at -20°C prior to gel electophoresis. 
 
Gel electrophoresis was carried out using a 2% agarose gel, for 60 minutes at 150V. 
Visualisation of bands was achieved by incubation of the gel in GelRed solution for 20-30 
minutes and visualised under UV light using Gel Capture software. The wildtype allele 
formed a 514bp band with the S892A allele forming a band at 670 bp (Fig 1b). 
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Figure 1 
a) The GABAB(2)-S892A mutant mouse contains a serine to alanine mutation at the serine 
892 site in exon 19 of the GABABR2 gene, rendering the generated protein 
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unphosphorylatable at this site. The S892A mutant allele also contains an inserted LoxP 
site, a relic of the early stages of the mutation insertion process, which allows the S892A 
gene to be distinguished from the wildtype through molecular weight via electrophoresis.  
b) When PCR products of the GABABR2 gene are separated by gel electrophoresis, WT 
bands appear at 514bp and the S892A allele appears at 670bp. Heterozygous mice are 
identified by the presence of both bands. 
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Appendix 2 – Validation of Conditoned Place Preference Protocol 
In order to validate our CPP protocol as described in chapters 6 and 7, we initially tested 8 
BALB/c mice from Harlan, UK (age6-8 weeks, with one week acclimatization to the lab). 
The CCP apparatus was as described in chapters 6 and 7, and 10 mg/kg of cocaine (IP 
injection) as our conditioned stimulus. Animals were randomly assigned to receive cocaine 
in the white or black chamber randomly with 4 animals being paired to black and 4 to 
white. Animals were allowed one 30 minute acclimatization session, followed by a pretrial 
session. Animals were allowed to freely explore the entire apparatus for 30 minutes. We 
analysed the behaviour of these animals to determine if any bias existed for either choice 
chamber. Behaviours analysed were the total time spent in the black and white “choice” 
chambers, total entries  the black and white “choice” chambers, exploration (breaks of the 
beam closest to the entrance of the chamber i.e. nose pokes) frequency of each chamber, 
activity (beam breaks of adjacent beams to the not moving away from the curent location) 
in each chamkber and movement (breaking a new beam and moving away from the current 
location). The results of our analyses are shown in Figure 1.
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Figure 1 – Baseline preference of BALB/c mice for the two “choice” compartments of the CPP apparatus. A) Total time spent in the 
white and black “choice” compartments, B) Total frequency of entries to the white and black “choice” compartment, C) Total 
exploration frequency in the white and black “choice” compartments, D) Total activity frequency in the white and black “choice” 
compartment and E) Total exploration frequency in the white and black “choice” compartments s. Data is presented as mean +/- 
SEM, n=8
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Students t-test revealed that although a trend towards more movement counts were 
observed in the white chamber (p=0.06) (possibly due to the novel odour), time spent in the 
chambers (p=0.50), entries to to the chambers (p=0.38), explorations of the chambers 
(p=0.15) and activity in the chambers (p=0.95) did not differ between compartments. We 
therefore accepted our CPP apparatus as unbiased. 
Subsequent to pretesting mice place preference conditioning was performed as per chapters 
6 and 7, with the test ending on the first assessment of place preference behaviour. 
Behviours analysed were identical to those in the pretest although with the difference that 
we examined preference for CS+ over CS- chambers. The results of our analyses are shown 
in Figure 2. 
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Figure 2 – Conditioned place preference behaviour of BALB/c mice for the CS+ and CS- compartments. A) Total time spent in the 
CS+ and CS- compartments, B) Total frequency of entries to the CS+ and CS- compartments, C) Total exploration frequency in the 
CS+ and CS- compartments, D) Total activity frequency in the CS+ and CS- compartments and E) Total exploration frequency in the 
CS+ and CS- compartments. Data is presented as mean +/- SEM, n=8, p>0.05 is represented as *.
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Students t-test revealed that mice in our prelimninary study displayed significantly more 
explorations of the CS+ chamber (p<0.05) and trended towards spending more time in the 
CS+ chamber (p=0.085). Total chamber entries (p=0.83), total activity frequency (p=0.47) 
and total movement frequency (p=0.84) did not differ between the CS+ and CS- chambers 
after place preference condition
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Appendix 3 – Preliminary CPP Characterisation of GABAB(1) Receptor 
Isoform Null Mice 
 
WT, GABAB(1a)
-/- 
and GABAB(1b)
-/- 
, as described in chapter 7, were examined using the 
same CPP protocol as utilised in Chapter 6 and 7, with the difference that all sessions were 
of 15 minutes as opposed to 30 minutes. Statistical analysis was performed as per chapter 7. 
Preference data is presented in Figure 1. 
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Figure 1 - Preference of Wildtype, GABAB(1a)
-/- 
and GABAB(1b)
-/- 
mice across the CPP 
paradigm. Preference data is described as the time in seconds spent in the drug paired 
chamber minus time spent in the saline paired chamber. Data is expressed as mean +/- 
SEM. N=8-9 
 
Levels of preference of WT, GABAB(1a)
-/- 
and GABAB(1b)
-/- 
mice for the CS+ chamber are 
displayed in Table 1.  WT,  GABAB(1a)
-/- 
and GABAB(1b)
-/- 
mice  displayed no preference for 
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either the CS+ or CS- chambers of the CPP apparatus at baseline, however none of the 
groups mice developed a clear preference for the drug paired chamber at either trials one or 
two. Two-way ANOVA showed no significant effect of time on levels of preference (F(2,42) 
= 1.3, p=0.28). Further Two-way ANOVA revealed no effect genotype on preference 
(F(2,42) =  0.11, p = 0.90) nor a time vs genotype interaction (F(4,42) =  0.99, p = 0.42). The 
use of a 15 minute protocol may have introduced a pharmacokinetic issue, in that mice 
reached peak CNS cocaine levels after the conditioning phases were over. In light of the 
failure of this method to generate robust place preference we extended conditioning and test 
sessions to 30 minutes for the experiments described in chapters 6 and 7. 
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